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Influenza disease has posed a global threat by seasonal epidemics and unforeseen 
pandemics. The narrow protection of conventional vaccines and the unpredictable outbreaks 
necessitate novel influenza vaccines that provide broad protection. Since influenza virus 
infects humans through the nasopharyngeal mucosa, local vaccine delivery that activates 
cross-reactive mucosal immunity may offer an attractive vaccination strategy against virus 
infection and control virus transmission. Viral vector-based influenza vaccines have been 
currently under study and shown good safety and high systemic immunity in animal models 
and some in human studies. Nevertheless, the data on mucosal immunity of these vaccines 
in humans are still limited. The study presented here investigates the potential of Pan 
paniscus adenovirus type3- (PanAd3) and modified Vaccinia Ankara (MVA)-based influenza 
vaccines to induce broad T and B cell immunity against influenza subtypes in human 
nasopharyx-associated lymphoid tissue (NALT) using an in vitro cell culture system.  
Firstly, influenza vaccine antigen expression was detected in adenotonsillar mononuclear 
cells (MNC), following stimulation by MVA-, but not PanAd3-based vaccines The MNCs, 
consisting of mainly lymphocytes, appeared to be refractory to PanAd3 virus infection, but 
susceptible to MVA virus infection. The influenza proteins (NP, M1 and HA) from MVA-
NP+M1 and MVA-pdmH1HA were found predominantly in B cells and dendritic cells. Both 
NP and HA were intracellularly synthesised although HA later appeared to migrate to the cell 
membrane, whereas NP remained in the cell cytoplasm. Having shown the efficient influenza 
protein expression in the MNCs, the immune responses in tonsillar MNCs elicited by MVA-
NP+M1 and MVA-pdmH1HA were further examined. Designed as a T cell-based vaccine, 
MVA-NP+M1 activated a marked increase of M1-specific cytotoxic T cell (CTL) response. 
The vaccine also significantly boosted M158-66-specific CTL responses in older children and 
adults, in an age-dependent manner. Besides, these cells were polyfunctional as shown by 
the co-expression of CD107a, IFN-γ and TNF-α in response to recall M158-66 peptide 
challenge and demonstrated the in vitro specific killing of peptide-pulsed target cells. In 
addition to MVA-NP+M1, MVA-pdmH1HA elicited cross-reactive HA-specific IgG antibodies 
that recognised pandemic H1N1 and heterosubtypic influenza strains in HA group1 
(seasonal H1, H5 and H9), but not group 2 (H3 and H7). The stronger magnitude and the 
greater breadth of vaccine-induced antibodies were found in adults compared to children. 
Using a HAI assay, the MVA-pdmH1HA-induced antibodies were shown to bind to the head 
HA of pdmH1N1, but not of H5N1. 
In summary, MVA-NP+M1 and MVA-pdmH1HA have the potential as mucosal vaccines to 
elicit cross-reactive mucosal T and B cell-mediated immune responses against a range of 
influenza viruses. These data provide important information for a new vaccination strategy 
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R10 RPMI-1640 medium containing 10% ΔFBS with HEPES, L-glutamine 
and penicillin/streptomycin 
R10AmpB R10 containing 0.25 µg/ml amphotericin B 
rAd Recombinant adenovirus  
RBC Red blood cell 
RBS Receptor-binding site  
RDE Receptor-destroying enzyme  
RIG-I Retinoic acid inducible gene-I  
RPE R-Phycoerythrin 
RPMI-1640 Roswell Park Memorial Institute-1640 medium 
SEB Staphylococcal enterotoxin B 
SEM The standard error of the mean 
SFC Spot forming cell  
SIgA Secretory IgA antibody 
SSC Side Scatter 
TCR T-cell receptor  
TFH T follicular helper cell  
Th1 T helper 1 
Th17 T helper 17  
Th2 T helper 2  
TLR Toll-like receptor  
TNF-α Tumour necrosis factor-alpha 
Treg Regulatory T cell  
TRM Tissue-resident memory T cells 
U/ml Unit/millilitre 
vp Virus particle 
vRNP Viral ribonucleoprotein  
VV Vaccinia Virus 
WCP Unfractionated adenotonsillar mononuclear cells 
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1.1. Influenza virus 
Influenza virus is a member of family Orthomyxoviridae. It is characterised as an eight-
segmented, negative-stranded RNA, enveloped virus. The shape of influenza virus is 
spherical, approximately 100 nm in diameter or filamentous in excess of 300 nm in length. 
As shown in Figure 1.1, the virus is formed of a lipid bilayer integrated with two 
glycoproteins; haemagglutinin (HA) and neuraminidase (NA) and the ion-channel; matrix 
protein 2 (M2). Underneath the envelope overlays matrix protein 1 (M1), which encloses 
virion core and nuclear export protein/nonstructural protein 2 (NEP/NS2). The core of the 
virus is composed of eight segmented-viral RNAs, each of which is coated with 
nucleoprotein (NP) complex and heterotrimeric RNA-dependent RNA polymerase (PB1, PB2 
and PA), called viral ribonucleoprotein (vRNP) [1].  
 
Figure 1.1   Structure of influenza virus  
The envelope of influenza virus consists of haemagglutinin (HA), neuraminidase (NA) and matrix protein 
2 (M2). HA0 is cleaved by host cell proteases into globular head (HA1) and stalk (HA2) and becomes 
active. Underneath the lipid envelope are matrix protein 1 (M1), non-structural proteins (e.g. NS1 and 
NS2) and eight-segmented viral ribonucleoproteins (vRNP). Each vRNP is composed of viral RNA, 
coated with nucleoprotein (NP) and RNA polymerase complex (PB1, PB2 and PA) (Adapted from [2], [3]). 
Enabling the ‘host jump’: structural determinants of receptor-binding specificity in influenza A viruses 
Scientific barriers to developing vaccines against avian influenza viruses 
of the avian influenza virus mainly occurs in the LRT in 
humans, which explains why avian viruses occasionally 
infect humans.
HA glycoprotein. HA is the most abundant protein on 
the surface of the virion, and it mediates binding to the 
host receptor and fusion between the viral and host 
endosomal membranes. In addition, it is the primary tar-
get of neutralizing antibodies directed against the differ-
ent viral subtypes. The HA precursor polypeptide (HA0) 
is a type 1 transmembrane glycoprotein of about 550 
amino acids, with an amino-terminal signal sequence, a 
transmembrane domain near the carboxyl terminus and 
a short cytoplasmic tail. The HA0 precursor is activated 
by proteolytic cleavage into two disulphide-linked poly-
peptides, HA1 and HA2. Three monomers of HA1–HA2 
form the mature 220 kDa homotrimeric HA protein.
The X-ray crystal structure of the HA ectodomain was 
first reported in 1981 (REF. 27). The HA trimer projects 
approximately 135 Å from the viral membrane and can be 
divided into two domains: the membrane-distal globu-
lar domain and the membrane-proximal stem domain 
(FIG. 2a). The receptor-binding site forms a shallow pocket 
at the tip of the globular domain and comprises three 
secondary structural elements and one base element6. 
The three secondary elements, namely the 130-loop, the 
190-helix and the 220-loop (the numbers correspond to 
the amino acids in the H3 subtype), form the edges of the 
receptor-binding site, and four highly conserved residues 
(Y98, W153, H183 and Y195, of the H3 subtype) form 
the base. The SA moiety of the receptor typically forms 
several conserved hydrogen bonds with the 130-loop and 
the base residue Y98, and the remaining glycan moieties 
interact with the 220-loop or the 190-helix. In addition, 
the residues W153, H183 and Y195 contribute to receptor 
binding via van der Waals interactions.
The avian α2,3-linked SA receptor typically has an 
extended configuration in the HA-bound state, and the 
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Figure 1 | Structure and life cycle of influenza A viruses. a | Influenza A viruses are enveloped, single-stranded, 
negative-sense RNA viruses that contain eight gene segments that encode 16 proteins (although not all influenza viruses 
express all 16 proteins). The non-structural segment encodes the nuclear export protein NS2 and the host antiviral 
response antagonist NS1; the matrix segment encodes the matrix protein M1, the ion channel protein M2 and  
the M2-related protein M42 (which can function lly replace M2); the haemagglutinin (HA) segment encodes the 
receptor-binding glycoprotein HA; and the neuraminidase (NA) segment encodes NA (which cleaves sialic acid from cell 
surfaces). In addition, nucleoprotein (NP) and the components of the RNA-dependent RNA polymerase complex (PB1, PB2 
and PA) are expressed from their res ective genome segments. The two newly identified proteins N40 (the function of 
which is unknown93) and PA-X94, which represses cellular gene expression, are encoded by the PB1 and PA segments, 
respectively. Another two forms of PA (with amino-terminal truncations) have been found recently, named PA-N155 and 
PA-N182, which are likely to have important functions in the replication cycle of influenza A viruses5. In addition, some 
viruses express the pro-apoptotic protein PB1-F2, which is encoded by a second ORF in the PB1 segment. b | Virus 
infection is initiated by binding of the virus to sialylated host cell-surface receptors, and entry is mediated by endocytosis. 
In the host cell, fusion of viral and endosomal membranes occurs at low pH, which enables the release of the segmented 
viral genome into the cytoplasm. The viral genome is subsequently translocated to the nucleus, where it is transcribed and 
replicated. Following synthesis in the cytoplasm, viral proteins are assembled into viral ribonucleoproteins (vRNPs) in the 
nucleus. Export of vRNPs to the cytoplasm is mediated by M1 and NS2. Virus particles are assembled at the cell membrane, 
and the newly generated progeny virus buds into extracellular fluid. 
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A type II integral membrane 
glycoprotein that facilitates 
virus release from cells by 
removing sialic acid from sialyl-
oligosaccharides on the cell 
and viral surfaces. It is also a 
target of the protective 
immune response.
Antigenic drift
A process by which circulating 
influenza viruses are constantly 
changing, which allows the 
virus to cause annual 
epidemics of illness. Antigenic 
drift occurs when mutations 
accumulate in the 
haemagglutinin and 
neuraminidase genes that alter 
the antigenicity of these 
proteins such that the ‘drifted’ 
strains are no longer 
neutralized by antibodies that 
were specific for previously 
circulating strains.
Antigenic shift
A process by which a 
new influenza A virus 
haemagglutinin subtype (with 
or without an accompanying 
new neuraminidase subtype) is 
introduced into the human 
population, which lacks prior 
experience of and immunity to 
the subtype. Antigenic shift can 
occur as a result of the direct 
introduction of an influenza 
virus from an animal or avian 
host into humans or by the 
exchange or reassortment of 
gene segments between 
human and non-human 
influenza viruses when they 
co-infect animals or humans.
Matrix protein
The most abundant structural 
protein of influenza virus, which 
li s beneath the virus envelope.
Nucleoprotein
Encapsidates viral genomic 
RNA and forms a 
ribonucleoprote n complex in 
association with viral 
polymerase proteins.
Aquatic birds do not usually show signs of disease 
when infected with avian influenza viruses7, but infec-
tions of domestic poultry can be associated with disease. 
In addition to ir division into subtypes on the basis of 
genetic and antigenic differences, avian influenza viruses 
can also be divided into two groups on the basis of their 
ability to cause severe disease in chickens — namely, 
HPAI viruses and low-pathogenicity avian influenza 
(LPAI) viruses. HPAI viruses are restricted to the HA 
glycoprotein subtypes H5 and H7 and cause systemic 
infection, which can result in 100% mortality within a 
flock. Specific NA subtypes have not been associated 
with the pathogenicity of HPAI viruses. LPAI viruses, 
which include viruses of all HA subtypes, cause milder 
infection and do not usually cause mortality7. 
The molecular basis of the difference in pathogenicity 
between HPAI and LPAI viruses is mainly attributed to 
the cleavability of the precursor HA glycoprotein HA0 
into HA1 and HA2 subunits. Cleavage of HA0 generates 
the carboxyl terminus of HA1 and the amino terminus of 
HA2, the latter being necessary for membrane fusion and 
for virus infectivity8 (FIG. 1b). The HA0 glycoproteins of 
LPAI viruses and human influenza viruses are cleaved at 
a conserved arginine residue by trypsin-like proteases9. 
Therefore, infection with these viruses is restricted to 
tissues in which trypsin and trypsin-like proteases are 
present: the respiratory tract of humans and the intesti-
nal tract of birds. By contrast, the HA0 glycoproteins of 
HPAI viruses are highly cleavable; they can have multiple 
basic amino acids at the cleavage site9 that can be cleaved 
by ubiquitous intracellular proteases, such as furins10, 
or by non-trypsin-like extracellular proteases. The HA0 
glycoprotein can also have additional glycosylation 
sites11 that are associated with virulence. Because the 
HA0 glycoproteins of HPAI viruses are easily cleaved 
in extrapulmonary sites, these viruses can replicate in 
extrapulmonary organs, including the brain, causing 
fatal disease and death of the infected birds7. However, 
the significance of the highly cleavable HA0 glycoprotein 
as a virulence determinant in human infections with 
HPAI viruses is not known. HPAI viruses are believed 
to emerge as a result of mutations that occur after LPAI 
viruses move into domestic poultry12. This has prompted 
the establishment of agricultural controls for LPAI virus 
H5 nd H7 subtype infection  in poultry in an effort to 
prevent the emergence of HPAI viruses13,14.
HA glycoproteins bind to sialic-acid residues with 
terminal oligosaccharides on the host cell surface. An 
important difference between avian influenza viruses 
and human influenza viruses is their preference for 
specific sialic-acid linkages. Most avian influenza 
viruses preferentially bind to sialic acids that are linked 
to galactose with α-2,3 linkages, whereas human influ-
enza viruses preferentially bind to sialic acids with 
α-2,6 linkages15–17. NA glycoproteins cleave sialic-acid 
residues from the surface of the infected cell to release 
progeny virions from that cell, thereby facilitating virus 
dissemination3.
The tra smission of avian influenza viruses to 
humans was thought to occur rarely because of the host-
range restric ion of the viruses. The observation that the 
1957 H2N2 an  1968 H3N2 viruses that caused human 
pandemics were reassortant viruses, with gene segments 
derived from both avian and hu an influenza A viruses, 
indicated that the transmission of avian influenza 
viruses to humans might require reassortment between 
a human and avian influenza virus. Reassortment was 
proposed to occur in an intermediate host, such as the 
pig, which has both α-2,3-linked and α-2,6-linked 
Figure 1 | Schematic of an influenza A virus. a | The 
influenza A virus particle has a lipid envelope that is 
derived from the host cell membrane. Three envelope 
proteins — haemagglutinin (HA), neuraminidase (NA) 
and an ion channel protein (matrix protein 2, M2) — are 
embedded in the lipid bilayer of the viral envelope. HA (rod 
shaped) and NA (mushroom shaped) are the main surface 
glycoproteins of influenza A viruses. The ratio of HA to NA 
molecules in the viral envelope usually ranges from 4:1 
to 5:1. b | The HA glycoprotein is synthesized as an HA0 
molecule that is post-translationally cleaved into HA1 and 
HA2 subunits; this cleavage is essential for virus infectivity. 
The HA glycoprotein is responsible for binding of the virus 
to sialic-acid residues on the host cell surface and for fusion 
of the viral envelope with the endosomal membrane during 
virus uncoating. The NA glycoprotein cleaves sialic-acid 
receptors from the cell membrane and thereby releases 
new virions from the cell surface. M2 functions as a pH-
activated ion channel that enables acidification of the 
interior of the virion, leading to uncoating of the virion. 
Matrix protein 1 (M1), which is the most abundant protein 
in the virion, und rlies the viral e velop  and associates 
with the ribonucleopro ein (RNP) complex. Inside the M1 
inner layer are eight single-stranded RNA molecules of 
negative sense that are encapsidated with nucleoprotein 
(NP) and associated with three RNA polymerase proteins — 
polymerase basic protein 1 (PB1), PB2 and polymerase 
acidic protein (PA) — to form the RNP complex. The PB1, 
PB2 and PA proteins are responsible for the transcription 
and re lication of viral RNA. The virus also encodes a non-
structural protein (NS) that is expressed in infected cells 
and a nuclear export protein (NEP). The location of NEP in 
the virion is not known.
R E V I E W S
268 | APRIL 2007 | VOLUME 7  www.nature.com/reviews/immunol
3 
Influenza viruses are classified into 4 types; A, B, C and D based on PB1 sequences [4]. 
Influenza A and B viruses are responsible for seasonal epidemics, causing human disease of 
any concern, while influenza C viruses causes sporadic mild illness in humans. Influenza D 
viruses affect cattle and are not known to infect or cause illness in people. Only influenza A 
viruses (IAV) are known to have caused pandemics [4]. IAVs are further classified into 
subtypes based on HA and NA glycoproteins [1], for example H1N1 and H3N2. To date, 18 HA 
and 11 NA have been identified, resulting in the large diversity of the virus. IAVs can also be 
classified into 2 groups based on the HA phylogeny; HA group 1 (H1, H2, H5, H6, H8, H9, 
H11, H12, H13, H16, H17, H18) and HA group 2 (H3, H4, H7, H10, H14, H15). Influenza B 
viruses (IBV) are classified into two antigenically distinct lineages; Victoria and Yamagata [5]–
[7] (Figure 1.2). IAVs have a variety of hosts ranged from mammals to avian e.g. swine, cattle, 
equines, humans, bats, chickens and the most important one; wild waterfowl which host almost 
all IAV subtypes. Although each virus subtype is likely to have a restricted host, some could 
have multiple hosts. For example, H1, H2 and H3 virus strains could infect fowl, swine and 
humans. In contrast to IAVs, IBVs have limited host ranges only in humans and seals [8].  
 
Figure 1.2   Phylogenetic tree of influenza viruses 
Influenza viruses are classified into 4 types; A, B, C and D based on PB1 sequences. Influenza A viruses 
are further classified into 2 groups based on HA phylogeny and influenza B viruses are also separated 
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Influenza virus infects humans by recognising sialic acid on host cell surfaces and facilitating 
its HA spike to bind. Sialic acid is normally found at the terminal of glycoconjugates, which are 
ubiquitous on many cell types [1]. Human influenza subtypes (H1, H3) target α-2, 6 linkage of 
sialic acid molecules, which are commonly found on tracheal epithelial cells. In contrast, avian 
influenza viruses (e.g. H5), causing zoonotic infection bind to α-2, 3 linkage of sialic acid 
molecules in lungs, causing higher pathology and more severe symptoms [10]. Following the 
attachment via binding globular head of HA to sialic acid, the virus is endocytosed into host cell 
cytoplasm. At this stage, M2 proteins, transmembrane ion channels, pump hydrogen ions from 
the endosome into the virus particle. The low pH then triggers the conformational change of 
HA, where fusion peptide on the stalk of HA mediates the merging of virus membrane and 
endosomal membrane in order to release vRNP. The synthesis of viral RNA segments occurs 
in nucleus, which they are later exported via nucleoporins to cell cytoplasm after the interaction 
of M1 protein with vRNP-NEP complex. Viral proteins; HA, NA and M2 are synthesised from 
viral mRNA in endoplasmic reticulum and post-translationally modified in the Golgi apparatus 
of the cell cytoplasm. Cleavage of the HA0 into HA1 and HA2 by cellular proteases is required 
for viral infectivity. They are subsequently located to the cell plasma membrane for virus 
assembly, where HA continues to bind sialic acid at the cell membrane and M1 accumulates at 
the lipid bilayer of the cell membrane together with a pack of eight segmented-RNA 
complexes. Finally, NA cleaves the terminal sialic residues from cell-surface glycoproteins to 
release progeny virus [1] (Figure 1.3). 
Due to the nature of RNA viruses, the error-prone RNA-dependent RNA polymerases enable 
the virus to undergo antigenic drift, where some amino acids of viral proteins including HA 
are mutated causing seasonal epidemics. Regarding their segmented genomes, it also 
enables the virus to undergo antigenic shift, where segmented genomes from different 
subtypes are reassembled, generating a novel virus strain, which could cause pandemic 
outbreak. This phenomenon is mainly observed among IAVs, when 2 or more virus subtypes 
co-infect in the same host [1]. For instance, pandemic H1N1 in 2009 is a swine origin, 
resulting from the reassortment of a triple reassortant (from human H3N2, North American 
avian and classical swine viruses) swine virus and a Eurasian avian-like swine virus [11]. 
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Figure 1.3   Life cycle of influenza virus 
Influenza virus infects the host by facilitating its haemagglutinin (HA) to bind either α 2,3 or α 2,6 –
linked sialic acid on host cells. The virus is endocytosed into the cell cytosol before becoming uncoated 
to release viral ribonucleoprotein (vRNP). The viral RNA is replicated in the cell nucleus before being 
exported to the cytosol, while viral proteins are synthesised from mRNA in the cell cytoplasm. All virus 
components are assembled at the cell membrane, where  progeny viruses are released [2]. 
Influenza viruses cause respiratory disease, which is easily transmitted between humans by 
inhalation of virus-containing aerosols produced by sneezing or coughing. Every year, 
seasonal IAV epidemics cause 3-5 million cases of severe infection and up to 500,000 
deaths around the world [12]. The viruses can infect all age groups and the infection rate 
could be as high as 40% in young children. Children under 2 years old, pregnant women and 
those who have underlying medical conditions are particularly at risk of hospitalisation. 
Moreover, mortality rate increases in the elderly over 65 years of age and immuno- 
compromised people [12]. Influenza pandemics on the other hand cause the higher rate of 
mortality and morbidity in humans due to the lack of memory immune responses to the new 
emerging viruses. The virus can infect people easily and rapidly spread from person to 
person. This has been shown during the outbreak by 1918 H1N1, 1957 H2N2, 1968 H3N2 
and the recent one 2009 pdmH1N1 (Figure 1.4) [13].  
of the avian influenza virus mainly occurs in the LRT in 
humans, which explains why avian viruses occasionally 
infect humans.
HA glycoprotein. HA is the most abundant protein on 
the surface of the virion, and it mediates binding to the 
host receptor and fusion between the viral and host 
endosomal membranes. In addition, it is the primary tar-
get of neutralizing antibodies directed against the differ-
ent viral subtypes. The HA precursor polypeptide (HA0) 
is a type 1 transmembrane glycoprotein of about 550 
amino acids, with an amino-terminal signal sequence, a 
transmembrane domain n a  the carboxyl terminus and 
a short cytoplasmic tail. The HA0 precursor is activated 
by proteolytic cleavage into two disulphide-linked poly-
peptides, HA1 and HA2. Three monomers of HA1–HA2 
form the mature 220 kDa homotrimeric HA protein.
The X-ray crystal structure of the HA ectodomain was 
first reported in 1981 (REF. 27). The HA trimer projects 
approximately 135 Å from the viral membrane and can be 
divided into two domains: the membrane-distal globu-
lar domain and the membrane-proximal stem domain 
(FIG. 2a). The receptor-binding site forms a shallow pocket 
at the tip of the globular domain and comprises three 
secondary structural eleme ts and one base element6. 
The three secondary elements, namely the 130-loop, the 
190-helix and the 220-loop (the numbers correspond to 
the amino acids in the H3 subtype), form the edges of the 
receptor-binding site, and four highly conserved residues 
(Y98, W153, H183 and Y195, of the H3 subtype) form 
the base. The SA moiety of the receptor typically forms 
several conserved hydrogen bonds with the 130-loop and 
the base residue Y98, and the remaining glycan moieties 
interact with the 220-loop or the 190-helix. In addition, 
the residues W153, H183 and Y195 contribute to receptor 
binding via van der Waals interactions.
The avian α2,3-linked SA receptor typically has an 
extended configuration in the HA-bound state, and the 
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Figure 1 | Structure and life cycle of influenza A viruses. a | Influenza A viruses are enveloped, single-stranded, 
negative-sense RNA viruses that contain eight gene segments that encode 16 proteins (although not all influenza viruses 
express all 16 proteins). The non-structural segment encodes the nuclear export protein NS2 and the host antiviral 
response antagonist NS1; the matrix segment encodes the matrix protein M1, the ion channel protein M2 and  
the M2-related protein M42 (which can functionally replace M2); the haemagglutinin (HA) segment encodes the 
receptor-binding glycoprotein HA; and the neuraminidase (NA) segment encodes NA (which cleaves sialic acid from cell 
surfaces). In addition, nuc oprotein (NP) and the components of the RNA-depend nt RNA polymerase complex (PB1, PB2 
and PA) are expressed from their respective genome segments. The two newly identified proteins N40 (the function of 
which is unknown93) and PA-X94, which represses cellular gene expression, are encoded by the PB1 and PA segments, 
respectively. Another two forms of PA (with amino-terminal truncations) have been found recently, named PA-N155 and 
PA-N182, which are likely to have important functions in the replication cycle of influenza A viruses5. In addition, some 
viruses express the pro-apoptotic protein PB1-F2, which is encoded by a second ORF in the PB1 segment. b | Virus 
infection is initiated by binding of the virus to sialylated host cell-surface receptors, and entry is mediated by endocytosis. 
In the host cell, fusion of viral and endosomal membranes occurs at low pH, which enables the release of the segmented 
viral genome into the cytoplasm. The viral genome is subsequently translocated to the nucleus, where it is transcribed and 
replicated. Following synthesis in the cytoplasm, viral proteins are assembled into viral ribonucleoproteins (vRNPs) in the 
nucleus. Export of vRNPs to the cytoplasm is mediated by M1 and NS2. Virus particles are assembled at the cell membrane, 
and the newly generated progeny virus buds into extracellular fluid. 
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Figure 1.4   Recent influenza pandemics and their impact  
The timeline shows recent influenza pandemic outbreaks in 1918, 1957, 1968 and 2009. The 
estimated number of deaths worldwide and the target group with the high mortality rate are shown [13].  
1.2. Immune responses to influenza virus infection 
Influenza virus infection induces innate and adaptive immune responses. While innate 
immunity provides early non-specific response to virus infection, adaptive immunity is 
generated later and offers a more efficient and specific response (Figure 1.5).  
 
Figure 1.5   Immune responses to influenza infection 
Influenza virus infection induces both innate and adaptive immune responses. Innate immunity 
involves mucus and collectins at the mucosal surface and innate immune cell response from 
macrophages, natural killer (NK) cells and dendritic cells (DC). DCs present virus antigens to T and B 
cells to trigger adaptive immunity, leading to the proliferation of antigen-specific T cells and the 









Death:  up to 0.5 million 
< 65 years of ages 
Death: 40-50 million 
All age groups 
(including healthy adults) 
Death: 1-2 million 
≥ 65 years of ages 
Death: 0.5-2 million 
≥ 65 years of age  
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Fig. 1. Immunity during influenza virus infection. The innate immune system forms the first line of defence against influenza infection. It consists of plethora of components,
such  as mucus, collectins and acute phase proteins, which aim to prevent infection of respiratory epithelial cells. Therefore, rapid innate immune cells like macrophages,
dendritic cells, natural killer and !" T cells are recruited with the objective of controlling and blocking virus replication and dissemination and to orchestrate the immune
response. These cells secrete different types of chemical mediators such as cytokines that will activate the T cells and induces their differentiation or elicit an adaptive
response with the production of specific IV-antibodies responses. This figure is mainly based on human and murine studies.
Similar results in M# culture supernatant from M# infected
with swIV H1N2 were shown by Kim et al. (2009). Significant
differences in TNF-! concentration between swIV-infected and
uninfected alveolar M# were detected at different h pi, with a peak
at 36 h pi. These results suggested that TNF-! may  be an impor-
tant mediator in the pathophysiology of swIV infection (Kim et al.,
2009).
Another in vitro study used 3D/4 cells, a spontaneoulsy-
transformed line of swine M# (ATCC), infected with a pandemic
H1N1 virus (Table 1) (Gao et al., 2012). This report demonstrated
that A (H1N1)pdm/2009 retains the ability to infect and replicate
in swine M#, inducing a typical cytopathic effect (16 h pi) and
destroying the cell monolayer (32 h pi). This study also examined
the pattern of cytokine responses in pH1N1-infected swine M# by
real time RT-PCR. IL-6 and IL-8 levels were up-regulated at 16 h
and level of IL-8 continued to rise up at 36 h pi. Robust induction of
antiviral IFN-" and TNF family members, which may  be attributable
to cell death, was  observed. FasL and TNF-! remained undetectable,
while the TNF-related apoptosis-inducing ligand (TRAIL) seemed
to be the most abundant one before infection. FasL and TNF-!
were induced most robustly, but TRAIL was only mildly induced
in response to infection. The level of IL-1" remained unchanged
throughout the infection (different from Barbe et al., 2011; Van
Reeth, 2000), indicating that IL-6 and IL-8, as well as TNF-! were
the main pro-inflammatory cytokines up-regulated. The authors
also observed the induction of RIG-1 and MDA-5, which appeared
to be suppressed completely by inhibitors of ERK1/2 or JNK1/2. This
indicated that the induction of RIG-1 or MDA-5 depends on the
activation of ERK1/2 and JNK1/2 in pig M# (Gao et al., 2012).
2.2.3. Dendritic cells
Conventional dendritic cells (cDCs), situated underneath the air-
way epithelium barrier and above the basal membrane, monitor
the airway lumen via their dendrites that are extended through the
tight junctions between the airway epithelial cells (Kreijtz et al.,
2011). cDCs can detect and opsonise (neutralize) virions and apop-
totic bodies from infected cells and can also be infected themselves.
Upon entry of the virion into the cells, the cDCs migrate via the
afferent lymphatic system to the draining lymph node. Here they
present the IV derived antigen through the MHC to T cells and
activate them (GeurtsvanKessel and Lambr cht, 2008). Among the
various other activities of DCs in IV infection, they can also exert
cytolytic activity and contribute to the formation of bronchus asso-
ciated lymphoid tissue (BALT) (GeurtsvanKessel and Lambrecht,
2008; Kreijtz et al., 2011). Although DCs have an important role
during IV infection, few studies have investigated the interaction
between IV and porcine DCs.
Our group described for the first time the interaction between
porcine bone marrow-derived DCs (poBMDCs) (cDCs) and swIV
H3N2 (Table 1) in vitro. Infection of poBMDCs resulted in struc-
ture resembling IV inside vesicles and also free in the cytoplasm
of the cells. Viral progeny was undetectable in the supernatant but
limited replication was  detected in the first 8 h pi. However, viral
particles from infected-poBMDCs were able to induce cytopathic
effect in susceptible cells only when cell-to-cell interaction was
favored (Mussá et al., 2011). Additionally Mussá et al. (accepted for
publication), observed that similarly to the swIV H3N2, porcine DCs
also supported a limited replication of other IVs (Table 1) during
the first 8 h pi, without release of infectious progeny. These viruses
also similarly modulated the expression of NF-#B, TGF-" and IL-
10 genes. However, they induced different kinetics and levels of
inflammatory cytokines. Infection of poBMDCs with swIV induced
a peak of IFN-! secretion at 24 h pi, whereas with the others the
production of IFN-! was not detected. SwIV and HPAI induced more
TNF-! compared to huIV and LPAI. SwIV, LPAI and HPAI induced an
increase of IL-12 from 16 to 24 h pi and all viruses used induced
IL-18 secretion in a time-dependent manner.
Summerfield’s group also used GM-CSF derived DCs and other
avian and porcine IVs (Table 1). They also generated recombinant
reassortants by reverse genetics to elucidate the role of the sin-
gle gene segments in the activation of cDCs. The highest IFN type I
responses were achieved by the porcine virus reassortant contain-
ing the avian polymerase gene PB2. This finding was not due to
the differential tropism since all viruses infected DCs  equally (and
also porcine PK-15 epithelial cells) and infectivity was independent
of the HA expressed by the virus. All viruses induced MHC-II, but
porcine H1N1 expressing the avian viral PB2 induced more promi-
nent nuclear NF-kB translocation compared to its parent virus.
Innate Immunity Adaptive Immunity 
Prevention of 









1.2.1. Innate immunity 
The innate immune system is the first defence mechanism to prevent the virus infection and 
to control the virus replication. Mucus and collectins (as antiviral agents) at the mucosal 
surface prevent virus infection of epithelial cells [14]. Influenza virus infection is sensed via 
pattern-recognition receptors (PRR) that recognise other virus-infected cells or different 
forms of viral RNA presented in infected cells. The PRRs are toll-like receptors (TLR), 
retinoic acid inducible gene-I (RIG-I) and the NOD-like receptor family pyrin domain 
containing 3 (NLRP3) proteins. Viral recognition by TLRs and RIG-I signals the production of 
proinflammatory cytokines and type I interferons. The strong antiviral activity of type I 
interferons inhibits the protein synthesis of host cells, limiting virus replication. Moreover, 
type I interferons induce interferon-stimulating genes (ISG), which also stimulate dendritic 
cells (DC), enhancing the viral antigen presentation to CD4+ and CD8+ T cells. NLPR3 as 
part of the inflammasome is activated by virus infection and M2 activity then converts pro-IL-
1β into IL-1β, which induces Th17 differentiation and expands the antigen-specific CD4+ T 
cells [16] (Figure 1.6).  
Virus spreading could be limited by the clearance of virus-infected cells via alveolar 
macrophage-mediated phagocytosis as well as via cell lysis by natural killer (NK) cells upon 
the recognition of antibody-bound virus infected cells. Importantly, innate immune cells such 
as professional antigen-presenting cells including DCs, also process and present viral 
antigens by MHC class I or class II molecules to either CD8+ or CD4+ T cells to trigger the 
adaptive immune responses [17], [15]. 
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Figure 1.6   Recognition of influenza virus infection by pattern-recognition receptors 
and their responses 
Influenza virus and influenza virus-infected cells are sensed via pattern-recognition receptors (PRR); 
TLRs, RIG-I, NOD2 and NLRP3 that recognise other virus-infected cells or different forms of viral RNA 
e.g. single-stranded RNA (ssRNA), double-stranded RNA (dsRNA) or virus proteins e.g. M2. Activation 
of these PRRs leads to the induction of interferon-stimulating genes (ISG) and the production of pro-




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.2.2. Adaptive immunity 
The adaptive immune system is the second line of protection, which consists of humoral and 
cellular immunity mediated by virus-specific antibody and T cells, respectively. Both mucosal 
and systemic immune responses are associated with the protection against subsequent 
influenza virus infection. 
1.2.2.1. Antibody-mediated immunity 
Influenza virus infection induces virus-specific antibody response particularly towards two 
viral glycoproteins; HA and NA. Neutralising HA-specific antibodies are considered the most 
important due to the induction of sterile immunity preventing infection. The antibodies are 
predominantly directed to the globular HA head due to its immunodominance. Binding to the 
virus, they inhibit virus attachment and entry into host cells, leading to the prevention of virus 
infection [15], [18]. Subdominant antibodies towards the conserved HA stalk are also elicited, 
but at relatively lower amount [19]. However, HA stalk-specific antibodies react to a wider 
range of influenza viruses compared to HA head-specific ones, therefore may provide cross-
reactive protection [20], [21].  
Following virus infection, antibodies to other viral proteins such as NA and M2 can be also 
induced [15]. Anti-NA antibodies inhibit enzymatic activity of NA, resulting in limiting virus 
release. Although NP is a target for T cell responses, NP-specific antibodies may also 
contribute to the protection against influenza. These antibodies are generally considered 
non-neutralising and most likely to act via antibody-dependent cell lysis or complement-
dependent cytotoxicity to confer protective potential [15], [18].  
IgA, IgM and IgG are the main antibody isotypes elicited in response to virus infection. 
Secretory IgA antibodies (SIgA) are produced locally and transported to mucosal surfaces 
via poly Ig receptors on epithelial cell membranes. Serum IgA is rapidly produced after virus 
infection, while IgM antibodies are the hallmark of response to primary infection. Serum IgG 
antibodies are predominantly produced and can be diffused to respiratory mucosa, providing 
long-lived protection for subsequent influenza infection [15]. 
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1.2.2.2. Cell-mediated immunity 
Upon influenza virus infection, CD4+ and CD8+ T cells are activated by the recognition of 
viral antigens presented on either MHC class I or class II together with costimulatory signals. 
The majority of CD4+ T cells have T helper properties. Th1 cells produce IL-2 and IFN-γ, 
which promote cytotoxic CD8+ T cell (CTL) responses, whereas Th2 cells secrete IL-4 and 
IL-10 that are involved in helping B cell responses. Th17 and Treg cells regulate the cellular 
immune responses during virus infection. CTLs play an important role in elimination of virus-
infected cells, thus reducing virus shedding. Antigen-specific CD8+ T cells are found in 
lymphoid tissues and in the circulation post infection. These memory CD8+ T cells can 
rapidly respond to subsequent influenza infection. In humans, CD8+ T cells induced by 
influenza viruses are mainly directed to internal viral proteins such as NP, M1 and PB. 
Owing to the highly conserved nature of these viral antigens, antigen-specific CD8+ T cells 
could recognise diverse influenza strains and provide cross-reactive protection [15]. 
1.3. Current influenza vaccines 
Vaccination is the most effective tool to prevent and control influenza infection [22]. The 
vaccines aim to induce adaptive immunity, providing protection against infection and disease 
and to induce herd immunity to restrict virus transmission within the population [22]. The 
current vaccines are composed of three or four virus vaccine strains; two IAVs (H1 and H3 
subtypes) with one or two IBVs (Yamagata and/ or Victoria lineages). The vaccine strains 
are annually predicted by the World Health Organization (WHO) based on the 
epidemiological data of predominantly circulating strains in either northern or southern 
hemispheres [23]. Annual immunisation with seasonal influenza vaccines is recommended 
for target groups, which are children, elderly, pregnant women, and those having any 
underlying medical conditions such as asthma, chronic lung disease and heart disease, who 
are at risk of developing influenza-related complications [24]. Two types of seasonal 
influenza vaccines are commercially available; inactivated and live attenuated vaccines. 
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1.3.1. Inactivated influenza vaccines 
Inactivated influenza vaccines (IIV) are available in different formulas ranging from whole 
virus to split virus and subunit vaccines. The vaccines are made of purified chemicals/ 
detergent-killed influenza viruses. While the subunit vaccine is composed of only purified HA 
and NA of influenza, the split one consists of other viral proteins and subviral elements such 
as M1 and NP. Inactivated-whole virus vaccines are mostly replaced by split and subunit 
ones, which provide comparable degrees of immunogenicity but less reactogenicity [22]. 
After intramuscular administration, IIVs predominantly induce serum IgG antibodies towards 
globular HA, showing positive haemagglutination inhibition (HAI), which indicates strain-
specificity. 90% of vaccinees showed protective antibody titres within 2 weeks post 
vaccination. Nevertheless, the antibodies rapidly wane to 2-fold lower at 6 months after 
immunisation [25]. The vaccine effectiveness is approximately 60% in adults aged 18-65 
years [26], but may reduce in young (immune-naïve) and elderly (immunosenescence) and 
in years of poor antigenic match [27]. IIVs are recommended for young children at 6-24 
months and older children including adults 18 years of age or older and are also advised for 
at risk groups e.g. pregnant women and immunocompromised people. Recently, MF59C.1 
adjuvanted IIVs are licensed and given in elderly 65 years of age or older to achieve 
protective responses [28]. 
1.3.2. Live attenuated influenza vaccines 
Live attenuated influenza vaccines (LAIV) are the more recently developed vaccines to 
mimic the natural influenza infection. The virus vaccine strains are developed by 
subpassaging in embryonated chicken eggs under suboptimal conditions so that they are 
able to only grow at restricted temperature between 25°C (cold-adapted, ca) and 35°C 
(temperature sensitive, ts). Consequently, the virus infects and replicates only at the mucosa 
of the upper respiratory tract, not in the lungs after intranasal administration [29]. LAIVs also 
elicit serum IgG antibodies, but at a lower magnitude than IIVs. In comparison to IIVs, LAIVs 
induce stronger mucosal IgA antibodies and CTL response, which may provide broader 
immunity against circulating virus strains. SIgA antibody in nasal washes of vaccinated 
children may persist for at least 1 year [25]. Efficacy of LAIVs is approximately 80% in young 
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children aged 6 months to 7 years [26]. However, LAIVs are unlikely to boost T cell 
responses in adults, which may be due to the abrogation of vaccine efficacy by pre-existing 
antibodies that could neutralise influenza vaccine strains after administration [30]. The 
vaccines thus are recommended in children from 2-18 years old in European countries. 
Table 1.1   Comparison of the immune response to inactivated influenza and live 
attenuated influenza vaccines [27] 




HA-specific antibody   
HAI response +++ + 
Antibody secreting cells ++ + 
Memory B cells + + 
Nasal IgA -/+ +++ 
NA-specific antibody -/+ ++ 
CD4+ T cells ++ ++++ 
CD8+ T cells - +? 
Cross protective immunity -/+ ++ 
1.3.3. Limits of current influenza vaccines 
IIVs mainly induce systemic antibody-mediated immune responses, whereas LAIVs have 
superior advantage in the induction of mucosal immunity and T cell response [27] (Table 
1.1). Nevertheless, both vaccines in general provide the protection against only identical or 
closely antigenically related influenza strains. The vaccine efficacy is still considerably 
variable, which depends upon how well the vaccine strains match the circulating virus strains 
in each season.  
Various host factors including age, gender, health status, history of influenza virus infection 
and previous influenza vaccination and genetic differences in immune responsiveness could 
have impacts on the vaccine efficacy. Of them, age is likely to be of most concern [31]. Older 
adults with ages over 65 years old have shown declines in immune responses to the 
vaccines, which would result from immunosenescence [32]. This results from the decreasing 
numbers and function of the main immune cells e.g. dendritic cells, NK cells, B and T 
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lymphocytes which could result from chronic infection by Cytomegalovirus and Epstein-Barr 
virus [31].  
In addition to the compromised efficacy of the vaccines, the zoonotic infection caused by 
avian influenza viruses especially high pathogenic H5N1 in the last decade and the 
unexpected outbreak of the pandemic in 2009 raise concerns for the need of more effective 
vaccines [33]. The current efforts therefore are focused on the development of new vaccines 
conferring broad protection against a wide range of influenza subtypes including these avian 
influenza viruses and unpredictable pandemics in the future.  
1.4. Novel influenza vaccines 
Novel influenza vaccines are being developed, aiming to elicit broadly cross-reactive 
immune responses across predominant IAV subtypes with the durable protection that last at 
least 1 year in all age groups [34]. These vaccines therefore target conserved influenza 
epitopes shared across influenza virus strains and novel platforms are employed to deliver 
the vaccine antigens. 
1.4.1. Conserved protective epitopes 
1.4.1.1. Ectodomain of matrix protein 2 (M2e)  
M2 is formed as a homotetramer, situated on the virus envelope membrane and functions as 
an ion channel (Figure 1.1). The extracellular domain of M2 (M2e), a linear peptide with 23 
amino acids, becomes one of the attractive targets for antibody-based vaccine owing to its 
highly conserved nature across human IAVs. The number of M2 molecules is normally low 
on the virus envelope; however, it is abundantly expressed on the surface of virus-infected 
cells [35]. It has been reported that protective antibodies against M2e were elicited in 
animals vaccinated with different forms of M2 such as recombinant M2 proteins [36], carrier-
conjugated M2 peptides [37] and virus-like particle (VLP) or liposome expressing M2e [38].  
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1.4.1.2. The stalk region of haemagglutinin 
The structure of HA is three identical copies of the HA monomer. Each monomer (HA0) is 
composed of a globular head (HA1) and a stalk region (HA2) (Figure 1.1). The head 
contains the sialic acid receptor-binding site (RBS), which is surrounded by variable 
antigenic sites, designated Sa, Sb, Ca1, Ca2 and Cb in H1 subtype and A, B, C and D in H3 
subtypes [1] (Figure 1.7). Isolated human monoclonal antibodies directed to RBS have been 
shown to have broadly neutralising activity. However, RBS-recognising antibodies are not 
easily induced because RBS is masked by many variable regions aforementioned. The 
crystal structure shows that in order to bind RBS, heavy-chain complementarity determining 
region 3 (HCDR3) of the antibody inserts into the receptor-binding pocket which closely 
mimics the interaction of sialic acid with the receptor [39], [40].  
The stalk region of HA shows the higher level of conservancy across influenza subtypes 
than the globular region. Three protective epitopes have been identified within the HA stalk. 
The first epitope is the centre of alpha helix A. Targeting this epitope provides protection 
against both IAVs and IBVs. The other two reside in the upper part of the long alpha helix 
CD and the base of the HA stalk including the fusion peptide and the helix-capping loop, 
respectively. These two epitopes are protective across HA group 2 of IAVs [41]. The 
boosting of HA stalk-reactive antibodies has been shown by vaccination with HA-based 
vaccines, whose HA molecules are modified to different forms e.g. chimeric HA, headless 
HA and glycosylated, from which the HA head is removed or shielded [42]. 
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Figure 1.7   Structure of influenza haemagglutinin  
Haemagglutinin (HA) is composed of three identical copies of the HA monomer. Each monomer has 
two regions; head and stalk. Located in the HA head are receptor-binding site (RBS) and antigenic 
sites which are hypervariant from strain to strain. The stem (or stalk) region includes fusion peptides 
and helix proteins, which are more conserved across influenza subtypes (Adapted from [1], [43]). 
1.4.1.3. Internal viral proteins 
Internal viral proteins such as NP, M1 and PB are the targets of T cell-based vaccines, 
aiming for T cell responses particularly CTL responses. During virus infection, a large 
number of internal viral peptides are generated in virus-infected cells.  However, only a small 
fraction of them are bound and presented on MHC class I molecules of antigen-presenting 
cells (APC) to trigger CTLs. This phenomenon results from 1) the HLA haplotype and its 
binding affinity to individual epitopes, 2) the repertoire of T-cell receptors, 3) processing and 
presentation of viral peptides and 4) interaction of CTL with APC [43]. 
CD8+ T cell IAV-specific epitopes are identified across influenza proteins [44]. One of the 
most frequently recognised conserved epitope is M158-66, which is presented in individuals 
with HLA-A*0201, one of the highest prevalence HLA types [43], [45]. In people who are 
HLA-A*0201 negative, NP has been shown to be highly immunogenic and displays 70-85% 
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disulfide bridges. The three monomers are assembled into a
central ! -helical coiled-coil that forms the stem-like domain,
and three globular heads containing sialic acid-binding sites.
Each globular domain consists exclusively of HA1 folded in
highly variable loops and eight antiparallel β-strands. The
globular heads contain both the rec ptor bindi g sites and the
antigenic epitopes (11,12). NA is a tetrameric glycoprotein
(∼240 kD) consisting of a hydrophobic stalk and a globular
head that contains the enzymatic and antigenic sites (11,12).
NA cleaves sialic acid and plays an important role in
transport of the virus particles through the mucin layer lining
the respiratory tract and also mediates the release of newly
assembled virus particles (11,12).
Antigenic Drift and Shift
Antigenically altered influenza strains are constantly
formed by amino acid changes in the surface proteins, in
particular HA. RNA replication lacks proof-reading mecha-
nisms and influenza virus a e theref re unable to repair
polymerase errors that occur during RNA-replication. Within
the viral genome mutations accumulate, resulting in replace-
ment of the existing by a new antigenic variant. Mutations are
seen in each of the gene products of the virus, but are most
pronounced in the surface protein HA. As a result of these
changes new influenza strains are constantly formed, that
result in yearly arising epidemics. The mechanism of acquir-
ing new influenza strains by mutations in HA is known as
antigenic drift.
In contrast to the antigenic drift, that occurs constantly,
antigenic shift occurs at irregular intervals and is defined as
the introduction of a new influenza A subtype into the human
population. Antigenic shift may be the result of either direct
transfer of a new avian influenza virus to humans or
reassortment between a human and avian virus, possibly in
an intermediate host such as the pig (13). Aquatic birds are
the natural reservoir of all known subtypes of the influenza A
virus. These birds are highly mobile and are known to carry
viruses over great distances. In addition, they transfer viruses
to other birds via the excretion of large quantities of virus in
their faeces. While often remaining healthy these birds form a
mobile pool from which intermediate hosts can be infected
with avian influenza virus. In these intermediate hosts
reassortment between human and avian viruses may occur,
resulting in new influenza strains that can infect and/or spread
from person to person (3,14). Recently, highly pathogenic
avian influenza (HPAI) viruses have been shown to infect
humans directly (zoonotic infection) without reassortment in
an intermediate host.
Antigenic shift results in influenza pandemics which
occur once in several decades. There have been three such
pandemics in the twentieth century: in 1918, 1957, and 1968.
At this moment a new highly pathogenic influenza subtype
(H5N1) is circulating in birds. This virus has so far infected
340 humans of whom 209 died (WHO, 18 Dec. 2007). These
cases are mainly found in South-East Asia. This new HPAI
subtype, which is able to infect humans but can not (yet)
spread between humans, forms a significant risk-factor for a
new pandemic (14). It is possible that an avian influenza virus
cha ges, so that it is able to infect huma s and to easily
spread from person to person. Because such a virus has not
circulated among humans before, there is no immune
protection in the human population (15). Consequently, an
influenza pandemic may arise (16,17).
INFLUENZAVACCINES
The currently used vaccines are mainly inactivated
formulations containing at least the two viral surface antigens,
HA and NA. There are four different types of inactivated
influenza vaccines: whole inactivated influenza vaccines, split,
subunit and virosomal influenza vaccines (Fig. 3). Also a live
attenuated influenza vaccine is on the market (18–20). The
seasonal vaccines are trivalent, containing the antigens from
two subtypes of influenza A and one subtype of influenza B
as recommended by the World Health Organization (WHO).
To ensure an antigenic match with new circulating influenza
viruses, the composition of these trivalent vaccines is updated,
on the basis of WHO’s worldwide surveillance of new
influenza strains twice a year. Following vaccination with
influenza A, around 90% of normal subje ts achieve serum
haemagglutination inhibition (HI) titers higher than 40, a
level generally associated with a 50% reduced chance of
contracting influenza. Implemented criteria for vaccine im-
munogenicity are based on the induction of an adequate level
of virus-neutralizing antibodies (21).
The influenza virus for vaccine production is generally
produced by propagation of virus in embryonated hen’s eggs,
although recent developments include vaccine virus produc-
tion in cultured cells, such as Madin–Darby canine kidney
Fig. 2. The three-dimensional structure of the influenza HA. The HA
monomer (left) and trimer (right). This figure was produced by André
van Eerde (University of Groningen), using MOLSCRIPT, on basis
of the co-ordinate file from the Protein Data Bank, code 3HMG.
1258 Amorij et al.
HA trim r 
N.M. Bouvier, P. Palese / Vaccine 26S (2008) D49–D53 D51
Fig. 1. Ribbon diagram of an uncleaved hemagglutinin monomer from the 1918
influenza A virus (H1N1), the causative agent of the “Spanish flu” pandemic. The
head contains the sialic acid receptor-binding site, which is surrounded by the five
predicted antigenic sites (Sa, Sb, Ca1, Ca2, and Cb). The stem comprises helices A
and B an the fusion peptide, as shown. (Adapted from a figure, kindly provided by
James Stevens and Ian Wilson, in [1].)
gressive pneumonia m y result; this clinical etting, fatality rates
exceed 60% [24].
The crystal structure of the HA molecule is a trimer with two
struct rally distinct regions: a stem, co prising a triple-stranded
coiled-coil of !-helices, and a globular head of antiparallel "-sheet,
positioned atop the stem [25]. The head contains the sialic acid
receptor binding site, which is surrounded by the predicted variable
a tigenic determinants, designated A, B, C, and D in the H3 subtype
[26] and Sa, Sb, Ca1, Ca2, and Cb in the H1 subtype (see Fig. 1) [1].
During virus replication, the HA protein is cleaved by serine pro-
teases into HA1 and HA2; this post-translational modification is
necessary for virus infectivity. The HA2 portion is thought to medi-
ate the fusion of virus envelope with cell membranes, while the HA1
portion contains the receptor binding and antigenic sites (reviewed
in [27]). Antibodies to HA neutralize virus infectivity, so virus strains
evolve frequent amino acid changes at the antigenic sites; however,
the stem-head configuration of the HA molecul rem ins conserved
among strains and subtypes. These relatively minor changes accu-
mulate in a process called antigenic drift. Eventually, mutations in
multiple antigenic sites result in a virus strain that is no longer
effectively neutralized by host a tibodies to the parental virus, and
the host becomes susc ptible ag i to productive infection by the
drifted strain.
4.2. Virus entry
Following attachment of the influenza virus HA protein (or the
HEF protein of i fl enza C virus) to si lic acid, the virus is endo-
cytosed. The acidity of the endosomal compartment is crucial to
influenza vi us uncoating in two ways. First, low pH triggers a
conformational cha ge in the HA, expo in a fusion peptide that
mediates the merging of the viral envelope with the endosomal
membrane, thus opening a pore through which the viral RNPs are
released into the host cell cytoplasm (reviewed in [28,29]). Second,
hydrogen ions from the endosome are pumped into the virus par-
ticle via the M2 ion channel. The M2 protein, a transmembrane ion
channel found only in influenza A virus, has portions external to the
viral envelope, along with the HA and NA. The M2 protein is the tar-
get of the amantadine class of anti-influenza drugs, which block ion
channel activity and prevent virus uncoating [30,31]; also, because
it is a surface protein, it has been proposed as a vaccine compo-
nent [32,33]. Internal acidification of the influenza virion via the
M2 channel disrupts internal protein–protein interactions, allow-
ing viral RNPs to be released from the viral matrix into the cellular
cytoplasm [34].
4.3. Synthesis of viral RNA
Once liberated from the virion, RNPs are trafficked to the host
cell nucleus by means of viral proteins’ nuclear localization sig-
nals (NLSs), which direct cellular proteins to import the RNPs and
other viral proteins into the host cell nucleus (reviewed in [35]). The
nucleus is the location of all influenza virus RNA synthesis—both of
the capped, polyadenylated messenger RNA (mRNA) that acts as the
template for host-cell translation of viral proteins, and of the vRNA
segments that form the genomes of progeny virus. The viral RNA-
dependent RNA polymerase—a component of the RNPs imported
into the nucleus—uses the negative-sense vRNA as a template to
synthesize two positive-sense RNA species: mRNA templates for
viral protein synthesis, and complementary RNA (cRNA) interme-
diates from which the RNA polymerase subsequently transcribes
more copies of negative-sense, genomic vRNA.
Unlike host cell mRNA, which is polyadenylated by a specific
poly(A) polymerase, the poly(A) tail of influenza virus mRNA is
encoded in negative-sense vRNA as a stretch of five to seven uracil
residues, which the viral polymerase transcribes into the posi-
tive sense as a string of adenosines that form the poly(A) tail
[36–38]. Messenger RNA capping occurs in a similarly unique man-
ner, in which the PB1 and PB2 proteins “steal” 5′ capped primers
from host pre-mRNA transcripts to initiate viral mRNA synthe-
sis; this process is called “cap snatching” (described further in
[39]).
Once polyadenylated and capped, mRNA of viral origin can be
exported and translated like host mRNA. Nuclear export of vRNA
segments, however, is mediated by the viral proteins M1 and
NEP/NS2 [35]. M1 interacts with both vRNA and NP, and is thus
thought to bring these two components together within the RNP
complex; M1 also associates with the nuclear export protein NEP,
which mediates the M1-RNP export via nucleoporins into the cyto-
plasm.
4.4. Synthesis of viral proteins
The envelope proteins HA, NA, and M2 are synthesized,
from mRNA of viral origin, on membrane-bound ribosomes
into the endoplasmic reticulum, where they are folded
and trafficked to the Golgi apparatus for post-translational
modification. All three proteins have apical sorting sig-
nals that subsequently direct them to the cell membrane
for virion assembly. Although comparatively little is known
about the translation and sorting of the non-envelope proteins,
M1 is thought to play a role in bringing the RNP–NEP complex
into contact with the envelope-bound HA, NA, and M2 proteins for
packaging at the host cell membrane [1].
4.5. Packaging of RNA and assembly of virus
Influenza virus is not fully infectious unless its virions contain
a full genome of eight segments (or seven segments, for influenza
C virus). Previously, vRNA packaging was thought to be an entirely
random process, in which vRNA segments are haphazardly incor-

















conservancy. Five such NP peptides are HLA-A*0301-NP265-273, HLA-B*0801-NP225-233, HLA-
B*1801-NP219-226, HLA-B*2705-NP383-391 and HLA-B*5701-NP199-207 [46]. In order to protect 
people from all ethnic groups that have a diversity of HLA types, T cell-based vaccines 
should contain immunodominant epitopes restricted to those different HLA types. 80-90% 
population coverage can be achieved in most prominent ethnicities by focusing on only three 
major HLA class I supertypes (A2, A3 and B7). 100% population coverage in all major 
ethnicities could be reached when including two additional supertypes (A1 and A24) [47]. 
1.4.2. Innovative vaccine platforms 
Unlike conventional vaccines, newly developed influenza vaccines often employ advanced 
platforms to efficiently deliver vaccine antigens [48]. These innovative approaches may be 
classified into two groups based on the form of immunogens [49]. The first group includes 
DNA vaccines and vector-based vaccines delivering influenza target genes, which are 
subsequently expressed to viral proteins in target cells. Another group contains virus-like 
particles, nanoparticles and synthesised proteins/peptides, which basically are in the form of 
protein or peptide antigens that could be readily recognised by immune cells when 
introduced into the human body. 
Viral vector-based vaccines are one of the novel and promising vaccine platforms to deliver 
antigens, with a number of advantages over conventional vaccines. They are considered as 
live vaccines, but exhibit replication restriction or deficiency [50], [51]. The use of live vectors 
allows the de novo synthesis of antigenic proteins in the cytoplasm of APCs, which 
subsequently undergo antigen processing and presentation to T cells. Moreover, protein 
antigens are expressed in the native conformation, inducing potent and specific antibody. 
The vaccines therefore can be designed to elicit antibody and/or cell-mediated immune 
responses [52]. In addition, viral vector-based vaccines can be rapidly produced and 
upscaled for industrial production, which is beneficial during pandemic outbreaks [53], [54]. 
Of them, Modified Vaccinia Ankara and adenovirus vectors are lead candidates to be studied 
as novel influenza vaccines.  
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1.4.2.1. Modified Vaccinia Ankara (MVA) 
MVA is an attenuated Vaccinia Virus (VV), which belongs to the family Poxviridae and genus 
Orthopoxvirus. It is a double-stranded DNA, enveloped virus [55]. MVA has been serial-
passaged in chicken embryo fibroblast, resulting in the major deletion of genes that influence 
virus virulence and immune evasion and the highly restricted replication in avian cells [56]. 
MVA can infect mammalian cells but cannot produce new progeny virus, therefore low 
reactogenicity in humans. Moreover, MVA has an excellent safety profile as it has been 
successfully used as a vaccine to combat smallpox and has been shown to be safe even in 
immunodeficiencies [57]–[59]. MVA has other advantages as a viral vector; easy insertions 
of antigen target genes into viral genome, transient expression of recombinant antigens [60] 
and induction of both humoral and cellular immune responses in animals and humans [61], 
[62]. Due to the loss of immune evasion, MVA itself has an adjuvant-like effect due to the 
influx of various immune cells [63]–[66]. Importantly, anti-MVA vector antibody is unlikely to 
abrogate the vaccine efficacy, which allow the vaccine to be used for boosting memory 
responses [67].  
1.4.2.2. Adenovirus  
Adenovirus is a double-stranded DNA, icosahedral, non-enveloped virus and belongs to the 
family Adenoviridae. It has been initially used in gene therapy. To construct adenovirus as a 
viral vector, E1 and/or E3 unit of the viral genome are deleted and replaced with genes of 
antigens of interest. Deletion of E1 and E3 units results in deficient viral replication and loss 
of immune evasion, respectively. Therefore, recombinant adenovirus (rAd) can infect and 
replicate in target cells, but cannot release new virions. rAd has many advantages as a viral 
vector. The genes of antigens of interest could be easily and stably inserted into viral 
genomes. The virus has high tropism with a wide range of susceptible hosts, tissues and cell 
types, so they induce immune responses after local or parenteral administration. Moreover, 
they could also be produced at high titres [68].  
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Human and simian adenoviruses are in the same genus, Mastadenovirus and are classified 
into 6 serotypes; A-F based on their hexon (capsid protein) sequences [69] (Figure 1.8). 
Human adenovirus type-5 (hAd5) is one of the adenoviral vectors in species C, widely 
constructed as viral vector-based vaccines against a number of pathogens including human 
immunodeficiency virus (HIV), dengue viruses, ebola viruses and influenza viruses [70]. 
Although the vaccines are safe and immunogenic, their efficacy is interfered with by pre-
existing antibodies to adenoviral vectors, which could be induced by natural infection or 
previous adenoviral-based vaccination [68]. To avoid anti-vector antibodies, hAd5 is 
replaced by other low prevalence human adenovirus species (e.g. species B; Ad35 and 
species D; Ad26, Ad28, Ad48) and also by those isolated from chimpanzee (ChAd) or 
bonobo (PanAd) [69].  
MVA and rAd-vectored influenza vaccine candidates have been constructed with various 
influenza target genes of antigens such as NP, M1 and conserved HA. They showed 
protective responses in animal models and some have shown protection in humans, which 




Figure 1.8   Phylogenetic tree of adenoviruses 
Adenoviruses isolated from human (hAd), chimpanzee (ChAd) and bonobo (PanAd) are classified into 





neutralize the infectivity of ChAd vectors encoding secreted alkaline
phosphatase (ChAd-SEAP) in human embryonic kidney (HEK) 293
cells. It has been previously shown that anti-adenovirus nAb titers of
more than 200 measured by this same neutralization assay can dampen
the immunogenicity of the vector in humans (11). Thirty-eight percent
and 22% of the human sera displayed a titer of more than 200 against
Ad5 and Ad6, respectively, whereas none of the sera showed titers of
200 against half of the ChAds, and less than 10% of the tested sera had
titers of more than 200 against the remaining half of ChAds (Fig. 5A).
By in vivo preimmunization studies in mice with high doses of
Ad5 and ChAds belonging to different species (subgroup C: ChAd3;
subgroup E: ChAd7 and ChAd63; subgroup B: ChAd30), we found
that only preinjection with the homologous virus prevented the induc-
tion of a T cell response after administra-
tion of Ad5-gag or ChAd-gag vectors
(Fig. 5B). These results confirmed that
the sequence analysis of hypervariable re-
gions in the hexon protein can predict an-
tibody cross-neutralization and that the
different ChAd genotypes that we have
identified represent individual serotypes.
ChAd3 induces long-lasting
T and B cell memory responses
To verify the ability of ChAds to induce long-
lasting responses, we immunized C57BL/6
micewith 108 vp of ChAd3 (ChAd3-NSmut)
expressing the nonstructural (NS) region
from hepatitis C virus (HCV) (20).
Sixteen weeks after immunization, antigen-
specific cellular immunity was still very
high and only about twofold lower than
that measured at 3 weeks [1630 versus
3244 IFN-g spot-forming cells (SFCs) per
million splenocytes, respectively; fig. S3].
Consistently, high levels of antigen-specific
IFN-g+ CD8 T cells were detected at week
16 (1.67 to 8.1%; fig. S3).
The longevity of the T cell response
induced by ChAd3 was then tested in NHPs.
Potent cellular immunity was induced upon
priming of macaques with a single dose
of 1010 vp of ChAd3-gag [group mean
average of 1128 IFN-g SFCs per million
peripheral bloodmononuclear cells (PBMCs)],
which then contracted but persisted for
more than 5 years (group mean of 392 IFN-g
SFCs per million PBMCs at week 274;
Fig. 6A).
We then tested if the long-lasting T cell
pool induced by ChAd3-gag could be ex-
panded in vivo upon reencounter of the
same antigen. ChAd3-gag–primed animals
were boosted with 1010 vp of the heter-
ologous PanAd3-gag vector at week 299.
All animals experienced a rapid expan-
sion of gag-specific IFN-g–secreting T cells
with a peak about threefold higher than
that observed after priming (mean of 2661 IFN-g SFCs per million
PBMCs; Fig. 6A). Both CD4+ and CD8+ T cells were detected after
boost, reaching a geometric mean value of gag-specific IFN-g+ CD4+
and CD8+ T cells of 0.19 and 4.08%, respectively (Fig. 6B). Antibodies
to HIV-1 gag were still detectable at the time of boost (week 299) in
two of three animals, and boosting with PanAd3-gag increased these
titers more than 10-fold in all three animals (Fig. 6C), indicating
that ChAd3-gag can induce long-lived T and B cell memory responses
in NHPs.
ChAd vaccine vectors are highly immunogenic in humans
Two of the most potent ChAd vectors, the group C ChAd3 and the





















































































Fig. 2. Phylogenetic analysis of ChAd. The phylogenetic tree showing the different human adenovirus
species (A to F) was obtained by aligning the adenovirus hexon sequences. Human adenovirus (hAd)
representative of each species and chimpanzee adenoviruses [ChAd from chimpanzees (P. troglodytes)
and PanAd from paniscus (P. paniscus)] were included in the analysis. The phylogenetic tree was calcu-
lated using the neighbor-joining method as implemented in ClustalX and displayed using Drawtree from
PHYLIP version 3.69. Alignment positions containing gaps were excluded from the analysis. The alignment
of hexon proteins was manually optimized taking into account structural restraints from the Ad5 hexon x-ray
structure. Bootstrap confidence values are reported at branch points (1000 bootstrap cycles).
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1.5. Immune correlates of protection against influenza viruses 
Unlike conventional vaccines that predominantly induce globular HA-specific neutralising 
antibodies, novel influenza vaccines could elicit various types of immune responses, whether 
neutralising or non-neutralising antibodies or T cell immunity depending upon the vaccine 
antigens. Immune correlates of protections and their functions have been extensively studied 
in order to assess the potential of these novel vaccines. 
1.5.1. Antibodies 
Vaccination with traditional vaccines dominantly elicited HA-specific neutralising antibodies 
(nAb), which are considered as a correlate of vaccine efficacy [18]. As these antibodies 
target hypervariant globular HA, the response is more likely to be strain or subtype-specific. 
The response has been measured by three classical immunoassays: haemagglutination 
inhibition (HAI), single-radial haemolysis (SRH) and virus neutralisation (VN) assays [73], 
[74]. The HAI assay measures the capacity of antibody to block the binding of virus to its 
receptor on target cells, preventing virus infection [75]. HAI antibody titre of 40 correlates 
with a 50% reduction in the risk of influenza infection [76]. However, this correlate of 
protection has been established from studies in healthy adults and is not appropriate for 
children [77]. The SRH assay measures antibodies that bind to the influenza virus and fix 
complement (usually guinea pig complement) [78]. A zone of 25 mm2 is defined as a 
correlate of protection. The VN assay mainly detects functional antibodies that bind the HA 
globular head and block receptor binding; however it can also measure antibodies that block 
entry at the stage of membrane fusion. No correlate of protection has been established for 
the VN assay [73].  
In contrast, broadly reactive antibodies (bnAb) target the stalk region of HA, which is more 
relatively conserved among diverse influenza subtypes. A number of HA stalk-binding 
monoclonal antibodies isolated from human memory B cell repertoires have been discovered 
to cross-react to many influenza viruses. Some only recognise subtypes in the same 
phylogenetic HA either group 1 (e.g. CR6261, F10) or group 2 (CR8020), while some have 
the cross-reactivity to both HA groups of IAV (FI6). Recently, CR9114 has been found to 
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react to both IAVs and IBVs [79]. The breadth of reactivity depends upon the antigenic sites 
that antibodies bind to [41]. Anti-HA stalk antibodies resulted in lower viral titre and delayed 
or no virus replication in ferrets after natural exposure to pdmH1N1 influenza virus [80]. The 
level of HA stalk-reactive antibodies in human sera correlated well with the reduction of 
weight loss in serum transfer to mice after virus challenge [81]. Recently, it was shown in 
humans that HA stalk-reactive antibody level correlated with a reduction in detectable viral 
shedding, but did not correlate with a reduction in clinical symptoms [82]. 
The magnitude of HA stalk-reactive antibodies in human sera is extremely low or 
undetectable after seasonal influenza infection or current vaccination [41]. However, these 
antibodies have been found to increase in patients infected with pandemic virus and in 
vaccinees after vaccination with pandemic H1N1 strain [20], [21], [83]–[85]. Many novel 
antibody-inducing vaccine candidates aim to enhance these broadly reactive HA stalk-
specific antibodies to confer broad protection. Anti-HA stalk antibody has been characterised 
as having no HAI activity with or without neutralising activity [83]. Despite the broad 
neutralisation of HA stalk-specific bnAbs, their activities are generally much weaker than the 
ones towards the HA head [86]. It has been showed that antibody binding to the HA stalk 
inhibits the conformation change of HA during endocytosis, resulting in no viral genome 
release into host cell cytoplasm after virus infection. HA-stalk reactive antibodies may also 
block budding of virus and inhibit HA maturation [87]. 
Table 1.2   Comparisons between the features of the antibody targeting influenza HA 
globular head epitopes and HA stalk region epitopes (Adapted from [19]) 
Antibody         









Globular head region +++ +++ +++ + 
Stalk region ++ + + +++ 
Remark: The number of (+) signs was arbitrarily determined.  
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Some broadly cross-reactive antibodies have no neutralising activitiy, but provide protection 
against influenza viruses. Without neutralisation, the antibodies confer protection by 
facilitating other mechanisms such as Fc-mediated cell cytotoxicity (ADCC), antibody-
mediated phagocytosis (ADP) and complement-dependent lysis (CDL) [87] (Figure 1.9). 
ADCC has been widely studied in monoclonal antibodies isolated from animals and humans 
vaccinated or infected with influenza virus. ADCC-triggering antibodies bind to HA or other 
virus envelope proteins such as NA and M2e present on virus-infected cells and engage 
CD16 Fc receptor to activate innate immune cells such as NK cells, releasing potent 
cytotoxic molecules e.g. perforin and granzymes including anti-viral cytokines e.g. IFN-γ and 
TNF. A study in rhesus macaques has suggested non-neutralising antibodies with ADCC 
activity induced by seasonal vaccination may be associated with protection from pandemic 
H1N1 infection [88]. Moreover, non-neutralising anti-HA antibodies protected mice from 
influenza H7 virus challenge by mediating Fc-mediated effector function [89]. DiLillo et al 
have shown that human anti-HA stalk antibodies required the interaction of Fc and FcγR to 




Figure 1.9   Functions of influenza virus antigen-specific antibodies 
1) NA-specific antibodies promote the trapping of virus in mucins at mucosal surface. 2) Antibodies 
binding to the globular HA block interactions between HA and sialic acid on cellular receptors, inhibiting 
attachment of the virus to the cell. 3) HA stalk-specific antibodies bind to the HA on virus particles and 
prevent the fusion of viral and endosomal membranes by blocking the rearrangement of the HA fusion 
machinery. 4) Head-, stalk- and NA-specific antibodies may inhibit budding of virus. 5) HA-stalk specific 
antibodies may inhibit HA maturation. HA stalk and possibly NA-specific antibodies also facilitate 6) 











































analysis of clinical trials with pandemic vaccine candi-
dates — including H5N1, H7N1 and swine-origin H1N1 
strains — which induced preferentially stalk-reactive 
antibodies62–64,148–150.
Interestingly, studies with H5N1 vaccines showed 
that the first vaccine administration induces high levels 
of stalk-reactive antibodies, whereas the second vaccina-
tion with the same vaccine formulation predominantly 
induces a response against the globular head domain63,64. 
This result indicates that the globular head domain regains 
immunodominance over the stalk domain once the 
immune system is primed for these novel head domain 
epitopes. Importantly, polyclonal anti-stalk responses 
induced by H5N1 vaccines are highly crossreactive 
towards group 1 haemagglutinins but do not signifi-
cantly crossreact with group 2 haemagglutinins when 
measured using quantitative methods63,64.
Broadly reactive antibodies against the haemagglutinin 
globular head domain and neuraminidase. In addition 
to broadly neutralizing stalk-specific antibodies, a small 
number of human antibodies that can neutralize a broad 
panel of influenza viruses through binding to the haem-
agglutinin head domain have been isolated121–124. Some 
of these antibodies bind to the receptor-binding site of 
haemagglutinin by mimicking sialic acid, the substrate 
Figure 2 | Mechanism of action of haemagglutinin-specific and neuraminidase-specific antibodies.  
Antibodies directed against the haemagglutinin (HA) globular head domain (red) and the stalk domain (green) or against 
neuraminidase (NA) (blue) may confer protection via a number of mechanisms. As viruses enter the host and come in 
contact with mucosal surfaces they are trapped by highly glycosylated innate defence proteins called mucins (step 1).  
NA helps the virus to pierce through this layer, and this activity may be inhibited by NA-specific antibodies. Antibodies 
that bind to the globular head domain of HA sterically block interactions between HA and sialic acid on cellular receptors, 
effectively inhibiting attachment of the virus to the cell (step 2). In rare cases, NA-specific antibodies can also have this 
function (also working through steric hindrance). Stalk-reactive antibodies bind to the HA on virus particles and prevent 
the fusion of viral and endosomal membranes by blocking the rearrangement of the HA fusion machinery (step 3). 
Head-, stalk- and NA-reactive antibodies may inhibit budding and viral egress (step 4). Stalk-reactive antibodies bound 
to HA sterically inhibit HA maturation (step 5). Stalk-reactive antibodies and possibly NA-reactive antibodies also act 
through antibody-dependent cell-mediated ytotoxicity (st p 6) or complement- ependent cytotoxicity (step 7). 
cRNA, complementary RNA; FcR, Fc receptor; NK, natural killer; vRNA, viral RNA.
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1.5.2. T cells 
The induction of T cell responses, particularly CTL responses, is the main target of novel T 
cell-based vaccine development. The CTL-mediated immune response plays a pivotal role in 
clearing virus-infected cells, resulting in the decrease of virus shedding. Although T cell 
response does not protect from virus infection, it reduces the disease severity [91]. As CTLs 
recognise most internal viral epitopes shared across IVA subtypes, they provide 
heterosubtypic immunity. This cross-reactive protection in the absence of virus-specific 
antibodies has been demonstrated in animal models, showing the correlation with cytotoxic 
CD8+ T cells [46], [92]. There is increasing evidence in humans to support the critical role of 
CD8+ T cell-mediated immunity. In individuals experimentally infected with influenza virus, 
the virus-specific cytotoxic T cell killing was shown to reduce virus shedding in the absence 
of specific antibodies [93]. Also, the presence of pre-existing cytotoxic CD8+ T cells was 
associated with a decreasing severity of symptoms in patients infected with pandemic H1N1 
virus during the outbreak in 2009 [94]. Moreover, rapid recovery of patients from a severe 
avian H7N9 infection was shown to correlate with an early onset of robust CD8+ T cell 
response following the infection [95].  
CTLs lyse virus-infected cells by facilitating different mechanisms (Figure 1.10). By 
recognising the viral peptide-MHC complexes presented on infected cells via T-cell receptor 
(TCR), CTLs release cytotoxic molecules e.g. perforin and granzymes in response. Perforin 
forms pores in cell membrane of virus-infected cells, where subsequently released 
granzymes enter into the cell cytoplasm and induce cell apoptosis. Granzyme-A and -B are 
the major prominent contents of cytolytic granules [96]. Moreover, the engagement of two 
membrane-bound TNF family ligands, FasL and TRAIL, on CTLs with their cognate 
receptors (Fas and TRAIL-DR) on infected cells also triggers the apoptotic-signaling 
cascade [97], [98].  
Virus-specific CTLs also produce a range of cytokines and chemokines. IFN-γ and TNF-α 
are the prominent effector cytokines produced by classical CTLs. IFN-γ has a potent antiviral 
activity and enhances cytotoxicity of other immune cells. TNF-α is a pro-inflammatory 
cytokine, inducing non-specific death of infected cells and regulating the functions of other 
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immune cells through TNF receptors. CTLs produce a small amount of IL-2 when receiving 
proper co-stimulatory signals, which promote proliferation and maintain survival of them and 
other CTLs. CTLs differentially produce combinations of these cytokines. CTLs that co-
produce IFN-γ, TNF-α and IL-2 are considered more potent than others that produce one or 
two cytokines. IL-10 was found to be produced by lung-resident CTLs during IVA infection. 
Owing to anti-inflammatory property of IL-10, CTLs producing both IFN-γ and IL-10 may 
balance their protective activity and tissue-pathogenic effect [99]. Both cytotoxicity and 
cytokine production by CTLs could contribute to protective immunity by regulating virus 
infection at host mucosa, resulting in virus clearance and limiting symptom severity [99]. 
 
 
Figure 1.10   Functions of influenza virus antigen-specific cytotoxic T cells  
By recognising the viral peptide-MHC complexes presented on infected cells via T-cell receptor (TCR) 
and CD8, CTLs release cytotoxic molecules. Perforin forms pores in cell membranes, where 
subsequently released granzymes enter into the cell cytoplasm and induce cell apoptosis. They also 
mediate two membrane-bound TNF family ligands, FasL and TRAIL, on CTLs with their cognate 





































1.6. Mucosal immune responses 
Mucosa could refer to the surfaces of the respiratory, gastrointestinal and urogenital tracts 
formed by a layer of epithelial cells. As most pathogens enter the human body at mucosal 
surfaces, mucosal immune responses therefore are necessary as the first line of defence. 
The mucosal immune system plays a pivotal role in providing mucosal protection against 
disease [100]. The system is composed of two functional compartments, which are inductive 
and effector sites (Figure 1.11). The inductive site is associated with the lymphoid tissues 
where the responses initially occur, in which B cells or T cells are primed or activated by 
pathogenic antigens presented by APCs. The antibody-secreting plasma cells and antigen-
specific T cells then migrate and persist at intraepithelial layers and mucosal surface, which 
are effector sites [101].  
 
Figure 1.11   Mucosal immune system 
The mucosal immune system is compartmentalised into the inductive site and the effector site. The 
figure shows the migration of memory B cells from inductive (top) to effector (bottom) sites, depicting 
the more or less preferred pathways (graded arrows) after the activation in nasopharynx-associated 
lymphoid tissue (NALT) represented by palatine tonsils and adenoids, bronchus-associated lymphoid 
tissue (BALT), and gut- associated lymphoid tissue (GALT) represented by Peyer’s patches, appendix, 
and colonic-rectal isolated lymphoid follicles (Adapted from [102]). 
antigens from commensal bacteria and food [51, 80].
Their decreased epithelial barrier function leads to a
hyperreactive immune system and the mice show pre-
disposition for systemic anaphylaxis after sensitization;
this development is, however, counteracted by enhanced
oral tolerance as a homeostatic back-up mechanism
[81].
Conclusions
Many variables influence mucosally induced tolerance and
productive IgA-dependent secretory immunity. Some of
these variables are reciprocally modulated to achieve
homeostasis [39, 40]. Increased epithelial permeability is
an important primary or secondary event in the pathogen-
esis of many diseases, including allergy, coeliac disease,
and inflammatory bowel disease. The barrier function is
determined by the individual’s age (e.g. preterm versus
term infant); genetics; mucus; interactions between mast
cells, nerves, and neuropeptides; concurrent infection; and
the mucosa-shielding effect of SIgA provided by breast
milk or produced by the infant’s gut. The remarkable
output of SIgA during feeding serves as an optimally
targeted passive immunization of the breast-fed infant’s
gut, and also may serve as a positive homeostatic feed-
back loop.
Many studies indicate that allergy is associated with
delayed or impaired development of the IgA system [45].
This is not surprising because secretory immunity is of
such great importance for the intestinal barrier function.
SIgA not only maintains mutualism with the indigenous
microbiota [82] but also forms the first line of defence
against commensals and pathogens as well as other harm-
ful agents (Fig. 3). In addition, epithelial integrity
depends on interaction with microbial components from
the environment and particularly from the indigenous
microbiota, both by direct engagement of epithelial PRR
and induction of mucosal tolerance via different immuno-
suppressive mechanisms, including tolerogenic APC and
Treg cells [40]. The SIgA system and the Treg cells seem
to be integrated in an effort to preserve the vulnerable
mucosal barrier (Fig. 2).
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In order to provide protection at the mucosa, secretory IgA (SIgA) promotes the entrapment 
of pathogens in the mucus, preventing pathogens from direct mucosal epithelial attachment. 
SIgA also has intracellular-neutralising activity, which traps and transports those epithelium-
infecting pathogens back into the lumen by mediating through epithelial polymeric 
immunoglobulin receptor (pIgR) or by mediating ADCC to lyse the infected cells [103]. Local 
IgG antibody, whether locally produced or diffused from serum, can potentially neutralise 
pathogens that enter the mucosa [104]. It is assumed that mucosal or serum IgG diffuse 
across epithelial barriers by paracellular leakage or transport by mediating IgG-specific Fc 
receptor expressed on epithelial cells [105]. Cytotoxic T lymphocytes at the mucosa cannot 
prevent the infection, but could limit the infection by the clearance of virus-infected cells 
(Figure 1.12). These cells have been shown to persist at mucosal sites after virus infection 
[106]. Both antibodies and CTLs at mucosa sites contribute to protection from the infection of 
such pathogens including influenza viruses [101]. 
Mucosal immunisation becomes a more attractive strategy against pathogens invading at 
mucosa. It has a superior advantage compared to parental immunisation in terms of the 
induction of local immune responses where pathogen infection and transmission occur. 
Mucosal vaccination via different routes has been shown to provide protection against 
influenza viruses. The nasal route is among others such as oral and pulmonary routes to be 
rigorously studied. LAIVs are the first licensed intranasal influenza vaccines. They efficiently 
elicit mucosal IgA antibodies, which are thought to be the immune correlates of protection. 
Nonetheless, serum IgG antibodies could also be observed, indicating that mucosal 
immunisation induces not only mucosal but also systemic immune responses [27]. Systemic 
immunity after mucosal immunisation may be due to the migration of locally antigen-uptaken 
mucosal DCs to other systemic inductive sites such as spleen and lymph nodes [100]. The 
number of influenza vaccine candidates has been tested and reported to protect animals 
from influenza infection following intranasal vaccination. Nasal delivery of avian influenza 
subunit vaccines (e.g. H5N1 and H7N9) with mucosal adjuvants has enhanced both mucosal 
and systemic immune responses as shown in mice by the increase of virus-specific SIgA 
and IgG antibodies in nasal wash and serum including T cell response [107], [108]. 
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Figure 1.12   Mechanisms of immune protection at mucosal surfaces.  
Multiple immune effector mechanisms contribute to protection at mucosal surfaces. Antigen-specific B 
and T cells from peripheral blood enter the mucosa via high endothelial venules (HEVs). Local plasma 
cells produce dimeric IgA that is exported along the mucus as secretory IgA (sIgA) to prevent mucosal 
invasion. Neutralising IgG may be derived from local plasma cells or diffused from blood. Infected cells 
could be lysed by antigen-specific cytotoxic T cells or by antibody-dependent cell-mediated cytotoxicity 
(ADCC). Pathogens can also be captured by dendritic cells and macrophages, and carried to draining 
lymph nodes [100].  
 
Similarly, intranasal vaccination with whole inactivated vaccine in primed healthy individuals 
induced local SIgA and systemic IgG antibodies [109]–[112]. In addition to conventional 
vaccines, novel vaccines such as nanoparticles, VLP and virosomes intranasally delivering 
conserved viral proteins e.g. NP, M2e and HA also induced robust immune responses and 
conferred cross-protection in mice [113]–[116]. Of them, the vaccine responses were 
enhanced when co-delivered with mucosal adjuvants. Adenoviral vector-based vaccines 
expressing either HA or NP activated antigen-specific T cell responses after intranasal 




(ADCC). A mechanism by 
which natural killer cells are 
targeted to antibody-coated 
cells, resulting in the lysis of 
the antibody-coated cells.
it has been estimated that there are more antibody-
producing cells in the intestinal mucosa than in the 
spleen and lymph nodes combined9,10.
Epithelial cells are active participants in muco-
sal defence. They function as sensors that detect 
dangerous microbial components through pattern-
recognition receptors such as Toll-like receptors (TLRs). 
They respond by sending cytokine and chemokine sig-
nals to underlying mucosal cells, such as dendritic cells 
(DCs) and macrophages, to trigger innate, nonspecific 
defences and promote adaptive immune responses8,11,12. 
In the intestine, where bacteria are abundant, epithelial 
cells, together with intraepithelial lymphocytes and 
underlying phagocytic cells, can modulate and dampen 
these signals to prevent undesirable responses to non-
threatening nutrients and the normal intestinal flora 
that could lead to mucosal inflammation13–15. Therefore, 
mucosal tissues are in a constant state of alert, but they 
are adapted to the presence of foreign microorganisms 
and their products. As a result, vaccines that would 
produce vigorous immune responses if injected into a 
sterile environment, such as muscle, might be ‘ignored’ 
when given mucosally, where the tissue is constantly 
exposed to microorganisms.
Adaptive immune protection at mucosal surfaces. 
Diverse strategies are used by mucosal pathogens to 
infect humans. Some pathogens such as V. cholerae and 
enteropathogenic Escherichia coli cause disease by colo-
nizing epithelial surfaces. Pathogens such as rotavirus 
and influenza virus infect the epithelium, whereas oth-
ers such as Shigella flexneri and S. typhimurium establish 
local infection in the lamina propria. Other pathogens, 
including HIV and S. typhi, use the intestinal mucosa 
as a staging area for systemic spread of infection. 
Protection against such diverse threats involves multiple 
immune effector strategies that operate on both sides of 
the epithelial barrier (FIG. 1).
An important characteristic of the mucosal adaptive 
immune response is the local production and secretion 
of dimeric or multimeric immunoglobulin A (IgA) anti-
bodies that, unlike other antibody isotypes, are resistant 
to degradation in the protease-rich external environ-
ments of mucosal surfaces. In humans, more IgA is 
produced than all the other immunoglobulin isotypes 
combined10, and high concentrations of IgA antibodies 
(over 1 mg per ml) are present in the secretions that are 
associated with mucosal surfaces in normal humans16,17. 
The protease resistance of secretory IgA (sIgA) is a result 
of its dimerization and high degree of glycosylation 
during its synthesis in mucosal plasma cells18, and its 
association with a glycosylated fragment (the secre-
tory component) derived from the epithelial polymeric 
immunoglobulin receptor (pIgR) that mediates transport 
of dimeric IgA across epithelial cells to the lumen19. 
sIgA has multiple roles in mucosal defence2. 
It promotes the entrapment of antigens or micro-
organisms in the mucus, preventing direct contact of 
pathogens with the mucosal surface, a mechanism that 
is known as ‘immune exclusion’. Alternatively, sIgA of 
the appropriate specificity might block or sterically 
hinder the microbial surface molecules that mediate 
epithelial attachment20, or it might intercept incoming 
pathogens within epithelial-cell vesicular compart-
ments during pIgR-mediated transport2,19. Interstitial 
fluids of mucosal tissues that underlie the epithelial 
barrier contain dimeric IgA that is synthesized by 
local IgA-secreting plasma cells and this might prevent 
mucosal-cell infection, by mediating the transport of 
pathogens that have breached the epithelial barrier 
back into the lumen through pIgR21 or by mediating 
antibody-dependent cell-mediated cytotoxicity (ADCC) 
that leads to the destruction of local infected cells10,22.
Local IgG synthesis also can occur in the mucosal 
tissues following the administration of antigen or 
vaccine to mucosal surfaces17,18,23,24. Large numbers of 
IgG-secreting plasma cells are present in the female 
genital tracts of macaques and humans23, and high 
concen trations of IgG as well as IgA have been measured 
in human cervical and vaginal secretions17,18. This IgG, 
as well as sIgA, could play a significant role in blocking 
infection by sexually transmitted pathogens at this site, 
Figure 1 | Mechanisms of immune protection at mucosal surfaces. Multiple 
immune effector mechanisms contribute to protection at mucosal surfaces. 
Antigen-specific effector B and T cells in the bloodstream recognize mucosal 
high endothelial venules (HEVs) and enter the mucosa. Mucosal B cells terminally 
differentiate to become mucosal plasma cells, most of which produce dimeric IgA 
that is expo ted into secr tions as secretory IgA (sIgA) to intercept antigens and 
pathogens, and to prevent mucosal invasion. Neutralizing IgG is also present within 
mucosal tissues; mucosal IgG might be derived from local plasma cells or from 
blood, by diffusion from local fenestrated capillaries. Infected cells might be killed 
by specific cytotoxic T lymphocytes (CTLs) or by antibody-dependent cell-mediated 
cytotoxicity (ADCC), a collabo ation b tween natural killer (NK) c lls  ant bodies. 
Pathogens can also be captured by dendritic cells (DCs) and macrophages, and 
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administration and fully protected mice from heterologous subtypes when given as a booster 
dose after a prior DNA immunization [117]. These data show the potential of different forms 
of influenza vaccines to induce mucosal responses via intranasal immunisation.  
1.7. Human nasopharyx associated lymphoid tissue (NALT) 
Mucosal immune responses in the upper respiratory tract are induced in nasopharyx-
associated lymphoid tissues (NALT). NALT is not only the inductive site for both T and B cell 
responses, but also the effector site, where primed lymphocytes frequently migrate to [101]. 
Human NALT, so-called Waldeyer’s ring is composed of nasopharyngeal tonsil (adenoid), 
paired tubal tonsils, paired palantine tonsils and lingual tonsil (Figure 1.13). Of them, palatine 




Figure 1.13   Human nasopharyx-associated lymphoid tissue (NALT)  
Human NALT is composed of nasopharyngeal tonsil (adenoid), paired tubal tonsils, paired palantine 
tonsils and linguial tonsil [118]. 
 
 
is filled with mobile and motile ‘free cells’ (Fig. 3) such as T cells, 
IgG-, IgA- and IgM-producing B cells, macrophages, interdigitating
dendritic cells (IDCs) and Langerhans cells (LCs). Since these cell
types are present in the crypt epithelium as early as week 15 of ges-
tation11, it is likely that reticulation is a normal developmental event
and continues throughout life. The infiltrating nonepithelial cells
are therefore considered a physiological characteristic of this epi-
thelium which, postnatally, are constantly exposed to airborne and
alimentary antigens. Any inflammatory changes, with the ad-
ditional presence of polymorphonuclear leukocytes, are superim-
posed onto the normal pattern of reticulation12. Studies on human
PT and NT showed that the tonsillar crypt epithelium functions as
an additional lymphoid compartment by contributing to the pro-
duction of immunocytes and to the protection of the mucosal sur-
face13; it also provides direct, transepithelial access for antigens. In-
deed, the pioneering work by Brandtzaeg and colleagues strongly
indicates a crucial numerical balance between the epithelial and
nonepithelial cells14. To be efficient, the reticulated epithelium needs
to contain not only the immigrant lymphoid cells but also sufficient
epithelial cells, some of which can synthesize secretory component
(SC) or the polymeric Ig receptor (pIgR), which stabilizes and trans-
ports secretory IgA to the mucosal surface15. However, other stud-
ies have failed to detect pIgR in either PT or LT (Refs 16–18), al-
though some epithelial cells of the NT may express pIgR (Ref. 19).
Epithelia covering surfaces or lining cavities are usually not pen-
etrated by blood vessels and only a few sites in the human body (the
stria vascularis of the cochlea, for example) possess true intraepi-
thelial capillaries. Importantly, within the tonsillar lymphoepi-
thelium, there is a network of intraepithelial blood vessels (Fig. 3).
In both the PT and NT, capillaries are arranged in loops oriented
perpendicularly to the crypt surface, and high endothelial venules
(HEVs) are located in the lower border regions of many reticulated
patches20,21 (Fig. 2). The rich intraepithelial blood flow provides for
the metabolic needs of this site, as well as increasing the area for in-
teractions between endothelial cells and leukocytes, and the transport
of immunoglobulins and other substances across the vessel walls.
An unusual feature of the lymphoepithelium covering the 
lymphoid tissue is the content of cells that are involved in immune
surveillance and effector functions22. In the intestine, specialized
epithelial cells with characteristic short microvilli and microfolds on
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Fig. 1. Pharyngeal lymphoid tissue of Waldeyer’s ring comprises the nasopharyngeal tonsil or adenoid (NT), the paired tubal tonsils (TT), the paired
palatine tonsils (PT) and the lingual tonsil (LT). All four micrographs show that the surface of the tonsils is in each case covered with pharyngeal 
epithelium. Note the branching crypt arrangement in the NT and the PT, and the single crypt in the LT. The intimate relationship of tonsils with 
salivary glands is especially obvious in the TT.
Immunology	of	the	tonsils	
30 
Tonsils are secondary lymphoid tissues, containing a set of cellular components required for 
both primary and secondary immune responses. The tonsil tissues consist of three 
compartments; reticulated crypt epithelium, lymphoid follicles and extrafollicular regions 
(Figure 1.14a). The reticulated crypt epithelium or lymphoepithelium is the outer layer. There 
is the formation of deep tubular crypts to increase the mucosal surface. This layer comprises 
epithelial cells and immune cells, most of which are memory B cells followed by T cells. A 
small numbers of dendritic cells and macrophage are distributed in here. Lining between 
epithelial cells are microfold cells (M cells), which are able to transport foreign antigens to 
subepithelium [119]. In the subepithelial compartment, B cells are also the predominant cell 
population, responsible for 60-75% of cells [120]. This part contains lymphoid follicles, where 
B cells undergo proliferation and differentiation to memory B cells or antibody-producing 
plasma cells as well as T cell activation. Unlike primary lymphoid follicles, secondary ones 
also contain germinal centres (GC), which are composed of a dark zone of centroblasts and 
a light zone of centrocytes, surrounded by a mantle zone of naïve B cells (Figure 1.14b). 
Follicular dendritic cells (FDC) are a subset of GC dendritic cells that activates T follicular 
helper cells (TFH) and also retains immune complexes on their plasma membrane to signal B 
cells during the affinity selection process in GC [119]. The extrafollicular region is the T-cell 
enriched area containing T cells (25-35%) with the majority of CD4+ T cells together with 
interdigitating dendritic cells, macrophages and antibody-forming cells [120]. GCs are 







Figure 1.14   Tonsils and their compartments  
Tonsils are part of the inductive sites for mucosal immune responses in the upper respiratory tract. a) 
Cross-section of tonsils shows tonsils crypts and lymphoid follicles underneath the epithelium. 
Enlarging the blue box in a), three compartments of tonsils are shown; reticulated crypt epithelium is a 
layer of epithelial cells and M cells, where immune cells (dendritic cells, B- and T-lymphocytes) reside.  
Subepithelial compartment located lymphoid follicles or B-cell zone and extrafollicular T-cell zone 
(Adapted from [100], [121]). b) In a germinal centre (GC) of a secondary lymphoid follicle, B cells 
undergo proliferation in dark zone and selection/ class switching in light zone before differentiating to 
memory B cells or plasma cells (Adapted from [122]).   
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M cells
(Microfold cells). Specialized 
epithelial cells that deliver 
antigens by transepithelial 
vesicular transport from 
the gut lumen directly to 
intraepithelial lymphocytes 
and to subepithelial lymphoid 
tissues.
Peyer’s patches
Large clusters of lymphoid 
follicles localized in the mucosa 
of the distal small intestine. 
Each B-cell follicle is capped by 
a dome area and is flanked 
by interfollicular T-cell areas.
Inductive sites
Organized lymphoid tissues 
containing B-cell follicles, T-cell 
areas and antigen-presenting 
dendritic cells, specialized for 
induction of adaptive immune 
responses. Mucosal inductive 
sites in the gastrointestinal 
tract include the Peyer’s 
patches, appendix, and 
isolated lymphoid follicles 
throughout the small intestine, 
colon and rectum.
as has been shown for infection with herpes simplex 
virus type 2 in mice25. Concentrations of IgG and IgA in 
secretions of the female reproductive tract are affected 
by hormonal signals and change dramatically during the 
menstrual cycle24, and this might be an important factor 
in the effectiveness of mucosal vaccines against sexually 
transmitted diseases. In the human intestine, 5–15% of 
mucosal plasma cells secrete IgG9, but IgG is suscep-
tible to degradation by luminal intestinal and bacterial 
proteases. In large intestinal secretions, for example, 
IgG concentrations are generally 30- to 100-fold lower 
than those of sIgA26. Nevertheless, intact IgG in mucosal 
tissues, whether locally produced or from serum, can 
potentially neutralize pathogens that enter the mucosa 
and prevent systemic spread.
It is often assumed that mucosal or serum IgG dif-
fuses across epithelial barriers and into secretions by 
para cellular leakage. However, receptor-mediated IgG 
transport might also occur. Recent studies have shown 
that an IgG-specific Fc receptor (neonatal Fc receptor, 
FcRn) is expressed by epithelial cells in the intestine and 
airways, and can mediate IgG transport in both direc-
tions across epithelial barriers27. Therefore, this system 
might export IgG, and might also mediate the uptake 
of antigens into the mucosa27. In addition, a new IgA-
specific receptor has been identified on apical surfaces 
of microfold cells (M cells) that can mediate uptake of 
luminal IgA into Peyer’s patches28. The immunological 
significance of these uptake mechanisms has yet to be 
determined, but there is some evidence that they might 
facilitate the sampling of luminal immune complexes by 
the mucosal immune system27,29.
Cytotoxic T lymphocytes (CTLs) in mucosal tissues 
cannot prevent pathogen entry, but they might have a 
crucial role in clearance or containment of mucosal viral 
infections. For example, mucosally immunized (but not 
systemically immunized) mice were protected against 
infection after mucosal challenge with a recombinant 
vaccinia virus expressing HIV glycoprotein 160 (gp160), 
but this protection was abrogated by treatment of the 
mice with CD8-specific antibodies30. Immunologically 
active mucosal tissues, such as the intestinal tract, con-
tain abundant CD4+ T cells that are targets for HIV. As a 
result, the intestinal mucosa becomes a reservoir of HIV 
infection regardless of the site of initial viral entry31,32. 
Both CTLs and antibodies within mucosal tissues might 
contribute to preventing the establishment of such 
mucosal reservoirs.
Induction of mucosal immune responses
Antigen sampling at mucosal surfaces. The induction 
of mucosal im une responses against foreign antigens, 
microorganisms and vaccines requires the presence of 
organized lymphoid tissue, either within the mucosa or 
in draining lymph nodes9 (FIG. 2). Organized mucosal 
inductive sites are concentrated in areas where pathogens 
are most likely to enter the body (for example, the palatine 
and lingual tonsils and adenoids in the oral and naso-
pharyx) an  at sites of high micr bial d nsity (such as the 
lower intestinal tract). In humans, aggregates of organized 
mucosal lymphoid follicles form the Peyer’s patches in 
the distal ileum, and abundant isolated follicles are pres-
ent in the appendix, colon and rectum33. The presence 
of a mucosal lymphoid follicle influences the overlying 
epithelium by inducing differentiation of a specialized 
follicle-associated epithelium (FAE), which contains 
M cells34. M cells form intraepithelial pockets into which 
lymphocytes migrate, and they deliver samples of foreign 
material by vesicular transport from the intestinal lumen 
directly into the pocket and to underlying DCs.
Figure 2 | Antigen sampling at mucosal surfaces: collaboration of epithelial cells and dendritic cells. Antigen 
sampling strategies are adapted to the diverse epithelial barriers that cover mucosal surfaces throughout the body, but 
all involve collaboration with dendritic cells (DCs). DCs might congregate immediately under epithelia, migrate into the 
epithelial layer, and even extend dendrites into the lumen to capture antigens. DCs from any mucosal surface might 
travel to the nearest draining lymph node to present antigen to T cells. At sites of organized mucosal lymphoid tissues, 
specialized microfold (M) cells in the lymphoid follicle-associated epithelium deliver antigens across the epithelial barrier 
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(SHM). A genetic mechanism 
that introduces mainly single 
nucleotide exchanges in a 
region encompassing ~2 kb 
from the transcriptional start 
site of the genes encoding the 
variable regions of the 
immunoglobulin receptors.
Light zone
A histological and functional 
compartment of the germinal 
centre in which B cells are 
selected on the basis of their 
affinity for the antigen.
GC reaction: it is induced early during GC initiation, it 
is tr nscriptionally suppressed i  dark zone B cells and 
it is transiently re-expressed in a subset of light zone 
B cells that are destined for dark zone re-entry18–21. 
Indeed, GC formation requires expression of MYC 
during the initial days of GC development, but its 
expression is then promptly silenced as a result of tran-
scriptional repression by B cell lymphoma 6 (BCL-6)18,19, 
which is a mast  regulator of the GC reaction. Although 
the biological importance of MYC suppression in dark 
zone B cells remains unknown, the role of the initial burst 
of MYC expression presumably involves the induction 
or the amplification22,23 of transcriptional programmes 
that are associated with many of the known functions 
of MYC, including the stimulation of metabolism, 
telomerase function and DNA replication24.
MEF2B. T  transcri tion factor myocyte-specific 
enhancer factor 2B (MEF2B) is expressed by GC B cells 
and is expressed early during GC formation25. Although 
its requirement for GC initiation has not been shown, 
the relevan  of MEF2B is indicated by the observation 
that it directly transactivates BCL6 (see below) and by 
the identification of specific mutations that dysregulate 
its activity in lymphoma9,25.
BCL-6. The transcriptional repressor BCL-6 controls a 
large transcriptional network that drives GC formation 
and maintenance26. The first burst of BCL-6 expression 
is detected in the interfollicular zone in a small subset 
of naive B cells that have been successfully engaged by 
interactions with antigen and T cells27,28. Interferon-
regulatory factor 8 (IRF8)29, IRF4 (REF. 30) and MEF2B25 
Box 1 | Ce lular and molecular characteristics of GCs
B cells that have successfully undergone V(D)J recombination and that express functional B cell receptors migrate as 
naive B cells from the bone marrow to the secondary lymphoid organs. Upon encounter with an antigen, naive B cells 
become activated by interaction with CD4+ T cells in the T cell-rich area of the lymphoid tissues and aggregate into 
primary follicles to form germinal centres (GCs)3. In the GC, B cells are targeted by immunoglobulin gene remodelling 
processes — namely, somatic hypermutation (SHM) and class-switch recombination — in order to generate cells with the 
ability to produce high-affinity antibodies of different isotype classes152,153. The outcome of the GC reaction is the 
generation of both plasma cells and memory B cells (see the figure).
On the basis of classical histological definitions, the GC structure is comprised of a dark zone, which almost exclusively 
contains highly proliferating B cells, and a light zone in which B cells are intermingled with follicular dendritic cells, T cells 
and macrophages3. The use of intravital imaging has contributed to the further characterization of the dark zone and the 
light zone, leading to the identification of CXC-chemokine receptor 4 (CXCR4) as a functionally relevant marker for dark 
zone B cells. This marker, combined with the expression of CD83 and CD86, can be used to discriminate dark zone B cells 
(CXCR4hiCD83lowCD86low) from light zone B cells (CXCR4lowCD83hiCD86hi)6,7,154,155. In situ photoactivation studies, which 
complement the data obtained by intravital imaging, have shown that the GC is functionally polarized: the dark zone is 
the site of B cell division and SHM, whereas the light zone is where B cells undergo activation and selection on the basis  
of the affinity of their B cell receptors6,156,157. However, the maturation of B cells does not follow a unidirectional pathway 
between the two compartments, but rather involves cyclic re-entries in which GC B cells, upon selection in the light zone, 
return to the dark zone for further rounds of SHM and cell division3 (see the figure). The signals that trigger these 
movements and/or that control the exit of B cells from the GC and their differentiation to memory B cells and plasma 
cells are now beginning to be elucidated.
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It was hypothesised that novel viral vector-based influenza vaccines have the capacity to 
induce mucosal immune responses if administered by the intranasal route. Since adenoid/ 
tonsillar tissues are parts of the mucosal immune system (NALT), known as an immune 
induction site for immunity against respiratory pathogens including influenza virus, using 
immune cells from NALT allows us to examine the mucosal immune responses to these 
novel viral vector-based vaccines. This project therefore aimed to study the capacity and 
functional properties of T cells or B cell-mediated antibodies induced by MVA- and PanAd3 
vector-based influenza vaccines using the in vitro cell culture system containing cells from 
NALT of children and adults.  
1.9. Objectives of the thesis 
The overall objectives of the thesis are: 
1. To study how the viral vector-based influenza vaccines work to induce the immune 
responses in human NALT. 
2. To investigate the capacity of these vaccines to induce antigen-specific cross-
reactive T cell responses and antibodies in human NALT.   










2. Chapter 2  





















Subjects included in this study were children (≤15 years old) or adults (>15 years old) 
undergoing tonsillectomy and/or adenoidectomy due to upper airway obstruction or tonsillitis 
at Alder Hey Children’s Hospital, Royal Liverpool and Broadgreen University Hospitals and 
Aintree University Hospital. Patients who received immunosuppressant within 3 weeks of 
surgery, or who had any known immunodeficiency were excluded from the study. Ethical 
approval was obtained (REC No: 14/SS/1058) and informed written consent was obtained in 
all cases from patients or their legal guardians. 
2.2. Samples 
2.2.1. Adenoidal and tonsillar tissues 
After surgery, adenoidal and tonsillar tissues were stored in Hank’s Balanced Salt Solution 
(Sigma Aldrich, UK) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin and 1% 
L-glutamine (all Sigma Aldrich, UK), named “HBSS” and delivered to the laboratory. 
2.2.2. Peripheral blood 
5-10 ml venous blood taken from the same patients as described above or 15-20 ml from 
healthy donors was collected into a 25-ml universal tube containing 100 µl of heparin (LEO 
Pharma, UK). 
2.3. Vaccines/ Viruses 
2.3.1. Pan paniscus Adenovirus type 3 virus (PanAd3) vector-based 
influenza vaccines  
PanAd3 vector-based influenza vaccines were kindly provided by Okairòs (Rome, Italy). 
Briefly, PanAd3 virus was isolated from a bonobo (Pan paniscus) [123] and was a member 
of adenovirus species C based on the hexon sequences [69]. The virus was deleted in its E1 
and E3 genes to obtain replication-deficient viral vector backbone, pPanAd3ΔE1ΔE3 with a 
human cytomegalovirus promoter (HCMV)-driven transgene expression, followed by the 
insertion of different conserved influenza gene cassettes; 1) nucleoprotein (NP) and matrix 
35 
protein 1 (M1) to obtain PanAd3-NPM1, 2) NP, M1 and hemagglutinin (HA) from pandemic 
H1N1 strain to obtain PanAd3-NPM1-pdmH1HA and 3) NP, M1 and HA from avian H5N1 
strain to obtain PanAd3-NPM1-H5HA. PanAd3 vector encoding HIV gag gene (PanAd3-gag) 
was used as a vector control. 
2.3.2. Modified Vaccinia Ankara (MVA) vector-based influenza vaccines  
MVA vector-based influenza vaccines were produced by the Jenner Institute (Oxford, UK). 
MVA-NP-GFP expresses NP from A/Panama/2007/99 under the control of Vaccinia p7.5 
early/late promoter and GFP under the control of fowlpox late FP4b promoter. MVA-
pdmH1HA expresses HA of A/California/04/2009 (pdmH1N1) under the control of the 
modified Vaccinia H5 (mH5) promoter. MVA-NP+M1 expresses NP and M1 from 
A/Panama/2007/99 as a fusion protein joined by a seven amino acid linker under the control 
of Vaccinia p7.5 early/late promoter. MVA-wt was non-recombinant virus used as a vaccine 
vector control.  
2.3.3. Live attenuated influenza vaccines (LAIV) 
FluMist® season 2011-2012 (NR-36465, BEI resources, USA) is a trivalent live attenuated 
influenza vaccine, containing A/California/07/2009 (H1N1) pdm09, A/Perth/16/2009 (H3N2) 
and B/Brisbane/60/2008 at a concentration of 106.5 to 107.5 fluorescent focus units (FFU) of 
each of the three strains in 0.2 ml. It was used as a positive control in antibody production 
study. 
2.3.4. Influenza viruses 
Inactivated whole influenza viruses were used for hemagglutination inhibition (HAI) assay. 
A/California/07/2009 (pdmH1N1) were formalin-inactivated purified viruses, obtained from 
the Government Pharmaceutical Organization (GPO), Thailand. A/Vietnam/1203/2004 (FR-
736) was BLP-inactivated virus, provided by International Reagent Resource (IRR), USA. 
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2.4. Recombinant influenza HA proteins and influenza peptides 
Recombinant HA proteins from different influenza virus strains; A/California/04/2009 (pdm 
H1N1, NR-13691), A/Brisbane/59/2007 (sH1N1, NR-28607), A/Brisbane/10/2007 (H3N2, 
NR-19238), A/Vietnam/1203/2004 (H5N1, NR-10510), A/Hong Kong/33982/2009 (H9N2, 
NR-41792) and A/Anhui/1/2013 (H7N9, NR-44081) were obtained from BEI resources, USA. 
Unless otherwise stated, each HA was a full-length glycosylated recombinant protein that 
was produced in Sf9 insect cells using a baculovirus expression vector system.
 
It was 
purified under conditions that preserve its biological activity and tertiary structure.  
M1 peptides of influenza A viruses (NR-2667, NR-18976, NR-18977, BEI resources, USA) 
were reconstituted with the diluent according to manufacturer’s instructions (the product 
information sheet). 9 to 11 of M1 peptides were pooled with a final concentration of 0.1 
mg/ml. M158-66 (GILGFVFTL) peptide (IBA GmbH, Germany) was reconstituted in 50% 
dimethyl sulphoxide (DMSO) to 1 mg/ml at a final concentration. All peptides were aliquoted 
and kept at -20°C or colder. 
2.5. Cytokines 
Recombinant human interleukin (IL)-2, IL-15 and recombinant human interferon-gamma 
(IFN-γ) were purchased from Peprotech (UK), dissolved in sterile deionised water to 100 
µg/ml and aliquoted before being kept at -80°C.  
2.6. Antibodies 
Fluorochrome-conjugated monoclonal antibodies used for flow-cytometry were purchased 
from BD Biosciences, Biolegend and eBiosciences (UK). The antibody panels for each 
experiment will be specified in each chapter. Antibodies against influenza subtypes used for 
ELISA assay were obtained from BEI Resources, USA and their details will be in chapter 5. 
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2.7. Tissue processing and cell isolation 
2.7.1. Tissue processing  
Upon receiving, adenoid and palatine tonsils were stored at 2-8°C and processed within 24 
hours according to the method described previously [124]. Briefly, the adenoid/tonsils were 
washed with Hank’s balanced salt solution (HBSS) to remove dead cells or tissue debris and 
contaminated blood. They then were minced in HBSS using sterile scalpel before passed 
through 70-µm strainer (Falcon Corning, USA) to be collected as cell suspension. The Ficoll 
Paque gradient (GE healthcare, Sweden) was carried out to isolate adenotonsillar 
mononuclear cells (MNC) by centrifugation at 400xg for 30 minutes with slowest acceleration 
and brake off settings. Adenotonsillar MNCs were collected and washed with phosphate-
buffered saline (1X DPBS, Invitrogen, UK), finally resuspended in L-glutamine and HEPES 
modification of RPMI-1640 (Invitrogen, UK), supplemented with 100 U/ml penicillin, 100 
µg/ml streptomycin (Invitrogen, UK) and 10% heat-inactivated fetal bovine serum (rFBS) 
(Sigma Aldrich, UK), from now on will be named “R10”.  
For peripheral blood mononuclear cell (PBMC) isolation, the heparinised whole blood was 
spun down to collect plasma (named autologous human plasma (aHP), to be used in some 
experiments. Blood samples were diluted in HBSS at the ratio of 1:3 and then carefully 
layered onto the Ficoll Paque, followed by centrifugation and the aforementioned steps as 
the isolation of adenotonsillar MNCs. Adenotonsillar MNCs and PBMCs were counted and 
suspended in R10 at 4x106 cells/ml. 
2.7.2. Magnetic separation of cell population 
Principle 
Magnetic separation is one of the methods to isolate cells of interest or deplete unwanted 
cell types from the cell population. The method allows separating viable and functional cells 
based on surface antigens. Cell separation with magnetic beads and columns is based on 
three steps: magnetic labeling, magnetic separation, and elution of labeled cells (Figure 2.1). 
The target cells are labeled via a particular surface antigen with a specific antibody 
38 
conjugated with superparamagnetic bead or in some case biotinylated, or fluorochrome-
conjugated. The latter would require magnetic labeling which is achieved by the use of anti-
immunoglobulin MicroBeads, anti-biotin MicroBeads, or anti-fluorochrome MicroBeads. 
Labeled cells then are passed through a magnetic column placed on a magnetic stand 
separator. The labeled cells are captured inside, while other unlabeled cells flow out of the 
column. Finally, the column is removed from the separator stand and the labeled cells are 




Figure 2.1   Magnetic separation of cell populations 
The figure illustrates the principle of cell separation by using magnetic beads and column based on 
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2.7.2.1. Depletion of CD69+ cells 
For some experiments, tonsillar MNCs were depleted of activated T cells (CD69+ cells) by 
the use of magnetic bead-based cell separation (Miltenyi Biotec, Germany) according to 
manufacturer’s instructions. Briefly, the MNCs (5 x107-1x108 cells) were washed once with 
1X DPBS (Invitrogen, UK) before being resuspended in depletion buffer (0.5% BSA in 1X 
DPBS). Cells were then incubated with anti-CD69-Biotin for 15 minutes at 4 °C in the 
refrigerator. Anti-Biotin MicroBeads were further added into the cell suspension and 
incubated in the fridge for 15 minutes. Cells were then washed by adding 5 ml of depletion 
buffer and centrifuged at 400xg for 5 minutes and finally resuspended in 0.5 ml of depletion 
buffer. A LS-column was prepared by being placed on the magnetic separator then rinsed 
with 2 ml of depletion buffer. MicroBead-labeled cells were passed through the column 
followed by adding 1 ml of depletion buffer twice. Cells coming out from the column were 
collected and centrifuged at 400xg for 5 minutes before being resuspended in R10 unless 
otherwise stated and counted and adjusted to 4x106 cells/ml. 
2.7.2.2. Positive selection of CD8+ T cells and CD19+ B cells 
For the in vitro cytotoxicity assay, CD8+ T cells and CD19+ B cells were isolated by using 
magnetic bead-based cell separation (Miltenyi Biotec, Germany). CD8+ T cells were 
extracted from MVA-NP+M1-stimulated tonsillar MNCs after 7-day culture and CD19+ B cells 
were isolated from cryopreserved tonsillar MNCs after 1-day resting (see 2.8). The MNCs 
(approximately 5x107 cells) were washed by adding 5 ml of 1X DPBS (Invitrogen, UK) and 
then centrifuged at 400xg for 5 minutes before being resuspended in 400 µl of isolation 
buffer (0.5% BSA in 1X DPBS). They were labeled with either 100 µl of anti-CD8 or anti-
CD19 MicroBead (Miltenyi Biotec, Germany) and incubated in the fridge for 15 minutes. 
Cells were washed by adding 5 ml of isolation buffer and centrifuged at 400xg for 5 minutes 
and finally resuspended in 0.5 ml of isolation buffer. Labeled cells were passed through a 
pre-rinsed LS-column placed on the magnetic separator stand. The column was then 
washed by adding 3 times of 3 ml of isolation buffer to remove non-labeled cells. Finally, 5 
ml of isolation buffer were added to the column while taken away from the magnetic stand. 
The plunger was pushed into the column to extract the labeled-cells out into a tube. The tube 
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was centrifuged and cells were resuspended in 0.5 ml of R10 unless otherwise stated for 
CD8+ T cells and 3 ml of R10 for CD19+ B cells. 
2.8. Cryopreservation of tonsillar MNCs  
Tonsillar MNCs were cryopreserved for later CD19+ B cell isolation used for cytotoxicity 
assays. Freezing medium (20% DMSO in rFBS) was prepared by adding 1 ml of DMSO 
(Sigma Aldrich, UK) in 4 ml of rFBS and pre-cooled by keeping on ice. 3 ml of pre-cooled 
tonsillar MNCs in R10 at 2x107 cells/ml were taken into a 50-ml tube before slowly dropwise 
adding of 3 ml of freezing media with gentle shaking. Each 1 ml of cells in freezing medium 
were aliquoted in cryovials on ice before placing in a pre-cooled Mr. Frosty (Thermo 
scientific, UK) and frozen down at -80°C overnight and kept there until use (no more than 5 
days). 
To thaw the cryopreserved cells, 5 vials of cells were taken from the -80°C freezer and 
immediately held in a 37°C water bath with gentle shaking until a small piece of ice remained 
inside. 1 ml of pre-warmed R10 was added dropwise into each vial before all the cells were 
transferred to a centrifuge tube and pelleted by centrifuge at 400xg for 7 minutes. Cells were 
suspended in 5 ml of pre-warmed R10 and seeded in T-25 flask and incubated at 37°C, 5% 
CO2 overnight for resting. 
2.9. Carboxyfluorescein succinimidyl ester (CFSE) labelling 
Principle 
CFSE was originally developed for the purpose of in vivo lymphocyte tracking and also in 
cytotoxicity assays either in vivo or in vitro. Later, using CFSE for the tracking of lymphocyte 
division becomes a routine procedure in many laboratories. Initially, carboxyfluorescein 
diacetate succinimidyl ester (CFDASE) is a highly cell permeant, non-fluorescent dye. Rapidly 
influxed across cell membrane into live cells, intracellular esterase cleaves acetate groups, 
resulting in green fluorescent CFSE trapped inside the cells. The succinimidyl ester group 
reacts with intracellular free amino groups to generate highly stable covalent bonds. The result 
is live cells with intracellular fluorescent label that persist for months [126]. At appropriate 
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concentrations, CFSE is non-toxic to cells and the fluorescence is retained after formaldehyde 
and alcohol fixation [127]. The fluorescence intensity of CFSE is diluted between daughter 
cells following cell division, which allows lymphocyte proliferation to be monitored by flow-
cytometry. Lymphocyte proliferation can be monitored for up to eight divisions before CFSE 
fluorescence decreased to the background fluorescence of unlabeled cells [126].  
Method 
To study T cell proliferation following vaccine stimulation, tonsillar MNCs were labeled with 
CFSE before vaccine stimulation and culture. If the MNCs were in R10, they needed to be 
washed by adding 5 ml of 1X DPBS and centrifuged at 400xg for 5 minutes. 1x106-1x108 
cells were suspended in 1 ml of 1X DPBS. 1 µl of 5mM CFSE in DMSO (Invitrogen, UK) was 
added into the cell supension and mixed thoroughly before incubating at 37°C for 15 
minutes. After complete incubation, 5 ml of pre-warmed R10 were added into the tube and 
incubated at 37°C for another 5 minutes before pelleting cells by centrifuge at 400xg for 5 
minutes. Cells were counted and finally resuspended in R10 at 4x106 cells/ml. The labeled 
cells should be kept with minimal light exposure. 
2.10. Surface and intracellular (cytoplasmic) staining 
Polychromatic flow-cytometry after surface and intracellular cell staining allows to study cell 
phenotypes and functionality (Figure 2.2). To stain cells for flow-cytometry, freshly isolated 
cells or cells harvested after vaccine stimulation were transferred to 1.5–ml microtubes. Cells 
were pelleted to remove culture medium then washed by adding 1 ml of FACS staining 
buffer (0.2% BSA in 1X PBS) and centrifuged at 500xg for 5 minutes. Cells were then 
incubated for 30 minutes in the fridge with 50 µl of master mix fluorochrome-conjugated 
antibodies to any cell surface markers (e.g. CD19, CD3 and CD4). Cells then were washed 
by adding 1 ml of staining buffer and centrifuged at 500xg for 5 minutes. If no intracellular 
staining (ICS), cells were resuspended in 400-500 µl of staining buffer.  If ICS was required, 
cells were dispersed after centrifugation then 100 µl of intracellular (IC) fixation buffer 
(eBioscience, UK) added with immediate vortex and incubation in the dark at room 
temperature for 20 minutes. To wash out fixative reagent, 1 ml of 1X permeabilisation buffer 
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(eBioscience, UK) was added in to the cell tube and centrifuged at 1000xg for 5 minutes. 
Supernatant was decanted as much as possible to avoid any effects of remaining fixative 
agent to antibodies added in the later step. Cells were then dispersed and incubated for 20 
minutes at room temperature with 50 µl of master mix fluorochrome-conjugated monoclonal 
antibodies to any cytokines or cytoplasmic markers (e.g. IFN-γ and perforin). Cells were then 
washed by adding 1 ml of 1X permeabilisation buffer and centrifuged at 1000xg for 5 
minutes. Washing was repeated with 1 ml of FACS staining buffer. Cell pellet was finally 
resuspended in 400-500 µl of staining buffer. Labeled cells were kept in the fridge with 
protection from light until flow-cytometry. 
To prepare the master mix antibody, each sample required 50 µl of master mix antibodies. 
The volume of each antibody was calculated based on the total number of samples before 
mixing them together and adjusting the volume with FACS staining buffer or 1X 
permeabilisation buffer for surface staining and ICS, respectively. For example, if 5 samples 
were stained with 2 surface markers; anti-CD4-PE and anti-CD8-PECy7 and 5 µl of each 
antibody was required to stain each sample, the master mix antibody was prepared as 
following; 
1. Calculate the total volume of each antibody based on the number of samples 
 Total volume of anti-CD4-PE        = 5 µl x 5 samples = 25 µl 
Total volume of anti-CD8-PECy7  = 5 µl x 5 samples = 25 µl 
2. Calculate the total volume of FACS staining buffer to add into master mix  
Total volume of staining buffer  
=  (50 µl x No. of samples) – total volume of each antibody 
=  (50 µl x 5 samples) – 25 µl of anti CD4-PE – 25 µl of anti CD8-PECy7 
=  250 – 25 – 25 = 200 µl 
3. In sum, mix antibodies and staining buffer as calculated to prepare master mix 
antibodies  
Anti CD4-PE  25 µl 
Anti CD8-PECy7 25 µl 
Staining buffer  200 µl  (or 1X permeablisation if ICS) 
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In case of using more than one conjugated with brilliant violent dye-conjugated antibody in 
the panel (e.g. BV421 together with BV650), 50 µl of brilliant stain buffer (BD Biosciences, 
UK) was replaced with FACS staining/ permeablisation buffer to dilute antibodies and make 
the master mix. The total volume of master mix added to each sample was the summed 
volume of all antibodies and brilliant stain buffer.  
 
Figure 2.2   Surface and intracellular cell staining 
The figure illustrates the principle of surface and intracellular cell staining using fluorescence-tagged 
monoclonal antibodies. Specific surface markers on the cell surface (e.g. CD4) are firstly stained. Cells 
then are fixed with compatible fixation agents to stabilise the cell morphology. Permeabilisation buffer 
generates pores on cell membrane, which allow the antibody enter into cell cytoplasm and bind to 
target proteins (e.g. cytokines and granzymes).  
 
2.11. Flow-cytometry 
Labeled cells were immediately analysed or kept in the fridge overnight away from light 
before flow-cytometry. The labeled cells were transferred to a FACS tube (Corning, UK). 
Flow cytometric data from each sample was acquired by FACS Calibur using CellQuest Pro 
software or FACS Accuri C6 or FACS Celesta using FACS Diva (BD Biosciences, USA). The 
number of events acquired was dependent upon each study. The data were analysed using 
FlowJo 8.7 software (FlowJo, LLC.) or BD AccuriC6 software (BD Biosciences, USA). 
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2.12. Enzyme-linked ImmunoSpot Assay (ELISPOT) 
Principle 
ELISPOT is a highly sensitive immunological assay to enumerate cytokines or antibody-
producing cells in peripheral blood mononuclear cells or lymphoid tissue-isolated cells such 
as splenocytes. One of the most common applications of the assay is to quantify the 
frequency of IFN-γ-producing cells in response to antigenic stimulation. In the assay, cells 
are cultured with the target antigen in an antibody-coated membrane microtitre plate. In 
response to the antigen recognition, cells secrete proteins; for example IFN-γ, that being 
captured by specific antibodies bound in the wells. Secreted cytokines are detected by 
biotinylated detection antibody with streptavidin-enzyme conjugate followed by the addition 
of its corresponding chromogenic precipitating substrate (Figure 2.3). The end result is 
visible as spots, which each spot corresponds to a single secreting cell [128], [129]. 
 
Figure 2.3   Enzyme-linked ImmunoSpot Assay (ELISPOT)  
The figure illustrates the principle of IFN-γ ELISPOT assay based on six steps; antibody coating, cell 
incubation, cytokine capture, addition of detection antibodies, addition of streptavidin-enzyme 
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Method 
To detect IFN-γ-producing cells in adenotonsillar MNCs following in vitro MVA-NP+M1 
stimulation, ELISPOT was performed using human IFN-γ ELISPOT kit (eBiosciences, UK) 
following manufacturer’s instructions. Briefly, the 96-well polyvinylidene fluoride (PVDF) 
membrane ELISPOT plate (MSIPN4510, Millipore, UK) was pre-wetted with 15 µl of 35% 
freshly prepared ethanol for 10-60 seconds. The plate was extensively washed with 200 µl of 
1X PBS for five times then coated with 100 µl of 1X anti-human IFN-γ capture antibody 
diluted in 1X coating buffer and kept in the fridge overnight. Next day, the plate was washed 
twice with 1X coating buffer followed by blocking with R10 for at least 60 minutes at room 
temperature. In the meantime, tonsillar MNCs following in vitro vaccine stimulation were 
harvested, counted and adjusted to 2x106 cells/ml. Cells were then stimulated with M1 
influenza peptide pools (BEI Resources, USA; detail see 4.3.6). R10 was removed from the 
plate and 100µl of peptide-stimulated cells were seeded in triplicate. Cells without any 
stimulation were cell control and only R10 was used as a negative medium control. Cells 
stimulated with 1 µg/ml Staphylococcal enterotoxin B (SEB) (NR-44235, BEI Resources, 
USA) were used as positive control. The plate was incubated at 37°C, 5% CO2 for 24 hours 
with minimal agitation. Following the complete incubation, cells were removed from the plate 
and the plate then was washed three times with washing buffer (0.05% Tween20 in 1X 
PBS). The plate was incubated with 100 µl of 1X anti-human IFN-γ detection antibody for 
120 minutes at room temperature. It was then thoroughly washed before incubating with 100 
µl of 1X Avidin-Horseradish peroxidase (Avidin-HRPO) for 45 minutes at room temperature. 
Finally, the plate was extensively washed with washing buffer followed by 1X PBS. Spots 
were developed by adding 100 µl of 3-amino-9-ethyl carbazole (AEC) substrate (see 
appendix-1) (Sigma Aldrich, UK). The plate was incubated in the dark for about 15-20 
minutes before stopping the reaction by removing substrate following by rinsing with cold tap 




2.13. Indirect Enzyme-linked Immunosorbent Assay (ELISA)  
Principle 
ELISA is a simple and rapid technique based on an enzyme-labeled antibody. It is capable 
of quantifying proteins immobilised to a solid surface. ELISA is traditionally performed in 
polystyrene microtitre plates where antigen or antibody binds via passive absorption. There 
are four different formats of ELISA; direct, indirect, sandwich and competitive. For the 
indirect ELISA, the antigen of interest is immobilised in 96- or 384-well plate. A blocking 
buffer is added to saturate all unbound areas; avoid any non-specific binding of analytes in 
the later step. Samples containing antibodies (or analytes) are then incubated in the pre-
coated plate, followed by enzyme-conjugated anti-species antibody specific to the analytes 
(e.g. anti-human IgG antibody). The corresponding substrate is finally added, which is 
catalysed by the enzyme, resulting in the colour-changed solution (Figure 2.4) whose optical 
density (OD) can be measured by a microplate reader [132]. 
 
Figure 2.4   Indirect Enzyme-linked Immunosorbent Assay (ELISA)  
The figure illustrates the principle of indirect ELISA to detect antigen-specific antibodies based on four 
steps; antigen coating, antibody capture, addition of detection antibody-enzyme and addition of 
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Cell culture supernatant from adenotonsillar MNCs following in vitro MVA-pdmH1HA 
stimulation was analysed for HA-specific IgG antibodies by indirect ELISA as described 
previously [84]. Briefly, a 96-well microplate (No. 3590, Corning, USA) was coated with 100 
µl of 0.25 µg/ml HA of an influenza strain (pH1N1 or sH1N1 or H3N2 or H5N1) or 100 µl of 
0.5 µg/ml HA of H7N9 or H9N2 diluted in 1X PBS (The concentration of HA of each influenza 
virus was pre-optimised, data not shown), then kept in the fridge overnight. Next day, the 
HA-coated plate was washed five times and blocked with 150 µl of blocking buffer 
(10%rFBS in 1X PBS) for at least 60 minutes. 50 µl of each diluted sample was applied in 
duplicate and incubated on a horizontal shaker at room temperature for 120 minutes. Along 
with the samples, human convalescent serum to H1N1 pdm09 (NR-18964) and human 
reference antiserum to A/Indonesia/05/2005 (H5N1) (NR-33669, both BEI resources, USA) 
were used as standard antiserum for specific detection of anti-pH1N1 and anti-H5N1 
antibodies, respectively. Human normal immunoglobulin; Sandoglobulin (CSL, Australia) was 
used as the standard for the detection of anti-H3N2, anti-sH1N1, anti-H7N9 and anti-H9N2 
antibodies due to unavailability of specific standard reagent. Blocking buffer was used as a 
negative control. After complete incubation, the plate was washed 5 times with washing 
buffer (0.05% Tween20 in 1X PBS) using a microplate washing machine. 50 µl of 1:2000 
mouse monoclonal anti-human IgG antibody, alkaline phosphatase conjugated (Sigma 
Aldrich, UK) was added and incubated for 90 minutes. Finally, the plate was washed 5 times 
with washing buffer, before adding 50 µl of p-Nitrophenylphosphate (PNPP) substrate (see 
appendix-1) (Sigma Aldrich, UK). OD was read at 405 nm at 60 and 120 minutes after 
substrate added by microplate reader (Dynex Opsys MR™). The antibody concentration in 
standard antiserum (Units/ml, U/ml) was defined from its dilution that showed the OD of 
1.0±0.1 at 60 minutes after adding the substrate. With the standard curve, the OD value of 
each sample was calculated to HA-specific IgG antibody concentration (U/ml) using 
DeltaSoft 1.61.0 programme (Biometallics Inc.).  
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2.14. Haemagglutination Inhibition (HAI) Assay  
Principle 
HAI assay is a gold standard to detect antibodies against a specific influenza virus strain. 
The assay takes advantage of the observation that HA protein of influenza virus could bind 
to red blood cells (RBC), causing agglutination. When antibodies specifically bind to HA of 
influenza virus, this antigenic site, which is around receptor-binding site (RBS) is blocked 
and unable to bind with RBCs, demonstrating the inhibition of haemagglutination, which is 
the basis of the assay (Figure 2.5). HAI assay is performed in microtitre plates. A 
standardised quantity of HA antigen is mixed with serially diluted samples containing virus-
specific antibodies (e.g. serum), followed by the addition of RBCs to assess the degree of 
binding of the antibody to the HA molecule of the virus [134] . 
 
 
Figure 2.5   The principle of Haemagglutination Inhibition  
The figure illustrates haemagglutination when co-incubating influenza and chicken red blood cells. The 
inhibition of haemagglutination occurs when antibodies specific to the HA epitope around the receptor 
binding site of the virus are introduced to the system, which block the binding of influenza viruses to 
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Anti-HA antibodies in cell culture supernatant from adenotonsillar MNCs following in vitro 
MVA-pdmH1HA stimulation were also analysed by HAI assay as described previously [134]. 
Human serum used as positive control was treated with receptor-destroying enzyme (RDE). 
100 µl of serum was added with 300 µl of 1X RDE (Denka Seiken, Japan) and incubated at 
37°C for 18-24 hours. Cell culture supernatant was omitted for RDE treatment. Next day, 
400 µl RDE-treated serum and 150 µl of cell supernatant samples were heated in a heat 
block at 56°C for 60 minutes before adding pre-cooled 1X PBS; 600 µl for serum and 150 µl 
for cell culture supernatant, making them 1:10 and 1:2 final dilution. 20 µl of packed chicken 
RBCs (First Link, UK) were added into each sample, gently mixed and incubated at room 
temperature for 60 minutes while inverting tubes every 15 minutes to resuspend RBCs. After 
centrifugation to pellet RBCs, supernatant was collected for HAI assay. To perform the 
assay, RDE-treated human serum was used as a positive control and PBS as a negative 
RBC control. 50 µl of 1X PBS was added in all wells of column 12. 50 µl of RBC-treated cell 
culture supernatants were added in duplicate in row A of column 1-10. The human serum 
was added in A11. All samples in column 1-11 were then 2-fold serial diluted by taking 25 µl 
of sample from row A into 25 µl of 1X PBS of successive row until row H of V-bottom 96-well 
plate (Nunc 249570, Thermo scientific, UK). 25 µl of 8 HA unit (HAU) standardised 
inactivated influenza virus antigen (pdmH1N1 or H5N1, see appendix-1) was added in all 
wells except RBC control in column 12, mixed well and incubated at room temperature for 30 
minutes. 50 µl of 0.5% chicken RBCs (see appendix-1) was finally added in all wells and 
incubated at room temperature for another 30 minutes (Figure 2.6). The HAI titre of each 







Figure 2.6   Schematic outline of haemagglutination inhibition (HAI) assay 
To perform the HAI assay, 50µl of cell culture supernatants are added in duplicate from A1-A10. Positive 
control RDE-treated human serum is added in A11. All are then 2-fold serial diluted in 1X PBS down to 
row H. 25µl of influenza virus antigen is added followed by 50µl of 0.5% chicken red blood cells (RBC) to 




Figure 2.7   Patterns of avian red blood cell agglutination  
Completely, partially and non-agglutinated chicken red blood cells are shown. Only non-agglutinated 
cells, which appeared as a sharp button of RBCs and flowed down when tilting the plate, were used to 
interpret the HAI titre [134]. 
 
Interpretation of results
If an antigen-antibody reaction does occur then haemagglutination of the RBCs will be 
inhibited. An illustration of the use of such HAI reactions in the identification of viral 
isolates is shown in FIGURE 2.E-6. In this example, viral isolate 1 is identified as influenza 
A(H3) and viral isolate 2 as influenza A(H1) when compared with the control antigens. An 
insignificant cross-reaction with influenza A(H3N2) reference antisera and viral isolate 2 
is shown in column 9. The RBC controls in columns 6 and 7 are correct.
To identify a viral isolate, the results for each isolate should be compared with those for 
the antigen controls. A viral isolate is identified as a particular type or subtype if it reacts 
with one reference antiserum at a 4-fold or greater HAI titre than it reacts with other 
antisera. The HAI titre is then the reciprocal of the highest dilution of antiserum that 
completely inhibits haemagglutination.
An example of how to interpret HAI titre results obtained for viral isolates using the 
WHO Influe za Reagen  Kit is shown in TABLE 2.E-2. The influenza A identifications are 
clear: isolate 2 is infl enza A(H1) with some cross-reactivity wi h influenza A(H3N2) anti-
s rum. Isolate 5 is influenza A(H3) with insignificant low-level cross-reactivity with influ-
enza A(H1N1) antiserum. Cross-reactions between influenza B viruses require careful 
interpretation. Viral isolates that are B/Yamagata/16/88-like will cross-react with refer-
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Key to FIGURE 2.E-5
A1 – Influenza A(H1) reference antiserum
A2 – Influenza A(H3) reference antiserum
A3 – Influenza B reference antiserum (B/Yamagata/16/88 lineage)
A4 – Influenza B reference antiserum (B/Victoria/02/87 lineage)
A5 – Negative control serum
A6 – RBC control (PBS)
A7 – RBC control (PBS)
A8 – Influenza A(H1) reference antiserum
A9 – Influenza A(H3) reference antiserum
A10 – Influenza B reference antiserum (B/Yamagata/16/88 lineage)
A11 – Influenza B reference antiserum (B/Victoria/02/87 lineage)
A12 – Negative control serum
FIGURE 2.E-5
Schematic outline for identifying viral isolates using HAI testing







































































Agglutinated cells     
Non-agglutinated  
cells 
3. Centrifuge at 1200 rpm for 10 minutes.
4. Carefully remove the adsorbed serum with ut disturbing the packed R Cs.
5. Check for the presence of non pecific agglutinins in the serum, as described above.
6. Repeat adsorption with RBCs until there is no haemagglutination associated with the 
serum.
Haemagglutination titration of control antigens and viral isolates
1. Choose the appropriate type of 96-well microtitre plate (TABLE 2.E-1) and label 2 plates 
oriented as shown in FIGURE 2.E-4. One plate will be used for the control antigens and 
a second plate for the viral isolates according to the key shown for FIGURE 2.E-4.
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FIGURE 2.E-2
Schematic outline approach for the detection of nonspecific agglutinins in treated sera
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2.15. Statistical analysis 
All statistical analyses were performed using Graphpad Prism 5.0. The difference of two 
groups was analysed either by paired, non-parametric test (Wilcoxon matched-pairs singed 
rank test) or by unpaired, non-parametric test (Mann Whitney test). The difference among a 
group of more than two was analysed by one-way analysis of variance (ANOVA) and then 




















3. Chapter 3  
The expression of influenza protein antigens in 
adenotonsillar MNCs following in vitro stimulation with 
Modified Vaccinia Ankara (MVA) and simian adenovirus 

















Influenza has continued to cause widespread morbidity and mortality in humans, resulting in 
major challenges to healthcare systems. Current influenza vaccines are of limited efficacy 
against mismatched or emerging new virus strains [4]. The H1N1 pandemic outbreak in 
2009 and the potential of future pandemics of avian influenza (e.g. H5N1, H7N9 and H9N2) 
highlight the urgent need for more effective vaccines. Current efforts are focused on the 
development of novel vaccines capable of inducing broad protection from multiple subtypes 
of influenza viruses including those with the potential to cause pandemics. To confer a 
broadly protective response, conserved viral proteins are considered as vaccine targets. 
These novel vaccine antigens include NP, M1, M2e and the stem region of haemagglutinin 
(HA2) [22], [35], [43], [136]. Moreover, a number of advanced vaccine platforms such as 
DNA vaccines, virus vector-based vaccines, virus-like particles, synthetic peptides and 
liposomes have been applied to develop novel vaccines delivering these target proteins for 
better and broader protection [22], [136].  
Among others, virus-vectored vaccines have become one of the promising approaches 
owing to the favourable feasibility and capacity of transgene insertion, the precise control of 
target protein expression and the relative ease of production at high titres of the virus. Viral 
vectors are live viruses but are attenuated or deficient in replication, thus considered to be 
safe in general [50], [51]. Orthopoxvirus especially Modified Vaccinia Ankara (MVA) and 
recombinant adenovirus (rAd) vectors have been widely employed for novel influenza 
vaccine development. They have been constructed to express various target protein 
antigens, and many of them have been investigated for protective responses in either pre-
clinical studies and/or clinical trials [54], [71].  
Poxvirus and adenovirus can infect a wide variety of cell types and tissues [137], [138]. This 
advantage also allows the vectored virus to be administered via many delivery routes both 
parental and mucosal [139], [140]. By infecting target cells, the encoded transgenes 
controlled by specific promoters could be expressed to produce influenza proteins in native 
conformation, inducing both antigen-specific T cell responses and B cell-mediated antibody 
production [52]. Different types of immune cells in peripheral blood have been collectively 
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studied and shown to have various degrees of susceptibility to MVA [141]–[143] and some 
rAd vectors [144]–[146] . However, there is no such data in human NALT.  
As the ultimate aim of the project is to study the immune responses elicited by MVA- and 
PanAd3 vector-based influenza vaccines in human NALT, it is necessary to understand how 
the virus-vectored vaccines behave at this mucosal inductive site. In this study, I investigated 
the expression of influenza proteins in different cell types in adenotonsillar MNCs and the 
cellular localisation of those expressed protein antigens in virus-vectored vaccine-infected 
cells following in vitro MVA- or PanAd3-vectored influenza vaccine stimulation.  
 
3.2. Aims of the study 
1. To determine the types of immune cells in adenotonsillar MNCs expressing influenza 
protein antigens following in vitro stimulation of MVA- and PanAd3-vectored influenza 
vaccine candidates 










3.3. Materials and methods 
3.3.1. Adenoidal and tonsillar tissues 
Adenoidal and/or tonsillar tissues were obtained from patients undergoing 
adenotonsillectomy at local hospitals. Patients who received systemic steroids within 3 
weeks prior to surgery, or who had any known immunodeficiency were excluded from the 
study. Adenotonsillar MNCs were isolated from the tissues following the standard protocol 
described in chapter 2 (see 2.7.1). Cells were resuspended in R10 at 4x106 cells/ml. 
3.3.2. Cell lines 
HEK 293T cells (kindly provided by Prof. Bill Paxton, Institute of Infection and Global Health, 
University of Liverpool) were cultured in T-75 flasks with Dulbecco's Modified Eagle Medium 
(Gibco, UK) containing 10% heat-inactivated fetal bovine serum (rFBS) and penicillin/ 
streptomycin (P/S), termed as “DMEM10”. Cells were incubated at 37°C with 5%CO2 and 
passaged when they reached approximately 80% confluence.  
3.3.3. Vaccines 
The following vaccines were studied for the expression of influenza vaccine antigens in 
adenotonsillar MNCs: MVA-wt (#1533), MVA-NP-GFP (#769), MVA-NP+M1 (#850), MVA-
pdmH1HA (#1531), PanAd3-gag, PanAd3-NPM1, PanAd3-NPM1-pdmH1HA and PanAd3-
NPM1-H5HA. MVA-wt and PanAd3-gag are vector only controls for MVA- and PanAd3-
based vaccines, respectively. The virus titres were expressed as plaque-forming unit/ml 
(pfu/ml) for MVA-based vaccines and as virus particle/ml (vp/ml) for PanAd3-based 
vaccines. 
3.3.4. Fluorochrome-conjugated monoclonal antibodies 
The following fluorochrome-conjugated monoclonal antibodies were used for cell staining 
and flow-cytometry; CD19-PE or FITC (clone HIB19), CD3-PECy5 or PECy7 (clone UCHT1), 
CD11c-APC (clone B-ly6), CD123-FITC (clone 7G3) (All BD Biosciences, UK) and FITC-
conjugated monoclonal antibody to influenza A NP (MA1-7322, Thermo scientific, UK). 
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Monoclonal antibodies to HA of A/California/04/2009 (pH1N1) (NR-42021), to HA of 
A/Vietnam/1203/2004 (H5N1) (NR-13444) (Both from BEI Resources, USA) and to influenza 
A M1 (GA2B, Abcam, UK) were in-house conjugated using R-Phycoerythrin (RPE)-LYNX 
conjugation kit (BioRad, UK) for measuring influenza protein expression in adenotonsillar 
MNCs. RPE was chosen due to its high brightness. RPE-conjugated antibodies were kept in 
the refrigerator and protected from light.  
3.3.5. Cell stimulation and culture 
Adenotonsillar MNCs were cultured with either MVA vector-based vaccines at a range of 
multiplicity of infection (MOI) or PanAd3 vector-based influenza vaccines at different virus 
particles/ cell in a 48-well cell culture plate (Corning, USA) and incubated at 37°C, 5%CO2. 
Cells were harvested at different time points for a kinetic study or at 24 hours to measure 
influenza protein antigen expression. The MNCs without any stimulation (medium control) 
were used as a negative control. MVA-wt or PanAd3-gag stimulated MNCs were used as 
vector only controls. 
MOI was calculated based on the virus titre in PFU/ml, indicating the number of infectious 
viruses per cell. Due to the difference in the evaluation of vaccine concentration, the number 
of virus particles per cell (vp/cell) was used instead of MOI for PanAd3-vectored vaccines. 
To study the expression of influenza proteins in HEK 293T cell lines following in vitro 
PanAd3 vector-based vaccine stimulation, cells were seeded at 2x105 cells/ well in 24-well 
plates and cultured in DMEM10 a day before performing the experiment. Culture media was 
removed and 200 µl of each vaccine at the concentration of 20 vp/cell were gently added to 
avoid disturbing cells, then incubated at 37°C, 5%CO2 for 90 minutes before washing out 
with pre-warmed DMEM. Fresh DMEM containing 2% rFBS and P/S was added to each 
well for a further 18-hour incubation.  
3.3.6. Measurement of influenza protein expression 
Following in vitro vaccine stimulation, adenotonsillar MNCs were harvested and washed 
once with FACS staining buffer prior to stain for the cell surface markers; CD19, CD3 or 
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CD4, CD11c and CD123. Table 3.1 described the CD markers used to identify different 
types of immune cells. The MNCs were fixed and permeabilised followed by intracellular 
staining for influenza HA of pdmH1N1 or H5N1, NP and M1 protein depending upon vaccine 
stimulation (see 2.10). In some experiments, influenza HA of pdmH1N1 and NP was stained 
without cell permeabilisation, aiming to detect the proteins present on the cell surface. For 
GFP expression study, the MNCs were only stained for the cell surface markers. 
HEK 293T cells, following PanAd3-vectored vaccine stimulation, were trypsinised by adding 
100 µl of 0.25% trypsin-EDTA before tapping to detach cells from the bottom of the wells. 0.5 
ml of DMEM10 was added into each well before cells were harvested in a tube and pelleted. 
Cells were then fixed and permeabilised followed by intracellular staining for influenza NP 
and HA as aforementioned. 
The data for labeled MNCs or HEK 293T cells were acquired by BD FACS Calibur or 
Celesta. The expression of each influenza protein antigen in the MNCs was presented as 
the percentage of M1+ or NP+ or HA+ cells among each cell population (T cells, B cells and 
dendritic cells).  
Table 3.1   CD markers for immune cell identification  
CD markers Immune cells 
CD3 Pan T cells (both CD4+ and CD8+ T cells) 
CD4 CD4+ T helper cells 
CD19 B cells 
CD11c Myeloid dendritic cells 
CD123 Plasmacytoid dendritic cells 
3.3.7.  Statistical analysis 
The difference among a group of more than two was analysed by one-way analysis of 
variance (ANOVA) and then for each pair by t-test. 
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3.4. Results 
3.4.1. The kinetic expression of MVA-encoded transgenes in adenotonsillar 
MNCs  
The kinetics of influenza NP expression in adenotonsillar MNCs were initially studied by the 
use of a GFP-expressing MVA construct; MVA-NP-GFP. In this construct, as the GFP gene 
is linked to the promotor of the NP gene, the level of GFP expression will therefore represent 
the level of NP antigen expression.  
Adenotonsillar MNCs were cultured with MVA-NP-GFP at MOI of 1 and GFP expression in 
the MNCs was examined at different time points. It was shown that GFP expression was 
observed mainly in CD19+ B cells. The GFP expression in the MNCs was detected at as 
early as 6 hours following in vitro stimulation. The proportion of GFP+ cells increased with 
time of incubation until reaching the peak, which lasted between 24 and 30 hours before 
decreasing. When the median fluorescence intensity (MFI) of GFP of these positive cells 
was analysed, the highest MFI was shown between 16 and 24 hours (Figure 3.1). Therefore, 
it was concluded that the optimal time to detect the expression of transgene in MVA vectored 















Figure 3.1   GFP expression in adenotonsillar MNCs following in vitro MVA-NP-GFP 
stimulation 
Adenotonsillar MNCs were stimulated in vitro with MVA-NP-GFP at MOI of 1 before the measurement 
of the GFP expression level at different time points from 0 to 42 hours. a) The representative flow 
cytometric dot plots showed the expression of GFP at 0 and 24 hours in CD19+ B cells. b) The kinetics 
of GFP expression was shown as the percentage of GFP+ cells (black line) and the median 
fluorescence intensity (MFI) of GFP (red line) (n=1). 
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3.4.2. Specificity and sensitivity of the method based on fluorochrome-
conjugated monoclonal antibody-labelling and flow-cytometry for the 
detection of vaccine antigen expression in adenotonsillar MNCs 
Having shown the optimal 24-hour time of transgene expression after MVA vectored vaccine 
infection, the expression of MVA-encoded protein antigens in adenotonsillar MNCs were 
directly measured using the developing method based on the intracellular staining of protein 
antigen with fluorochrome-conjugated monoclonal antibody, followed by flow-cytometry. The 
range of MOIs of the vaccines was set regarding the previous study [147]. 
The specificity of the established method was firstly tested. Influenza M1 expression in 
adenotonsillar MNCs was examined following in vitro MVA-NP+M1 stimulation and compared 
with MVA-pdmH1HA (expressing HA) stimulation at the MOI of 0.025. M1 expression was 
detected in a significant number of the B cells in the MNCs stimulated with MVA-NP+M1, but 
not those with MVA-pdmH1HA and MVA-wt (Figure 3.2a,c), suggesting the high specificity of 
this method. 
The sensitivity of this method was then assessed. Influenza HA expression in adenotonsillar 
MNCs was measured following in vitro MVA-pdmH1HA stimulation at low MOIs ranging from 
0.0025 to 0.0125. HA antigen was shown to be expressed in adenotonsillar B cells with a 
dose-dependent manner upon MVA-pdmH1HA infection. The intermediate dose with MOI of 
0.006 showed a significant difference in HA expression compared to medium control, 
showing 3.6 times higher positive cells. An increased proportion of HA-expressing B cells 
was found at the higher MOI of 0.0125.  The results suggested that the method would 
accurately determine the protein expression in the MNCs when the proportion of protein-













Figure 3.2   Specificity and sensitivity of the method based on fluorochrome-
conjugated antibody labeling and flow-cytometry to measure the expression of 
influenza vaccine antigens 
Adenotonsillar MNCs were stimulated in vitro with MVA-vectored influenza vaccines for 24 hours as 
compared to unstimulated MNCs (medium control). (a,c) The specificity of the method was shown as M1 
expression was detected in CD19+ B cells stimulated with MVA-NP+M1, but not with MVA-wt and MVA-
pdmH1HA. Bars and error bars indicated means and SEMs (n=4). (b,d) The sensitivity to detect HA 
expression was shown following MVA-pdmH1HA stimulation. The proportion of HA-expressing B cells 
was shown upon stimulation with different vaccine doses (MOIs). The intermediate and highest doses 
showed significant HA expression compared to medium control (pair by t-test, **p=0.0070 and 
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3.4.3. Expression of influenza NP, M1 and HA in adenotonsillar MNCs following 
in vitro MVA-vectored vaccine stimulation  
Intracellular protein staining with flow-cytometry is a highly specific and sensitive method to 
detect influenza protein expression in virus-vectored vaccine-stimulated adenotonsillar 
MNCs.  Thus, the types of immune cells in the MNCs targeted by MVA-vectored vaccines 
were then examined. Adenotonsillar MNCs were in vitro stimulated with either MVA-NP+M1 
or MVA-pdmH1HA and the expression of influenza NP, M1 and HA was measured in 
different cell types including T cells, B cells and dendritic cells (DC) (Figure 3.3). To 
maximise the chance of MVA-vectored vaccine infection to DCs, which are in a small 
proportion in the isolated adenotonsillar MNCs, a relatively high titre of the vaccine (MOI of 
1) was applied for cell stimulation. 
 
 
Figure 3.3    Gating strategy for the measurement of influenza protein expression 
Viable adenotonsillar mononuclear cells (according to appendix-2) were gated from FSC-SSC plot. 
Then, either CD19+ B cells or CD4+ T cells as well as CD11c+ myeloid DCs or CD123+ plasmacytoid 
DCs were gated from the double antibody-stained dot plots. The influenza protein expression (e.g. M1) 
in each cell types was measured by gating on the histogram the population with high fluorescence 
intensity of influenza protein.  


























































































































CD4+ T cells 
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Following in vitro MVA-NP+M1 stimulation, both NP and M1 were shown to be mainly 
expressed in B cells (Mean ± SEM; NP 42.40 ± 6.31%, M1 35.20 ± 7.55%). Only a few 
positive cells were detected in CD4+ T cells (NP 3.04 ± 0.91%, M1 3.56 ± 1.08%). The 
results from pan CD3+ T cells were comparable as those from only CD4+ T cells (data not 
shown). Most B cells showed the co-expression of both NP and M1 (Figure 3.4c), which 
indicated that each infected cell expressed both proteins, most likely owing to the vaccine 
construct where NP and M1 genes are linked to each other driven by the same promoter. 
According to the results, the expression of M1 could represent the expression of NP, the 
expression of only M1 was further examined in dendritic cells, which were a small population 
(<0.5%) in the MNCs. M1 expression was also detected in both myeloid dendritic cells 
(mDC; 21.17 ± 3.18%) and plasmacytoid dendritic cells (pDC; 22.07 ± 7.14%). By contrast, 
NP and M1 expressions were undetectable in any cell types following in vitro MVA-wt 
stimulation (vector control) (Figure 3.4a,b).  
The expression of HA in adenotonsillar MNCs was examined following in vitro MVA-
pdmH1HA stimulation. The vaccine dose to stimulate cells was reduced to MOI of 0.025 as 
cell morphology was affected when stimulated at MOI of 1 (data not shown). Similar to M1 
and NP expressions, HA protein expression was also predominantly observed in B cells 


















Figure 3.4   Expression of influenza nucleoprotein (NP) and matrix protein 1 (M1) 
following in vitro MVA-NP+M1 stimulation 
Adenotonsillar MNCs were cultured with MVA-NP+M1 at MOI of 1 for 24 hours followed by intracellular 
staining for NP and M1 and flow-cytometry. a) The histograms showed the expression of M1 (red line) 
and NP (green line) in CD19+ B cells, CD4+ T cells, myeloid (mDC) and plasmacytoid dendritic cells 
(pDC) following in vitro MVA-NP+M1 compared to MVA-wt (grey shade) stimulation. b) Bar charts 
compared the percentage of M1+ cells in each cell types between MVA-NP+M1 (red bar) and MVA-wt 
(grey bar) stimulation (n=3). Bars and error bars indicated means and SEMs. c) Gating on CD19+ B 
cells, the representative flow cytometric dot plot showed the co-expression of NP and M1 following in 
vitro MVA-NP+M1 stimulation. 
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Figure 3.5   Expression of influenza haemagglutinin (HA) following in vitro MVA-
pdmH1HA stimulation 
Adenotonsillar MNCs were cultured with MVA-pdmH1HA at MOI of 0.025 for 24 hours followed by 
intracellular staining for HA of pandemic H1N1 strain (pdmH1HA) and flow-cytometry. a) The histograms 
showed HA protein (blue line) following in vitro MVA-pdmH1HA compared to MVA-wt (grey shade) 
stimulation  in CD19+ B cells and CD3+ pan T cells. b) Bar charts compared the percentage of HA+ cells in 
each cell types between MVA-pdmH1HA (blue bar) and MVA-wt (grey bar) stimulation (n=3). Bars and 



































3.4.5. Cellular localisation of influenza NP and HA in MVA vector-infected 
adenotonsillar B cells 
By using cell surface and intracellular staining to detect influenza protein antigen expression, 
the different localisation pattern between influenza NP and HA was observed in MVA 
vaccine-infected adenotonsillar B cells. At 24-hour culture, HA expression following in vitro 
MVA-pdmH1HA stimulation was detected on the B cell surface directly; but surface NP 
expression was not shown following in vitro MVA-NP+M1 stimulation. Nevertheless, both HA 
and NP expression were detected when these cells were intracellularly stained for HA and 
NP with the same antibodies (Figure 3.6a). According to the intracellular staining protocol, 
proteins detected are present in the cell cytoplasm rather than in the nucleus. These results 
suggested that following in vitro stimulation by the two different MVA-based vaccines, HA 
protein antigen localised both in the cell cytoplasm and on the cell membrane, whereas NP 
protein antigen remained in the cell cytosol.  
As the synthesis of foreign proteins delivered by viral vectors generally occurs in the cell 
cytoplasm, it was queried whether HA migrated to the cell membrane after being 
synthesised. To examine this, the MNCs were stimulated with MVA-pdmH1HA in the 
presence or absence of brefeldin A (BFA), which inhibits protein transportation from the 
endoplasmic reticulum to the Golgi apparatus. After 6-hour culture in the absence of BFA, 
HA appeared on B cell surface, as shown previously. However, when BFA was introduced 
into the cell culture, the level of HA expression on cell surface drastically reduced, whereas 
no significant change in HA expression was seen in the cell cytoplasm of B cells (Figure 
3.6b). This would be consistent with our hypothesis that HA encoded in MVA-pdmH1HA is 
initially expressed in the cytoplasm before transported to the cell surface of MVA-infected 














Figure 3.6   Cellular localisation of influenza NP and HA following in vitro MVA-
vectored vaccine stimulation 
Adenotonsillar MNCs were stimulated in vitro with either MVA-pdmH1HA or MVA-NP+M1 at MOI of 
0.025. a) The flow cytometric dot plots showed the detection of influenza HA of pandemic H1N1 strain 
(pdmH1HA) on the cell surface and in the cell cytoplasm, while nucleoprotein (NP) only in the cell 
cytoplasm after 24-hour incubation. b) Following 6-hour vaccine stimulation, the reduction of influenza 
HA at the cell surface was seen when brefeldin A (BFA) was present. However, in the same cell 
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3.4.6. Expression of influenza proteins in adenotonsillar MNCs following in 
vitro PanAd3-vectored vaccine stimulation 
The expression of influenza proteins NP and HA in adenotonsillar MNCs was also 
investigated following in vitro stimulation with PanAd3-based influenza vaccines using the 
same method aforementioned. Firstly, the expression of influenza NP was measured 
following PanAd3-NPM1 stimulation at the ratio of one virus particle per cell (1 vp/ml). 
However, there was no significant NP protein expression in the MNCs either in B or T cells, 
which was in contrast to the prominent NP expression in B cells following in vitro MVA-
NP+M1 stimulation (Figure 3.7).  
To determine the infectivity of the PanAd3-based influenza vaccines, the expression of 
protein antigens from each PanAd3-based influenza vaccine was examined in a susceptible 
cell line, HEK293T at 20 vp/cell. NP and HA of either pandemic H1N1 or avian H5N1 were 
measured after the PanAd3-vectored vaccine stimulation, with MVA vaccine-stimulated cells 
as positive controls. Interestingly, NP and/or HA were shown to be efficiently expressed in 
HEK293T cells. Apart from that following PanAd3-gag (vector control) stimulation, NP 
expression was detectable in the cells cultured with all the PanAd3-vectored vaccines 
encoding NP transgene. Moreover, HA expression was shown in the cells stimulated with 
PanAd3-NPM1-pdmH1HA and PanAd3-NPM1-H5HA (Figure 3.8). The results indicated that 
these PanAd3 vector-based influenza vaccines were infectious.  
Adenotonsillar MNCs were thus retested with higher doses of PanAd3-NPM1 at 10 and 50 
vp/cell, but still the level of NP expression was marginal (Figure 3.7). Despite the fact that 
PanAd3-NPM1 vaccine was infectious, influenza NP was not found in either B or T cells, 
suggesting that lymphocytes are likely to be refractory to PanAd3 virus vector. Therefore, the 
measurement of the expression of influenza proteins from other PanAd3-vectored influenza 






Figure 3.7   Expression of influenza nucleoprotein following in vitro PanAd3-NPM1 
stimulation in adenotonsillar MNCs 
Adenotonsillar MNCs were cultured with PanAd3-NPM1 at different virus particles per cell (vp/cell) 
ranging from 1 to 50 for 24 hours before intracellular staining for nucleoprotein (NP) and flow-
cytometry. The flow cytometric dot plots showed the marginal expression of NP in both CD19+ B cells 
and CD3+ T cells at any vaccine doses. MVA-NP+M1-stimulated MNCs were positive control and 
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Figure 3.8   Expression of influenza proteins following in vitro PanAd3-based 
influenza vaccine stimulation in HEK293T cells 
HEK293T cells were cultured with each PanAd3-based influenza vaccine encoding different influenza 
transgenes at 20 virus particles per cell for 24 hours before intracellular staining for influenza proteins 
(NP and HA). MVA-NP+M1-stimulated MNCs were positive control, whereas unstimulated MNCs 
(medium control) were negative control. The flow cytometric dot plots showed that the efficient 
expression of influenza HA and/ or NP encoded in PanAd3 vectored vaccines in HEK293T cells as 

































































































































































3.5. Discussion and conclusion 
Viral vector-based vaccines have been extensively studied in recent years to tackle cancer 
and infectious diseases, including influenza [50], [54], [71]. Most viral vectors are attenuated 
or replication-deficient viruses, hence they do not cause harmful infection while still being 
able to induce immunity towards foreign antigens [50], [51]. The first critical step to 
successfully induce immune responses by vector-based vaccines is that the transgene 
inserted in the vector is efficiently expressed and presented by APCs [52]. 
As the ultimate aim of this project is to study the immune responses activated by MVA- and 
PanAd3 vector-based influenza vaccines in human NALT by using an adenotonsillar cell 
culture system, the expression of influenza proteins in adenotonsillar MNCs was initially 
studied following in vitro vaccine stimulation. Firstly, the kinetics of influenza NP expression 
in the MNCs was shown following MVA-NP-GFP stimulation by the indirect measurement of 
GFP expression. GFP-expressing cells were detected at as early as 6 hours and peaked at 
24 hours (Figure 3.1), indicating the rapid kinetics of MVA infection and transgene 
expression. The results were in agreement with previous studies performed in human 
peripheral mononuclear cells (PBMC) [141]–[143]. The reduction of GFP-expressing cells 
after 24 hours would result from MVA infection-induced cell apoptosis, which was also 
previously observed in monocytes and B cells in PBMCs [143].  
In the absence of GFP expression, the detection of the protein expression from the inserted 
transgene in vectored-vaccines mostly relied on the use of western blotting. However, this 
traditional method is time-consuming and lacks the ability to identify the cell types 
expressing the protein of interest. A new method based on fluorescence-conjugated 
monoclonal antibody labeling and flow-cytometry was established to overcome those 
limitations. The method was shown to be highly specific and sensitive to examine the 
expression of influenza protein antigens in adenotonsillar MNCs following MVA-vectored 
vaccine stimulation (Figure 3.2).  
By using the established method, the cell populations in adenotonsillar MNCs targeted by 
MVA-NP+M1 and MVA-pdmH1HA vaccines were assessed. Among the MNCs, B cells are 
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the major cell population, accounting for 60-70% in NALT followed by T cells at 20-30%. Of 
T cells, CD4+ T cells are the majority of them. Dendritic cells are at less than 0.5% [120], 
[148]. Following in vitro culture with MVA-NP+M1 or MVA-pdmH1HA, NP, M1 or HA 
expression was predominantly detected in B cells (Figure 3.4 and 3.5). Further investigation 
showed both myeloid and plasmacytoid DCs also expressed M1 antigen following the MVA-
NP+M1 stimulation (Figure 3.4). The results suggested that MVA-NP+M1 and MVA-
pdmH1HA target antigen-presenting cells (APC) mainly B cells and DCs in human NALT in 
vitro and influenza proteins were efficiently expressed. As B cells are the largest proportion 
in NALT, they may serve as the main APCs to trigger immune responses. Previous studies 
indicated that poxviruses had a broad cellular tropism to PBMCs including monocytes, B 
cells, NK cells and also monocyte-derived DCs [141]–[143]. The lower proportion of T cells 
expressing influenza protein antigens may be explained as they were resistant to MVA 
infection, and those showing positive expression are likely to be activated T cells, which are 
more susceptible to MVA than resting T cells [141]. Despite the collectively available data on 
the susceptibility of immune cells to MVA, the major types of target cells and the percentage 
of MVA-infected cells may not be simply compared between studies. Of the in vitro 
experiments, there are differences in cell populations used (either single isolated cell or 
mixed cell populations like PBMCs), vaccine dose and time to measure the transgene 
expression. Likewise, differences in the cell types predominantly infected by MVA have also 
been found in vivo when different animal models and different respiratory administrations 
were studied, which showed that MVA targeted alveolar macrophages in lungs of mice after 
nasal instillation, whereas it targeted dendritic cells in lungs of cynomolgus macaques after 
aerosol inhalation [149]. Nonetheless, it suggests that APCs are among other immune cells 
to be preferentially targeted by MVA as shown in this study and previous studies. 
Following the vectored-vaccine stimulation, it was demonstrated that both influenza NP and 
HA proteins were synthesised in the cell cytoplasm before they differently localised in MVA 
vaccine-infected cells. Only HA migrated to the cell membrane by using the host cell protein 
transportation machinery, while NP remained in the cell cytoplasm (Figure 3.6). The 
differences in cellular localisation of NP and HA were also shown in monkey kidney 
fibroblast (CV-1) upon infection with influenza protein-expressing Vaccinia virus [150]. In 
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influenza virus-infected host cells, HA continuously binds to sialic acid at the cell membrane, 
while NP binds to viral RNA in the nucleus before being transported to the cell cytoplasm for 
virus assembly [1]. Given that there is no gene modification of both influenza NP and HA 
transgenes in MVA-NP+M1 and MVA-pdmH1HA vaccines, both NP and HA proteins are 
considered to be expressed in the native conformation the same as generated during 
influenza virus infection. This may explain the mimicry of influenza protein localisation in 
MVA-infected cells to that in influenza-infected cells. A similar finding has been previously 
reported showing that non-modified influenza NP expressed from MVA vector behaved the 
same as the one after A/PR/8 influenza infection in Hela cells [151]. The different cellular 
sites of the proteins after expression would lead to different arms of immune responses 
being induced. The presence of intracellular foreign antigens such as NP and M1 generally 
results in antigen processing and presentation via MHC class I, resulting in the activation of 
a CTL response [52]. In contrast, it is thought that the antibody response relies on the 
engagement of B cell receptor to protein antigens anchored at cell membrane of infected 
cells [152]. In addition, the understanding of the protein localisation following viral vectored 
vaccine infection could lead to a better vaccine design to enhance the immune responses. 
By any modifications of inserted transgenes, influenza NP protein could have longer 
retention in the cell cytoplasm or could be highly degraded [151], while influenza HA protein 
could accumulate on the cell membrane or could be secreted from infected cells and 
captured by APCs [152].  
In contrast to MVA-vectored vaccines, the expression of influenza NP from PanAd3-NPM1 
was undetectable in either B cells or T cells in adenotonsillar MNCs following in vitro vaccine 
stimulation despite the use of the highest vaccine dosage at 50 vp/cell (Figure 3.7). Although 
the proportion of infectious particles in PanAd3-NPM1 vaccine was not determined, it was 
shown that the vaccine was infectious as the expression of influenza NP and/or HA was 
observed in permissive HEK293T cell line when the lower vaccine dose was used (Figure 
3.8). This suggested that the lymphocytes may not be susceptible to PanAd3 infection. It 
could be explained by the similar findings reported on human adenovirus type 5 (hAd5) 
[153], [154], which belongs to the same species as PanAd3 [69]. The resistance of 
lymphocytes to hAd5 infection has been shown to be due to the lack of the surface 
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expression of cellular receptor for adenovirus and coxsackievirus (CAR) [155], which is the 
primary receptor necessary for most adenoviruses to facilitate cell attachment and infection 
[156]. The importance of CAR was demonstrated when adenovirus infection rate was 
improved in dendritic cells and T cells expressing recombinant CAR [155]. Although T and B-
lymphocytes are resistant to hAd5 infection, DCs in peripheral blood have been shown to be 
relatively more susceptible than lymphocytes and were infected by hAd5 in vitro when a high 
titre of the virus was used [145], [157]–[160]. In this study, the expression of influenza 
proteins from PanAd3-vectored vaccines in DCs of adenotonsillar MNCs was not examined. 
It may be worthwhile to perform experiments in the future using a very high virus titre to 
evaluate if the mononuclear cells isolated from human NALT could be used to study the 
immune responses to PanAd3-vectored vaccines. 
In summary, influenza protein antigens from MVA- but not from PanAd3-vectored vaccines 
were efficiently expressed in APCs, predominantly in B cells and DCs in the in vitro cell 
culture system modeling human NALT, hence the successful antigen delivery. Expressed 
from MVA vector, influenza NP accumulated in cell cytoplasm, whereas HA migrated to cell 
membrane of vaccine-infected cells. It suggests the different pathways of antigen processing 
and presentation. Based on these results, the next studies are to examine the T cell immune 










4. Chapter 4 
Activation of cross-reactive influenza antigen-specific 





















The protection from influenza infection is mediated by virus-specific antibodies and T cells 
[15]. Although neutralising HA-specific antibodies are generally considered the major 
protective responses to the virus, there is increasing evidence to support an important role 
for CD8+ T cell-mediated immunity in humans. In individuals experimentally infected with 
influenza virus, virus-specific cytotoxic T cell killing was shown to reduce virus shedding in 
the absence of virus-specific antibodies [93]. Also, the presence of pre-existing cytotoxic 
CD8+ T cells was associated with decreased symptom severity in patients infected with 
pandemic H1N1 virus during the 2009 outbreak [94]. Moreover, rapid recovery of patients 
from avian H7N9 infection correlated with an early onset robust CD8+ T cell response [95].  
The majority of influenza virus-specific CD8+ T cells recognise antigen epitopes shared 
among virus subtypes including internal viral protein antigens; nucleoprotein (NP) and matrix 
protein 1 (M1) [46], [92]. These viral antigens are highly conserved and share over 90% 
homology at amino acid level among different influenza strains [161]. The activation of such 
antigen-specific T cell response would mediate a broadly cross-reactive protection [91]. 
Given the potential of cytotoxic CD8+ T cells for protective responses, novel T cell-based 
influenza vaccines are being developed [62], [162]. Of viral vectored-vaccines, Modified 
Vaccinia Ankara virus (MVA) is outstanding because of its excellent safety profile and 
immunogenicity [53], [59], [163]. MVA-NP+M1 is one of the promising vaccine candidates, 
showing the activation of antigen-specific T cell responses in peripheral blood of healthy 
donors following parenteral immunisation [164]–[167].  
Since influenza virus infects humans through the nasopharyngeal mucosa, local vaccine 
delivery that activates cross-reactive mucosal T cell immunity may offer an attractive 
vaccination strategy against influenza. Intranasal live attenuated influenza vaccine (LAIV) 
has been shown to induce local and systemic antibodies and T cell immunity in children [30], 
[168], [169]. Recently, aerosol delivery of a candidate universal influenza vaccine was shown 
to induce local cellular immune responses associated with protection against heterosubtypic 
influenza A virus infection in pigs [170]. Intranasal immunisation relies on the local immune 
system, e.g. nasopharynx-associated lymphoid tissue (NALT) to induce T and B cell immune 
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responses and local draining lymph nodes [27], [171], [172]. Adenoids and tonsils are major 
components of human NALT and are known to be important induction sites for immunity 
against respiratory pathogens including influenza [171], [173], [174]. It was previously 
demonstrated that cross-reactive memory B cell responses in human NALT were primed 
following 2009 pdmH1N1 infection [84]. In order to investigate the potential of MVA-NP+M1 
as a mucosal T cell-based vaccine, the activation of T cell responses in human NALT was 
studied. We previously showed that MVA-NP+M1 activated antigen-specific T cell responses 
mainly to NP in human NALT in vitro [147]. In this study, MVA-NP+M1 was further assessed 
for its capacity to elicit M1-specific T cell responses in human NALT following in vitro vaccine 
stimulation. The functional properties of vaccine-activated T cells were also studied. 
 
4.2. Aims of the study 
1. To examine the capacity of MVA-NP+M1 to elicit M1-specific T cell responses in human 
NALT in vitro 
2. To compare MVA-NP+M1-activated T cell responses in children and adults 
3. To examine the functionality of MVA-NP+M1-elicited M1-specific CD8+ T cells  
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4.3. Materials and methods 
4.3.1. Adenoidal/ tonsillar tissues and peripheral blood 
Adenoidal and/or tonsillar tissues were obtained from patients undergoing 
adenotonsillectomy at local hospitals. Patients who received systemic steroids within 3 
weeks prior to surgery, or who had any known immunodeficiency were excluded from the 
study.  
Adenotonsillar MNCs were isolated from the tissues as in the standard protocol described in 
chapter 2 (see 2.7.1). In some experiments, the MNCs needed screening for the positivity of 
HLA-A2 type by cell surface staining with mouse anti-human HLA-A2-PE followed by flow-
cytometry (Figure 4.1). CD69+ cell depletion was performed using magnetic anti-CD69 
microbeads (Miltenyi Biotec, Germany), which removed pre-existing activated T cells 
expressing high levels of CD69 (see 2.7.2.1) and CD69+cell-depleted MNCs were 
resuspended in R10 medium containing 0.25 µg/ml amphotericin B– named “R10AmpB” at 
4x106 cells/ml. Peripheral blood taken from the same patient was spun down to collect its 
plasma, from now termed “autologous human plasma (aHP)”. 
 
         
Figure 4.1   Cell surface staining for HLA-A2 type screening 
Adenotonsillar MNCs were stained for HLA-A2 on their surface followed by flow-cytometry. The 
histogram shows HLA-A2 negative (red line) and HLA-A2 positive (blue line) samples compared to 
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4.3.2. Vaccines 
MVA-NP+M1 (#850) is Modified Vaccinia Ankara (MVA) virus expressing NP and M1 from 
A/Panama/2007/99 as a fusion protein joined by a seven amino acid linker under the control of 
the Vaccinia p7.5 early/late promoter. MVA-wt (#1533) was non-recombinant MVA used as a 
vector control. The vaccines are provided by the Jenner Institute, University of Oxford (UK). 
4.3.3. Influenza peptides 
MHC class I-restricted 9-mer synthetic peptides of influenza M1 proteins (NR-2667, Table 
4.1) and MHC class II-restricted 15-mer synthetic peptides of influenza M1 proteins (NR-
18977, Table 4.2) were obtained from BEI resources, USA. Some 15-mer peptides were 
selected from all peptides spanning across M1 protein based on their conservancy among 
IAVs [44], [175]. Each individual peptide was reconstituted in 50% acetonitrile or DMSO 
according to manufacturer’s instructions. 10 to 11 peptides were then pooled at the 
concentration of 0.1 mg/ml per peptide for subsequent cell stimulation. M158-66 (GILGFVFTL) 
was purchased from IBA GmbH, Germany and was reconstituted in 50% DMSO at a final 
concentration of 1 mg/ml. 
4.3.4. Fluorochrome-conjugated monoclonal antibodies and M1-tetramer 
The following fluorochrome-conjugated antibodies were used in cell staining and flow-
cytometric analysis including HLA-A2-PE (clone BB7.2), CD8-FITC (clone RPA-T8), CD103-
PE (clone Ber-ACT8), CD45RO-FITC (clone UCHL1), granzymeB-BV510 or AlexaFluor® 
647 (clone GB11), CD107a-BV421 (clone H4A3), IFN-γ-APC-R700 (clone B27), TNF-α-PE-
CF594 (clone MAb11), IL-2-BV650 (clone MQ1-17H12) and IL-10-APC (clone JES3-19F1) 
(BD Bioscience, UK); IFN-γ-PECy7 (clone 4S.B3), granzymeA-PECy7 (clone CB9) 
(eBioscience, UK); and perforin-APC (clone B48), granzymeA-PerCPCy5.5 (clone CB9), 
CD8-PerCPCy5.5 (clone SK1), CD4-Pacific blue (clone RPA-T4) and CD69-APC (clone 
FN50) (Biolegend, UK).  
HLA-A02*01- GILGFVFTL (M158-66)-PE tetramer (T01011, MBL, USA), termed as “M1-Tm” 
was used for surface staining to detect M1-specific CD8+ T cells. 
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Table 4.1   List of 9-mer M1 peptides (NR-2667) and their HLA restriction 
Influenza proteins Pool No. Amino acid sequences (9) HLA restriction [44], [175] 
M1 1 29-EDVFAGKNT-37  HLA-A*03 
31-VFAGKNTDL-39  HLA-A*2402, HLA-B*08 
37-TDLEALMEW-45  HLA-A*01 
49-RPILSPLTK-57  HLA-A*03 
51-ILSPLTKGI-59  HLA-A*0201 
56-TKGILGFVF-64  HLA-A*02 
58-GILGFVFTL-66  HLA-A*02, HLA-A*2402 
60-LGFVFTLTV-68  HLA-A*02 
66-LTVPSERGL-74  HLA-A*02 
68-VPSERGLQR-76  HLA-A*02 
2 71-ERGLQRRRF-79  HLA-A*02 
75-QRRRFVQNA-83  HLA-A*02 
76-RRRFVQNAL-84  HLA-A*02 
122-GALASCMGL-130  HLA-B*35 
123-ALASCMGLI-131  HLA-B*35 
124-LASCMGLIY-132  HLA-B*35 
126-SCMGLIYNR-134  HLA-B*35 
177-NRMVLASTT-185  HLA-A*0301, HLA-A*11 
179-MVLASTTAK-187  HLA-A*0301, HLA-A*11 
180-VLASTTAKA-188  HLA-A*0301, HLA-A*11 
181-LASTTAKAM-189  HLA-A*0301, HLA-A*11 
 
Table 4.2   List of 15-mer M1 peptides (NR-18977) and their HLA restriction 
Influenza proteins Pool No. Amino acid sequences (15) HLA restriction [44], [175] 
M1 1 13-SIIPSGPLKAEIAQR-27  HLA-DR1, DR3 
17-SGPLKAEIAQRLESV-31  HLA-DR1, DR3 
37-TDLEALMEWLKTRPI-51  HLA-DP4 
41-ALMEWLKTRPILSPL-55  HLA-DP4 
57-KGILGFVFTLTVPSE-71  HLA-DR4 
77-RRFVQNALNGNGDPN-91  HLA-DR7, DR1 
229-LKDDLLENLQA YQKR-243  HLA-DR1 
233-LLENLQA YQKRMGVQ-247  HLA-DR1 
237-LQAYQKRMGVQMQRF-251  HLA-DR1 
242-KRMGVQMQRFK-252  HLA-DR1 
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4.3.5. Cell stimulation for T cell assays 
CD69+ cell-depleted tonsillar MNCs were cultured with either MVA-NP+M1 or MVA-wt at a 
final concentration of 1x105 pfu/ml then incubated in 48-well cell culture plates (Corning, 
USA) at 37°C, 5%CO2. The MNCs without any stimulation (medium control) were used as 
negative control. Culture medium was supplemented with 2%v/v aHP and 5 ng/ml interleukin 
(IL)-15. At day 2, 0.5 ml pre-warmed fresh R10AmpB medium with 2%v/v aHP and 5 ng/ml IL-
15 were added in each well. Unless otherwise stated, cells were then incubated for another 5 
days (7 days in total) before performing any further experiments. Non-HLA typed tonsillar 
MNCs were used for quantifying M1-specific T cell responses by IFN-γ ELISPOT assay or 
intracellular cytokine staining, whereas the MNCs from HLA-A2 positive individuals were 
used for analysing M1-specific CD8+ T cell responses by tetramer staining.  
4.3.6. IFN-γ ELISPOT and intracellular cytokine staining 
At day 7 following in vitro stimulation with MVA-wt or MVA-NP+M1 (see 4.3.5), tonsillar 
MNCs were rested in R10AmpB medium for 2 days before performing IFN-γ ELISPOT 
assays (eBiosciences, UK). At day 9, the MNCs from each stimulation were separately 
harvested from culture plates and pelleted. Cells were then resuspended in R10AmpB and 
adjusted to 2x106 cells/ml and aliquoted at 350 µl per tube. SEB (NR-44235, BEI Resources, 
USA) and M1 peptide pools were pre-diluted in R10AmpB at the ratio of 1:10 and 1:5, 
respectively. MVA-wt and MVA-NP+M1-stimulated MNCs were restimulated with diluted M1 
peptide pools at final concentration of 10 µg/ml per peptide (No.1-3, Table 4.3). Some cells 
were left without peptide stimulation as background control (No.4, Table 4.3). Unstimulated 
MNCs were restimulated with SEB at a final concentration of 1 µg/ml for positive control 
(No.5, Table 4.3). R10AmpB medium without MNCs was used as negative control. 100 µl of 
peptide-restimulated MNCs (containing 2x105 cells) were seeded in triplicate into a pre-
coated ELISPOT plate as shown in the layout (Figure 4.2). The plate was then incubated at 
37°C, 5% CO2 for 24 hours with minimal agitation. Next day, spots were developed 
according to the ELISPOT protocol (see 2.12). 
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To analyse the data, the number of spots in each stimulation (No.1-5 according to Table 4.3) 
in triplicate was averaged and adjusted to the spot forming cells per 1x106 cells (SFC/ million 
cells) by multiplying by 5. Of either MVA-wt or MVA-NP+M1 stimulated MNCs, the SFC/ 
million from each peptide restimulation (No.1-3) was subtracted from the one without peptide 
stimulation (No.4 as background). The background-subtracted SFC/ million from pool No. 1 
and 2 of 9-mer M1 peptides were added together (No.1+2). Finally, the SFC/ million from 
MVA-wt and MVA-NP+M1-stimulated MNCs from each individual towards 9-mer or 15-mer 
M1 peptides were compared.  
Table 4.3   Peptide restimulation for IFN-γ ELISPOT assay 
No. Peptides/ protein 









1 MHC class I-restricted 9-mer 
peptides (1:5)      (Table 4.1) 
M1 Pool 1 N/A 17.7 17.7 
2 M1 Pool 2 N/A 19.5 19.5 
3 MHC class II-restricted 15-mer peptides (1:5)      (Table 4.2) M1 Pool 1 N/A 17.7 17.7 
4 No peptides N/A 0.0 0.0 
5 SEB (1:10); positive control 7.0 N/A N/A 
Note: N/A means no sample 
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H (-) MVA-NP+M1 (4)         
 
Figure 4.2   Sample layout for IFN-γ ELISPOT assay 
The layout illustrates the position of each sample in the plate from column 1 to 4. MVA-wt or MVA-
NP+M1-stimulated MNCs were restimulated with peptide pools indicated as No.1-3 in Table 4.3. SEB-
stimulated MNCs (+) as No.5 in Table 4.3 is a positive control and R10AmpB medium without cells (-) 
is a negative control. Cells were then seeded in triplicate in the pre-coated ELISPOT plates. 
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In the parallel experiment, the type of T cells responding to M1 peptides was also examined 
by intracellular cytokine staining. The MNCs following in vitro vaccine stimulation (the same 
as the ones analysed by ELISPOT assay) were also restimulated with the peptide pools 
(Table 4.3) at final concentration of 10 µg/ml per peptide in the presence of brefeldin A and 
incubated at 37°C, 5%CO2 for 6 hours. Cells were then stained for surface CD4 and CD8 
and intracellular staining for IFN-γ, followed by flow-cytometry. 
4.3.7. Detection of M158-66-specific CD8+ T cells and intracellular cytotoxic 
molecules  
Following in vitro 7-day MVA-NP+M1 or MVA-wt stimulation (see 4.3.5), tonsillar MNCs were 
harvested before co-incubation with anti-CD8 antibody and M1-Tm at 4°C for 30 minutes to 
detect M158-66-specific CD8+ T cells. In some experiments, cells were further intracellularly 
stained for perforin, granzyme-A and granzyme-B, followed by flow-cytometry. T cell 
responses in the MNCs from each individual to MVA-wt and MVA-NP+M1 were then 
compared. 
4.3.8. Measurement of T cell proliferation  
CD69+cell-depleted tonsillar MNCs from HLA-A2 positive individuals were labelled with CFSE 
(see 2.9). CFSE-labeled cells were resuspended in R10AmpB medium supplemented with 
2%aHP and 5 ng/ml IL-15 before stimulation with either 1x105 pfu/ml of MVA-NP+M1 or MVA-
wt or without stimulation (see 4.3.5) then incubated at 37°C, 5% CO2 for 5 days. Cells were 
then harvested and stained for CD8 and M1-Tm, followed by flow-cytometry. T cell proliferation 
in the MNCs from each individual to MVA-wt and MVA-NP+M1 were then compared. 
4.3.9. Detection of surface CD107a expression and intracellular cytokines 
Following in vitro 7-day MVA-NP+M1 stimulation (see 4.3.5), tonsillar MNCs were harvested, 
pelleted and resuspended in pre-warmed R10AmpB medium then pulsed with 0.25 µg/ml 
M158-66 peptide and co-cultured with anti-CD107a antibody (CD107a-BV421) in the presence 
of brefeldin A (BFA) and monensin (eBiosciences, UK) and incubated at 37°C, 5% CO2 with 
light protection. Cells were collected at every hour for 5 hours followed by staining for 
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surface CD8 and M1-Tm with intracellular IFN-γ to study the kinetics of surface CD107a 
expression and IFN-γ cytokine production. In another experiment, cells were collected at 5 
hours post peptide restimulation before staining for CD8, M1-Tm and a set of cytokines; IFN-
γ, TNF-α, IL-2 and IL-10, followed by flow-cytometry. The functional profile of M1-Tm+ cells 
was then analysed using SPICE 5.0 software (NIH, NIAID, USA). 
4.3.10. In vitro cytotoxicity assay 
Isolated CD8+ T cells following MVA-NP+M1 stimulation (see 4.3.5) were co-cultured with 
M158-66-pulsed autologous B cells before measuring the number of B cells being killed 
(Figure 4.3) as described previously [176]. Briefly, autologous B cells were isolated from 
cryopreserved tonsillar MNCs (see 2.8) using a CD19 isolation kit (see 2.7.2.2) (Miltenyi 
Biotec, Germany) and incubated overnight with 40 ng/ml recombinant human IFN-γ 
(Peprotech, UK) to increase the expression of MHC-I and CD86 on the B cells, limiting the 
variability of B cells from different donors and also to enhance B cell viability. Autologous B 
cells were labelled with CFSE (see 2.9) at a final concentration of either 0.02 µM (Tlow) or 0.2 
µM (Thigh). Tlow were further pulsed with 5 µg/ml M158-66 peptide for 45 minutes at 37°C, 
5%CO2, while some Tlow were left without peptide pulsing. Both Tlow with or without peptide 
pulsing and Thigh were adjusted to 2x105 cells/ml. Tlow, pulsed and Thigh were mixed at the ratio 
of 1:1. Tlow, unpulsed and Thigh were also mixed at the ratio of 1:1. CD8+ T cells were isolated 
from tonsillar MNCs following in vitro 7-day MVA-NP+M1 stimulation using a CD8 isolation 
kit (see 2.7.2.2) (Miltenyi Biotec, Germany). Isolated CD8+ T cells were resuspended in 0.7 
ml R10AmpB medium, containing 4-10x106 cells/ml and 2-fold serial dilutions made  from 1:1 
to 1:32. 100 µl of CD8+ T cells at different serial dilutions were co-cultured with 100 µl of 
mixed Tlow, pulsed and Thigh in a round-bottom 96-well plate (Corning, USA) for 6 hours at 37°C, 
5%CO2. Only 100 µl of mixed Tlow, pulsed and Thigh were cultured in 100 µl of R10 as negative 
control. 100 µl of undiluted isolated CD8+ T cells co-cultured with 100 µl of mixed Tlow, unpulsed 
and Thigh for peptide pulsing control. After complete incubation, cells were harvested from 
each well and washed once before staining with LIVE/DEAD Far red (Invitrogen, UK) at 
room temperature for 30 minutes followed by surface staining for CD8 and M1-Tm. 4,000 
events of Thigh were acquired during flow-cytometry for each sample. Effector T cells (E) 
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were the number of M1-Tm+ cells, while target cells (T) were the total numbers of Tlow in the 
culture. The percentage of specific lysis at different E/T ratio was calculated by the following 
formula, which was based on the reduction of the fraction of Tlow/ Thigh cells after co-culturing 
with CD8+ T cells compared from that without CD8+ T cells. 
% Specific lysis = 100 x [(Tlow/Thigh) alone – (Tlow/Thigh) effector] x (Tlow/Thigh) alone -1 
Tlow     the number of CFSElow B cells 
Thigh    the number of CFSEhigh B cells 
(Tlow/Thigh) alone   the number of Tlow/ the number of Thigh of negative control 
(Tlow/Thigh) effector  the number of Tlow/ the number of Thigh of a well, co-cultured    
with CD8+ T cells 
 
Figure 4.3   Diagram of in vitro cytotoxicity assay 
The figure depicts the steps of in vitro cytotoxicity assay along with the timeline started from day 0 to 
day 7. The assay is composed of two main parts, which are 1) CD8+ T cell isolation from MVA-NP+M1-
stimulated adenotonsillar mononuclear cells (MNCs) and 2) B cell isolation from the MNCs followed by 
CFSE labeling and peptide pulsing. Isolated CD8+ T cells are co-cultured with labeled B cells at 
different ratios and the number of dead B cells is measured by live/dead staining and flow-cytometry. 
Day 0 Ts MNCs – MVA-NP+M1 stimulation Ts MNCs cryopreservation 
Day 5 Ts MNCs thawing and resting 
Day 6 CD19+ B cell isolation and cultured with IFN-γ 
Day 7 CD8+ T cell isolation CFSE labeling of B cells 
B cells with 
0.02 µM CFSE 
(Tlow) 
B cells with 
0.2 µM CFSE 
(Thigh) 
M158-66 peptide pulsing 
Mix Tlow, pulsed : Thigh (1:1) 
Co culture each dilution of CD8+ T cells and mixed CFSE-labeled B cells   
Serial dilution from 1:1 to 1:32 
LIVE/DEAD staining and flow cytometry 
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4.3.11. Flow-cytometry 
Flow cytometric data was acquired by FACS Calibur using CellQuest Pro software or FACS 
Celesta using FACS Diva (BD Biosciences, USA). Otherwise stated, 2x105 or more events of 
lymphocytes were required. The data were analysed using FlowJo 8.7 software (FlowJo, LLC.). 
4.3.12. Statistical analysis 
For two-group comparisons, based on the normality of distribution of data, parametric 
paired-t test, nonparametric Wilcoxon matched-pairs signed rank test and nonparametric 





4.4.1. Optimisation of in vitro cell stimulation with MVA-NP+M1 vaccine  
To start with, some key parameters of the in vitro cell culture with MVA-NP+M1, which were 
incubation time, vaccine dose and cytokine supplement were optimised for the detection of 
antigen-specific CD8+ T cells. The frequency of CD8+ M1-Tm+ cells was measured using M1 
tetramer. PBMCs from a HLA-A2 positive healthy donor were used to perform this 
experiment initially.  
Incubation time was firstly optimised. The MVA-NP+M1 dose at 5x104 pfu/ml was used 
regarding the previous study [147] to stimulate PBMCs. As shown in Figure 4.4a, the number 
of CD8+ M1-Tm+ cells in PBMCs following in vitro vaccine stimulation detectably increased 
compared to medium control at day 7 (9.63% vs 0.13%), but not at day 3 (0.062% vs 0.067%).  
To optimise vaccine stimulation concentration, PBMCs were stimulated with MVA-NP+M1 at a 
range of doses of 5x104, 1x105 and 5x105 pfu/ml, respectively for 7 days. The frequency of 
CD8+ M1-Tm+ cells was in a dose-dependent manner, showing 9.63%, 19.5% and 24.6%, 
respectively compared to medium control at 0.15%. Cell viability was roughly obtained from 
gating the viable cell population from the FSC-SSC plot based on the data from propidium 
iodide staining (see appendix-2). The MNCs stimulated with MVA-NP+M1 at any dose showed 
lower cell viability at day 7 compared to medium control (88.5%). However, using the highest 
vaccine dose demonstrated noticeably decreasing cell viability (76%) than the other two doses 
(80.7% and 80.6%) (Figure 4.4b). Therefore, the intermediate vaccine dose at 1x105 pfu/ml 
was chosen for cell stimulation. 
Finally, the effect of cytokines; interleukin (IL)-2 and IL-15, on cell culture was studied following 
in vitro stimulation of MVA-NP+M1 at 1x105 pfu/ml. As shown in Figure 4.4c, PBMCs 
stimulated with MVA-NP+M1 with the supplement of 5 ng/ml IL-15 activated the highest 
number of CD8+ M1-Tm+ cells (23.09%), followed by those supplemented with 20U/ml IL-2 
(20.36%) and those with no cytokine supplement (18.82%). CD8+ M1-Tm+ cells in unstimulated 
MNCs (medium control) remained low and comparable in the absence and the presence of IL-
2 or IL-15, showing 0.15, 0.14 and 0.13%, respectively. In addition, cell viability was likely to be 
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improved by the supplement of IL-15 (86.2%) and IL-2 (81.1%) compared to no cytokine 
supplement (80.6%).  Therefore, 5 ng/ml of IL-15 (as manufacturer recommended dose) was 







Figure 4.4   Optimisation for MVA-NP+M1 vaccine-cell stimulation 
Incubation period, vaccine dose and cytokine supplement were optimised in in vitro MVA-NP+M1-cell 
stimulation for the detection of antigen-specific CD8+ T cells, peripheral blood mononuclear cells (PBMCs) 
were stimulated with MVA-NP+M1 and CD8+ M1-Tm+ cells and cell viability were assessed. a) Using 
5x104 pfu/ml of vaccine without cytokine supplement, CD8+ M1-Tm+ cells were measured at day 3 and 7. 
b) Following 7-day incubation without cytokine supplement, CD8+ M1-Tm+ cells and cell viability were 
compared in three different concentrations of the vaccine used. c) Following 1x105 pfu/ml of MVA-NP+M1 
stimulation, CD8+ M1-Tm+ cells and cell viability were compared when cell culture was supplemented with 
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Having obtained such optimal parameters, further optimisation was performed using tonsillar 
MNCs on cell preparation and vaccine concentration. Unlike PBMCs, tonsillar MNCs contain 
a larger number of CD69+ activated cells. They are most likely to die because of in vitro over 
stimulation, which may have an impact on other viable cells during the culture. CD69+ cell 
depletion removed pre-existing activated T cells expressing high levels of CD69 from both 
CD4+ and CD8+ T cells, but retained naïve and memory T cells including CD45RO+ CD103+ 
tissue-resident memory CD8+ T cells in the MNCs (Figure 4.5). The comparable frequency of 
CD8+ M1-Tm+ cells was observed in the MNCs between before  (0.23%) and after (0.25%) 
the depletion. As CD69+ cell depletion removed a number of CD4+ T cells, which resulted in 
an increased proportion of CD8+ T cells in the MNCs, this may explain the comparable 
number of CD8+ M1-Tm+ cells observed. Following in vitro vaccine stimulation, the frequency 
of CD8+ M1-Tm+ cells was higher with the use of CD69+cell-depleted MNCs (10.72%) than 
that of unfractionated MNCs (8.59%).  
Besides, the optimal MVA-NP+M1 vaccine dose to stimulate CD69+cell-depleted tonsillar 
MNCs was also shown at 1x105 pfu/ml among three concentrations as same as previously 
titrated in PBMCs. The frequency of CD8+ M1-Tm+ cells was comparable between the use of 
1x105 and 5x105 pfu/ml vaccine (0.67% vs 0.81%). However, the higher cell viability was 
observed at the former dose (78.1%) compared to the latter dose (71.4%). The MNCs 
without stimulation showed 0.04% CD8+ M1-Tm+ cells with 81.6% cell viability. 
All optimised parameters were shown in Table 4.4. 
 Table 4.4   Optimised parameters for MVA-NP+M1-tonsillar mononuclear cell stimulation 
Parameters Results 
Cell preparation CD69+cell-depleted MNCs 
Vaccine dose 1x105 pfu/ml 
Cytokine supplement 5 ng/ml Interleukin (IL)-15 









Figure 4.5   Cell phenotypes in unfractionated and CD69+cell-depleted MNCs 
Phenotypic study was performed before and after CD69+ cells depletion of tonsillar MNCs by surface 
staining a panel of CD4, CD8, CD69, CD45RO and CD103. a) Comparison of the expression of CD69, 
CD45RO and CD103 of either CD8+ or CD4+ T cells in unfractionated (red) and CD69+cell-depleted 
MNCs (blue). b) Gating on CD8+ T cells, flow cytometric dot plot compared CD45RO and CD103-





4/13/18 10:05 AM Page 1 of 3 (FlowJo v8.7)
CD8




























































































































































































































































100 101 102 103 104
































































































































































4/13/18 10:05 AM Page 1 of 3 (FlowJo v8.7)
CD8




























































































































































































































































100 101 102 103 104
































































































































































4/13/18 10:05 AM Page 1 of 3 (FlowJo v8.7)
CD8












































































































































































































































100 101 102 103 104















100 101 102 103 104

































































































































































14.6 / 2.  
2 .7 / 14.7 
.31 / . 9 
CD69 CD45RO CD103 
CD8 
phenotypes_CD69- Layout
4/13/18 10:05 AM Page 1 of 3 (FlowJo v8.7)
CD8


























































































































































































































































100 101 102 103 104































































































































































4/13/18 10:05 AM Page 1 of 3 (FlowJ  v8.7)
CD8




























































































































































































































































100 101 102 103 104
































































































































































5/2/18 1:37 PM Page 1 of 3 (FlowJo v8.7)
CD8




























































































































































































































































100 101 102 103 4



























































































































































































































4.4.2. MVA-NP+M1 activated conserved M1-specific T cell responses. 
In chapter 3, it was shown that MVA-NP+M1 efficiently expressed influenza NP and M1 
proteins in adenotonsillar MNCs following in vitro vaccine stimulation. The use of lower 
vaccine dose (1x105 pfu/ml or MOI at 0.025) to stimulate the MNCs for T cell response study 
still demonstrated that approximately 3% of lymphocytes mainly B cells expressed M1 
protein, indicating that vaccine antigen is present in the cell culture system. MVA-NP+M1 
was then investigated whether it would be able to activate cell-mediated immunity in human 
NALT in vitro, particularly focusing on CD8+ T cells (CTL) recognising M1 epitopes. 
To assess the capacity of MVA-NP+M1 to elicit M1-specific cross-reactive T cell responses, 
tonsillar MNCs from non HLA-typed subjects following 7-day MVA-wt or MVA-NP+M1 in vitro 
stimulation were restimulated with 9-mer synthetic conserved M1 peptide pools. IFN-γ-
producing cells in response to the peptides were analysed by ELISPOT assay and 
intracellular cytokine staining (ICS). The magnitude of M1-specific T cell responses to 9-mer 
peptides were highly variable in individuals; however, all of them exhibited an increasing 
proportion of IFN-γ-secreting cells following MVA-NP+M1 compared to MVA-wt stimulation 
(n=7, p=0.0156). A set of longer 15-mer M1 peptides was also selected from peptide library 
for the assessment of CD4+ T cell response. The increasing T cell response to 15-mer M1 
peptides was also observed in MVA-NP+M1 stimulated MNCs, but could not reach 
significance (n=3, p=0.25) (Figure 4.6b). However, ICS data demonstrated that the 
responses to both 9-mer and 15-mer M1 peptide pools were generated from CD8+ rather 







b                         
        




Figure 4.6   MVA-NP+M1 activated T cell responses to conserved M1 peptides 
Following 7-day MVA-NP+M1 or MVA-wt in vitro stimulation, CD69+cell-depleted tonsillar MNCs were 
rested for 2 days before restimulating with conserved M1 peptide pools (either 9-mer or 15-mer) 
followed by measuring the frequency of IFN-γ producing cells by ELISPOT assay and intracellular 
cytokine staining (ICS). a) A representative sample showed spots in MVA-NP+M1 compared to MVA-
wt stimulated cells at day 9 before and after M1 peptide restimulation. b) Comparison of each 
individual spot forming cells (SFC)/ a million cells in MVA-wt and MVA-NP+M1-stimulated MNCs 
towards 9-mer (n=7, *p=0.0156) and 15-mer M1 (n=3, p=0.25). Wilcoxon matched-pairs signed rank 
test was used for comparison between two groups. c,d) The overlay of flow cytometric dot plots 
showing IFN-γ producing CD8+ or CD4+ T cells before (red) and after (blue) c) 9-mer or d) 15-mer M1 
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4.4.3. MVA-NP+M1 activated M158-66-specific CD8+ T cells in HLA-matched 
individuals. 
Having shown that MVA-NP+M1 activated CTLs in human NALT in vitro directed to 
conserved M1 peptides, the further study was to examine M158-66-specific CD8+ T cell 
responses following in vitro MVA-NP+M1 stimulation using M1 tetramer staining. From now 




Figure 4.7   Gating strategy for M1-Tm+ cell analysis 
To measure M1-Tm+ cells following in vitro MVA-NP+M1 stimulation, lymphocytes were firstly gated 
from the FSC-SSC plot (the gate referred to viable cells according to the data from propidium iodide 
(PI) staining in Appendix-2). Only singlet cells were selected by plotting FSC-H against FSC-A.  Then 
CD8+ T cells were gated. Among CD8+ T cells, M1-Tm+ cells were gated from the plot of CD8 against 
M1-Tm. 
 
As each antigen epitope is differently restricted to the HLA haplotype, the specificity of the 
use of M1 tetramer to detect M1-Tm+ cells following in vitro MVA-NP+M1 stimulation was 
tested in tonsillar MNCs from subjects who were either HLA-A2 positive or negative. Among 
the subjects of comparable age, M1-Tm+ cells were only detected in individuals who were 
HLA-A2 positive (Figure 4.8), suggesting that these M156-88-specific T cell responses are 
elicited in only HLA-matched individuals.  
 

































































Figure 4.8   M158-66-specific T cell responses needed HLA-A2 restriction. 
Adenotonsillar MNCs from either HLA-A2 positive or negative subjects at similar ages (ranging from 2 
to 16 years olds) were stimulated with MVA-wt or MVA-NP+M1 for 7 days and the frequency of M1-
Tm+ cells was measured. The number of M1-Tm+ cells following MVA-NP+M1 stimulation was 
compared to those after MVA-wt stimulation in subjects who have either HLA-A2 positive or HLA-A2 
negative.  
  
The pre-existing M1-Tm+ cells were firstly measured in each individual. The frequency of M1-
Tm+ cells in freshly isolated tonsillar MNCs varied, but were generally low (0.03-0.16%, 
median 0.1%). Only one adult sample showed as high as 0.25%. Following in vitro 
stimulation, MVA-NP+M1 elicited a significant increase in M1-Tm+ cells in tonsillar MNCs 
(median 0.37%), compared to MVA-wt (vector alone) (median 0.05%) (n=22, p<0.0006) and 
medium control (median 0.05%) (Figure 4.9a).  
When M1-Tm+ T cell responses were compared among different age groups (Table 4.5), an 
age-dependent increase was shown in the magnitude of M1-Tm+ cell response. Children <4 
years of age in general showed very low response to the vaccine (0.00-0.03%, median 
0.00%), while the older children had significantly higher responses (p=0.0413) with the 
variable magnitude of M1-Tm+ cells (0.01-1.44%, median 0.22%). All adults responded to 
the vaccine with significantly higher numbers of M1-Tm+ cells (0.29-4.47%, median 0.60%) 























Table 4.5   Study subjects information 
Subjects Average age (Range) n 
Children Group 1 2.5     (2-3.5) 5 
Group 2 5.7     (4-9) 10 
Adults 20.6   (16-34) 7 
 
 
    a    b 
  
Figure 4.9   M158-66-specific CD8+ T cells activated by MVA-NP+M1. 
M1-Tm+ cells were measured in CD69+cell-depleted tonsillar MNCs following in vitro MVA-wt or MVA-
NP+M1 stimulation or left without any stimulation (medium control). a) The proportion of M1-Tm+ cells 
was shown in freshly isolated cells from tonsils at day 0 (D0) and at day 7 (D7) after vaccine 
stimulation. MVA-NP+M1 activated an significant increase in M1-Tm+ cells in both children (black open 
circles) and adults (red open circles) compared to MVA-wt (Wilcoxon matched-paired signed rank test, 
n=22, ***p=0.0006). At day7, MVA-wt showed a similar number of M1-Tm+ cells as medium control. b) 
Comparison of the frequency of M1-Tm+ cells among different age groups. Older children and adults 
had a stronger response than younger children (Mann Whitney test, *p=0.0431, **p=0.0025). Bars and 





























































































































































Further analysis with CFSE cell tracing demonstrated that MVA-NP+M1 activated a 
proliferative M1-Tm+ cell response in tonsillar MNCs in vitro, compared to the absence of 







Figure 4.10   Proliferation of M158-66-specific CD8+ T cells following in vitro MVA-NP+M1 
stimulation. 
M1-Tm+ cells were measured in CFSE-labelled CD69+cell-depleted tonsillar MNCs following in vitro 
MVA-wt or MVA-NP+M1 stimulation or left without any stimulation. a) Gating on CD8+ T cells, the flow 
cytometric dot plots showed newly proliferating M1-Tm+ cells defined as M1-Tm+ CFSElow cells (top left 
quadrant) in each stimulation. b) The histogram overlaid the M1-Tm+ cells following MVA-NP+M1 (blue 
line) compared to MVA-wt (grey shade) stimulation. Proliferation index was the proportion of M-Tm+ 
cells having the low intensity of CFSE (or the proportion of proliferating cells). MVA-NP+M1 activated 
the significant higher number of newly proliferating M1-Tm+ compared to MVA-wt (Paired-t test, n=3, 
*p=0.0475). 
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4.4.4. M158-66-specific CD8+ T cells exhibited effector functions and in vitro 
killing capacity 
To determine whether MVA-NP+M1-activated M158-66-specific CD8+ T cells were functionally 
active, the expression of cytotoxic effector molecules and cytokines in M1-Tm+ cells was 
examined. Following 7-day in vitro vaccine stimulation, MVA-NP+M1 activated a significantly 
higher number of M1-Tm+ cells expressing perforin (p=0.0098), granzyme-A (p=0.0078) and 
granzyme-B (p=0.0313) compared to MVA-wt (Figure 4.11a). Besides, MVA-NP+M1-
stimulated MNCs contained substantial amounts of M1-Tm+ cells that intracellularly stored 






Figure 4.11   Expression of cytotoxic effector molecules in M158-66 specific CD8+ T cells.   
CD69+cell-depleted tonsillar MNCs following 7-day in vitro stimulation with either MVA-wt or MVA-
NP+M1 were measured for frequency of M1-Tm+ cells and the expression of cytotoxic molecules. a) 
MVA-NP+M1, compared to MVA-wt, activated M1-Tm+ cells that expressed perforin (n=10, 
**p=0.0098), granzyme A (n=8, **p=0.0078) and granzyme B (n=8, *p=0.0313). Wilcoxon matched-
paired signed rank was used for comparison between two groups. b) Gating on CD8+ T cells, the 
representative flow cytometric dot plots showed the expression of perforin, granzyme-A and -B in M1-
Tm+ cells following MVA-NP+M1 stimulation. The number on the top right corner indicated the 
percentages of each cytotoxic molecule-expressing M1-Tm+ cells of total M1-Tm+ cells.  
MVA-wt MVA-NP+M1 


















































































































































































































































































































































MVA-NP+M1-stimulated MNCs were then restimulated with M158-66 peptide followed by the 
detection of surface CD107a (a marker for cytotoxic degranulation) and cytokine expression.  
As shown in Figure 4.12a, surface CD107a expression was markedly upregulated in M1-Tm+ 
cells after M158-66 peptide restimulation. Similarly, as shown in Figure 4.12b, cytokine 
expression was also upregulated. IFN-γ was produced by most activated M1-Tm+ cells 
compared to the lower expression in non-M1-specific CD8+ T cells (M1-Tm-). The kinetics of 
surface CD107a and IFN-γ expression was further studied and a similar pattern was shown 
(Figure 4.12c, d). Notably, a more rapid upregulation in the expression of CD107a than IFN-
γ was clearly seen at one hour after peptide pulsing. Approximately 40% of M1-Tm+ cells 
expressed surface CD107a, compared to 10% producing IFN-γ (n=4, p=0.0155). Both 
surface CD107a expression and IFN-γ production appeared to peak at 3 hours (Figure 
4.12d). As shown in Figure 4.12e, IFN-γ and TNF-α were abundantly expressed in M1-Tm+ 
cells following peptide pulsing. A modest number of M1-Tm+ cells were also shown to 
express IL-2, but a few expressed IL-10. Due to the marginal expression of IL-10, IL-10 was 
not included in the functional profile analysis of M1-Tm+ cells as shown in Figure 4.12f. The 
most frequently detected M1-Tm+ cells were those expressing CD107a with IFN-γ and TNF-
α (45%), following by those that co-expressed of IFN-γ and TNF-α (10%), CD107a and 
either IFN-γ (9%) or TNF-α (4%). Some M1-Tm+ cells (3%) were shown to express CD107a 
and all three cytokines (IFN-γ, TNF-α and IL-2). Approximately 20% of these cells did not 
















Figure 4.12   Functional properties of M158-66-specific CD8+ T cells 
Following 7-day in vitro MVA-NP+M1 stimulation, tonsillar MNCs were pulsed with M158-66 peptide for 6 













M1 Tm - M1 Tm +
****
































































M1 Tm - M1 Tm +

















































































































0 3 hour (s) 


























61.6 14.3 0 












































































0 3 hour (s) 


























61.6 14.3 0 






































































































































































































































































































































cytometry. Levels of CD107a and IFN-γ expression were compared between M1-Tm+ and M1-Tm- 
cells. a) Surface CD107a was highly expressed in M1-Tm+ as compared to the lower level in M1-Tm- 
cells (Paired-t test, n=6, ****p<0.0001). b) IFN-γ expression was also significantly higher in M1-Tm+ 
compared to M1 Tm- cells (Paired-t test, n=13, ****p<0.0001). c) Representative flow cytometric dot 
plots and d) the kinetic curves showed the co-expression of surface CD107a and intracellular IFN-γ in 
M1-Tm+ cells following peptide pulsing. At 1 hour, the percentages of CD107a+ cells were significantly 
higher than those of IFN-γ+ cells (Paired-t test, n=4, *p=0.0155). Means and SEMs were shown at each 
time point. e) Representative flow cytometric dot plots showed the expression of IFN-γ, TNF-α, IL-2 
and IL-10 in M1-Tm+ cells. The number on the top right corner indicated the proportion of M1-Tm+ cells 
expressing each cytokine of total M1-Tm+ cells. f) The functional profile of M1-Tm+ cells was analysed 
using SPICE 5.0 software (n=2). With the pie chart, the different colours of arcs around showed the 
proportion of M1-Tm+ cells expressing each marker; CD107a (red), IFN-γ (green), IL-2 (light blue) and 
TNF-α (dark blue). The pie slices were shown in five different colours, which referred to the number of 
CD107a/ cytokines co-expressed; 4 in purple, 3 in orange, 2 in yellow, 1 in grey and 0 in white. These 
same coloured pie slices were also appeared in the bar chart together with the legend below informing 
different combinations of the CD107a/cytokine expression, where (+) referred to positive and (-) to 
negative expression of each marker.  Black bars demonstrated the proportion of M1-Tm+ cells in 
different functional profiles. For example, the first bar showing in the purple pie slice demonstrated 
approximately 3% of M1-Tm+ cells expressing all four markers; CD107a, IFN-γ, IL-2 and TNF-α. 
 
Having shown that M1-Tm+ cells mobilised CD107a to their cell surface after peptide 
restimulation, implying degranulation, the expression of cytotoxic molecules including 
perforin and granzyme-A and –B were then measured in CD107a+ M1-Tm+ cells in tonsillar 
MNCs at every hour until 5 hours after M158-66 peptide restimulation. Median fluorescence 
intensity (MFI) of perforin and granzyme-A gradually increased in the first three hours, while 
the decrease of granzyme-B was observed in the first two hours. All three cytotoxic 
molecules stabilised at 4 hours before increasing at 5 hours (Figure 4.13a). It was convinced 
that the tiny fraction of M1-Tm+ cells (less than 1% of total CD8+ T cells) resulted in the very 
low absolute number of M1-Tm+ cells among large number of total events being acquired for 
analysis and the kinetics of cytotoxic effector molecule release observed may not be truly 
representative.  
As a much higher number of M1-Tm+ cells could be detected in PBMCs upon MVA-NP+M1 
stimulation (~20% of total CD8+ T cells), the same experiment was carried out using PBMCs to 
further identify the degranulation kinetics of CTLs activated by MVA-NP+M1. In accordance 
with tonsillar MNCs, the majority of these cells contained perforin and granzymes in their 
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cytoplasm. After the M158-66 peptide pulsing, the kinetics of surface CD107a expression was in 
a similar pattern (data not shown) to that in tonsillar MNCs. Interestingly, both granzyme-A and 
-B in CD107a+ M1-Tm+ cells of PBMCs were shown to continuously decrease in the first three 
hours before increasing in at 5 hours. However, perforin gradually increased at all times as 
similarly observed in tonsillar MNCs (Figure 4.13b).  
       a       b 
              Tonsillar MNCs        PBMCs 
  
 
Figure 4.13   The kinetics of cytotoxic molecule release of M1-Tm+ cells following       
M158-66 peptide restimulation.  
a) CD69+cell-depleted tonsillar MNCs (n=3) or b) peripheral blood mononuclear cells (PBMCs) 
following 7-day in vitro stimulation with MVA-NP+M1 were pulsed with M158-66 peptide in the presence 
of anti-human CD107a antibodies (CD107a-BV421) and brefeldin A plus monensin during culture. The 
expression of cytotoxic molecules; perforin (purple line), granzyme A (red line) and granzyme B 
(orange line) in CD107a+ M1-Tm+ cells was measured in different time points. Dots and error bars 
indicated means and SEMs at each time point. 
 
Finally, the capacity of M1-Tm+ cells in tonsillar MNCs to mediate cytotoxic killing of target 
cells was examined in vitro. Isolated CD8+ T cells following in vitro MVA-NP+M1 stimulation 
containing M1-Tm+ cells were used as effector T cells (E) and co-cultured at different ratios 
with M158-66 peptide-pulsed autologous B cells (as target cells, T), followed by the analysis of 
target cell lysis using LIVE/DEAD staining followed by flow-cytometry.  The proportion of M1-
Tm+ cells in total isolated CD8+ T cells following vaccine stimulation varied from 1 to 3% 
among samples, resulting in the highest E/T ratio that also varied from 0.77 to 1.57. 
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Representative data as demonstrated in Figure 4.14a showed there was a significant decrease 
in peptide-pulsed B cells (Tlow), but not B cells without peptide pulsing (Thigh) following co-
culture with CD8+ T cells, indicating specific lysis of peptide-pulsed B cells. Of three individuals 
tested, the capacity of lysis killing at the highest E/T ratio was shown at 24, 26 and 56%. All of 
them showed linear regression with R2 over 0.85, where the increase of target cell-lysis 






Figure 4.14   Specific killing capacity of M158-66-specific CD8+ T cells 
Isolated CD8+ T cells following MVA-NP+M1 stimulation were co-cultured at different ratios with 
autologous B cells labeled with low (Tlow) and high CFSE intensities (Thigh) for 6 hours. Tlow were either 
pulsed with M158-66 peptide or left without pulsing, while Thigh were always left without pulsing. a) The 
representative flow cytometric plot and the histogram showed the decreasing number of Tlow after 
peptide pulsing (green box or red middle peak on histogram) compared to non-pulsing (blue box or 
middle grey shade on histogram), which indicated specific target cells being killed. b) Graph plotted 
between % specific lysis and E/T ratio exhibited the linear regression. E was referred to M1-Tm+ cells 
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4.5. Discussion and conclusion 
MVA-NP+M1 has been designed to confer broadly protective cellular immunity as the 
vaccine antigens contain widely conserved CD8+ T cell epitopes among influenza A viruses 
[35]. Since intranasal vaccination (e.g. LAIV) is considered a biologically more relevant and 
effective vaccination strategy against respiratory pathogens [30], [168], [169], the potential of 
MVA-NP+M1 as a mucosal vaccine to activate cross-reactive T cell responses was 
investigated in human NALT in vitro.  
The optimisation of in vitro cell stimulation with MVA-NP+M1 vaccine was initially performed 
and it was shown that the highest magnitude of M1-specific CD8+ T cell response was 
obtained following the stimulation of PBMCs or CD69+cell-depleted tonsillar MNCs with the 
final concentration of 1x105 pfu/ml MVA-NP+M1 vaccine with IL-15 supplement followed by a 
7-day incubation period (Figure 4.4 and 4.5). As MVA infection could induce cell apoptosis 
[143], the optimal vaccine dose would result in the balance of cell viability and T cell 
response. IL-15 has the essential roles to induce human naïve and memory CD8+ T cells 
proliferation and is also involved in maintaining memory CD8+ T cells [177]. Moreover, IL-15 
producing cells were found in T cell areas and the squamous epithelial cells lining human 
tonsils [178]. Therefore, IL-15 supplement may provide physiological environment for the cell 
culture. Although CD8+ T cells in the MNCs without stimulation (medium control) seemed to 
proliferate during the culture, there was no increase of antigen-specific CD8+ T cells 
observed, suggesting that the IL-15 dose used in this study does not cause non-specific T 
cell induction. Finally, the detectable T cell response was shown at day-7 following in vitro 
stimulation. Within this period of time, it would allow antigen-specific CTLs to expand after 
the recognition of influenza NP/M1 antigens. Similarly, it was previously shown that T cell 
responses in healthy volunteers were detectable in peripheral blood as early as 1 week 
following MVA-NP+M1 vaccination [167].  
CTLs have been shown to positively correlate with protection from different subtypes of 
influenza virus [91], [179]. In this study, the capacity of MVA-NP+M1 to activate antigen-
specific CD8+ T cell responses was examined in human NALT in vitro. Data from IFN-γ 
ELISPOT assay and ICS demonstrated that MVA-NP+M1 activated a marked increase in 
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IFN-γ-secreting CD8+ T cells in tonsillar MNCs specific to conserved influenza M1 epitopes 
(Figure 4.6). This was in accordance with previous studies showing the increasing 
magnitude of T cell responses to the epitopes spanned across NP and M1 in peripheral 
blood of MVA-NP+M1-vaccinated healthy people [165], [167].  
CD4+ T cells as T helper cells also play an important role in enhancing CD8+ T cell response. 
By using 15-mer peptides, T cell response to M1 peptides was observed in an ELISPOT 
assay; however, the data from ICS showed that the responses were likely to be originated 
from CD8+ T cells rather than CD4+ T cells. The 15-mer peptides should be principally 
presented by MHC class II molecules to CD4+ T cells; however, the peptides may be able to 
bind to the MHC class I if there is carboxy terminus at both ends of them [180], activating 
CD8+ T cell response instead. A study suggested that the use of 17-mer rather than 15-mer 
peptides to stimulate splenocytes gave more optimal respiratory syncytial virus (RSV)-
specific CD4+ T cell response [181]. To this point, the optimal peptide length and sequences 
may be considered for the study of CD4+ T cell response to the vaccine.   
M158-66–specific CD8+ T cell responses were further examined using HLA-A2-restricted M158-
66 tetramer staining. M158-66 is one of the immunodominant M1 epitopes, which is conserved 
among influenza A viruses including H1, H3 and H5 [44], [182], [183]. The epitope is 
restricted to HLA-A2, which is among the highest frequencies in most ethnic groups, 
responsible for 20-30% overall and 50% in Caucasians [184], [185]. The frequency of pre-
existing M1-Tm+ cells was generally low in tonsillar MNCs. A similar finding has been 
observed in peripheral blood from young adults and elderly, and in whom these M1-specific 
T cells had central memory T cell phenotypes [186]. Following in vitro stimulation, MVA-
NP+M1 elicited M1-Tm+ T cell response in tonsillar MNCs from HLA-matched individuals 
(Figure 4.9a). The similar finding was previously shown that the frequency of M1-Tm+ cells in 
peripheral blood tended to be in higher in MVA-NP+M1-vaccinated donors than controls 
although it did not reach significance. However, it should be noted that the measurement of 
M1-Tm+ cells in this study was not performed at the peak time of T cell response (week 3), 
but 1 week later when the T cells showed contraction. Despite the insignificant increase of 
M1-Tm+ cells, they showed that these cells in vaccinees were highly activated [187]. The 
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results in this study showed that the CTL response was age-dependent (Figure 4.9b). The 
markedly increased response was observed for the first time in older children and the 
response was strongest in adults. The results in this study support the hypothesis that MVA-
NP+M1 has the capacity to boost M1-specific mucosal CD8+ T cell responses in addition to 
systemic T cell responses in adults [165], [167] and elderly [164]. This is likely via activating 
the memory CD8+ T cells primed by previous natural exposure to influenza viruses or 
vaccination. MVA-vectored vaccines have been shown to induce memory T cells in other 
studies. Clonality studies in vaccinated-elderly showed MVA-NP+M1 expanded pre-existing 
epitope-specific T cells [164]. MVA expressing HIV-1 genes also predominantly induced 
central memory CD8+ T cells specific to HIV-1 Gag [188]. 
Having shown the activation of M158-66-specific CD8+ T cell responses, the functionality of 
these cells was then studied. It is generally thought that cytotoxic CD8+ T cells exert their 
effector activities to limit virus infection and disease severity [46], [91] through cytotoxic 
effector molecule release and pro-inflammatory cytokine secretion [99]. It was demonstrated 
herein that many M1-Tm+ cells in tonsillar MNCs activated by MVA-NP+M1 in vitro 
expressed perforin, granzyme-A and –B (Figure 4.11), which were subsequently released 
upon the recognition of M158-66 peptide, as implied from the rapid upregulation of surface 
CD107a expression. In addition, it was also shown that the kinetics of surface CD107a 
expression correlated well with that of cytokine (IFN-γ) production in M1-Tm+ cells (Figure 
4.12c,d). However, the more rapid upregulation of surface CD107a than IFN-γ expression at 
the first hour after peptide challenge suggests a rapid or perhaps an immediate 
degranulation and cytotoxic molecule release rather than cytokine secretion at the initial 
stage of CD8+ T responses. This was supported by the results demonstrating that perforin 
and granzymes were already stored intracellularly in M1-Tm+ cells before peptide challenge. 
In contrast, IFN-γ was not detected in M1-Tm+ cells and was likely to be produced de novo 
following antigen challenge. 
Many M1-Tm+ cells co-expressed CD107a with anti-viral cytokines; IFN-γ and TNF-α (Figure 
4.12f). In addition to these two cytokines, some of these cells also co-expressed IL-2, which 
may exhibit more potent cytotoxic functions than those producing only one or two cytokines 
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[99]. Similar functional profiles showing the co-expression of CD107a and pro-inflammatory 
cytokines of human cytotoxic T cells in peripheral blood were reported previously following in 
vitro influenza virus infection [189] and after MVA-NP+M1 vaccination [167]. The results 
suggest that M1-Tm+ cells produce both cytotoxic effector molecules and inflammatory 
cytokines upon specific antigen recognition. The functional profile suggests that M1-Tm+ 
cells are likely to be short-lived effector and effector memory CD8+ T cells [190], [191]. 
Despite the fact that the majority of M158-66-specific CTLs were functionally active, it was 
noteworthy that some of these CTLs seemed to be unresponsive upon the recalled peptide 
restimulation. Future study may answer whether or not these cells are dysfunctional. 
As surface CD107a expression implies degranulation, the release of cytotoxic molecules 
was also assessed (Figure 4.13). Although a consistent reduction of cytotoxic molecules in 
the responding CTLs (M1-Tm+ CD107a+) was not observed in tonsillar MNCs, the pattern 
was observed in PBMCs. It is likely that the low number of M1-Tm+ cells in tonsillar MNCs 
tested and the gradual loss of these cells over the course of peptide restimulation in the 
experiment may have affected the consistency of this observation. By performing the same 
experiment in PBMCs containing larger number of M1-Tm+ cells, the continuous decrease of 
granzyme-A and –B in CD107a+ M1-Tm+ cells was obviously displayed at the first 3 hours 
upon the peptide restimulation. The rising level of granzymes at 5 hours may be explained 
as the accumulation of newly synthesised granzyme molecules [192]. In contrast, the 
gradual increase of perforin seemed to result from the use of clone B-D48 antibody for 
staining, which sensitively detects different conformations of perforin (both pre-existing and 
de novo synthesised) [193], [194].  
Having shown that MVA-NP+M1-activated M1-Tm+ cells in tonsillar MNCs were 
polyfunctional, the in vitro cytotoxic killing assay was finally performed and the results 
supported that MVA-NP+M1-activated M1-Tm+ cells possessed a potent cytotoxic killing 
activity capable of specific target cell lysis in human NALT (Figure 4.14). 
In conclusion, the results demonstrated that MVA-NP+M1 had the capacity to activate a 
cross-reactive M1-specific mucosal CD8+ T cell response in an age-dependent manner. 
These M1-specific CTLs exhibited classical cytotoxic effector markers and produced pro-
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inflammatory cytokines leading to specific killing of target cells in human NALT in vitro. It 
suggests that this novel vaccine has the potential to act as a mucosal vaccine to activate a 




5. Chapter 5 
Activation of cross-reactive HA-specific IgG antibody 




















Neutralising antibodies (nAb) are considered as the benchmark of protective immune 
responses to influenza viruses [18]. This type of antibody can be induced by seasonal 
influenza vaccines, either inactivated or live attenuated, and provide the protection from 
circulating viruses that are identical or closely antigenically matched to vaccine strains [22]. 
On the other hand, the broader protective responses across influenza subtypes could be 
mediated by broadly neutralising antibodies (bnAb), in addition to cytotoxic T cell immunity 
[35], [136]. 
Broadly neutralising monoclonal antibodies to influenza viruses have been discovered from 
isolated human memory B cells. They target the more relatively conserved HA stalk instead 
of the HA globular head. Binding to different epitopes on the HA stalk results in the 
difference in the breadth of reactivity. Most antibodies have been shown to cross-react to 
either phylogenetic HA group 1 or group 2. A few have the cross-reactivity to both HA 
groups, and recently, one has been found to recognise HA of both influenza A and B viruses 
[41], [79], [195]. The anti-HA stalk antibodies are found in some individuals following 
seasonal vaccination or natural infection [196], [197]. Nevertheless, the frequencies of the 
HA stalk specific antibody-producing B cells are relatively rare, which results from the 
subdominant activation of HA stalk-reactive memory B cells during seasonal epidemics [19]. 
Although the magnitude of anti-HA stalk antibody response is low during seasonal 
vaccination, the HA stalk-reactive antibodies were found to increase markedly in people 
infected with pandemic H1N1 virus during the outbreak in 2009 [20], [21], [83]–[85]. It was 
hypothesised that the significant changes in the immunodominant globular head epitopes of 
the pandemic H1 HA compared to the contemporary seasonal H1 HAs lead to decreased 
competition for antigen among pre-existing memory B cells, which in turn allowed for the 
expansion of the subdominant stem-specific memory B cells [19]. Later, it has been also 
shown that the HA stalk reactive antibodies could be more efficiently boosted by sequential 
immunisation with divergent HAs [41], [42]. Vaccination with the subunit pandemic H1N1 
vaccine also boosted the HA stalk-specific antibodies in healthy adults; however, the 
antibodies waned faster than those induced by natural infection [198]. The HA stalk-reactive 
110 
antibodies have been characterised as having no haemagglutination inhibition (HAI) activity 
as they do not bind to the globular HA head [198].  HA stalk-reactive antibody-mediated 
protection is most likely via neutralising activity by trapping an internalised virus in the 
endosome or by inhibiting HA maturation of virus or via requiring Fcγ-R interaction for cell-
mediated cytotoxicity [87], [199], [200] as shown in Figure 1.9.  
Given the cross-reactivity of anti-HA stalk antibodies, recent efforts are focused on the use 
of novel vaccines and vaccination strategies to boost these antibodies in order to confer 
broadly protective response to multiple subtypes of influenza viruses [201], [202]. Various 
vaccine platforms such as DNA vaccines, vector-based vaccines and modified HA protein 
vaccines have been employed together with or without the use of adjuvants. Of them, MVA 
expressing influenza HA is one of the candidate vaccines and have been reported to induce 
cross-reactive protection in different animal models [54]. MVA-expressing HA of A/Vietnam/ 
1194/2004 (H5N1) has been shown to induce cross-clade neutralising antibodies to different 
H5N1 subtypes in animal models [203], [204] and in humans [67]. 
Despite the accumulative findings of the protective responses induced by MVA-vectored 
vaccines, a few have shown the potential of the vaccines to induce mucosal antibody 
responses, which may provide superior protection from virus infection in humans. We have 
previously shown that MVA-pdmH1HA elicits the mucosal cross-reactive HA-specific IgG 
antibodies to influenza subtypes in human NALT following in vitro vaccine stimulation [147]. 
In this study, the potential of MVA-pdmH1HA to activate such B cell-mediated antibody 
response was further studied. The MVA-pdmH1HA-elicited antibodies were assessed for the 
magnitude and the breadth of cross-reactivity to heterologous subtypes including seasonal 
H1, H3, H5, H7 and H9 and the antibodies were also characterised for the HA-binding site. 
5.2. Aims of the study 
1. To measure the capacity of MVA-pdmH1HA to elicit HA-specific IgG antibodies against 
influenza A viruses in HA group 1 and group 2 in human NALT in vitro 
2. To compare the magnitude and the breadth of cross-reactive antibody response 
between children and adults 
111 
5.3. Materials and methods 
5.3.1. Adenoidal/ tonsillar tissues and peripheral blood 
Adenoidal and tonsillar tissues were obtained from children (average age 6.2, 2-15) and 
adults (average age 27.4, 16-54) undergoing adenotonsillectomy at local hospitals. Patients 
who received systemic steroids within 3 weeks prior to surgery, or who had any known 
immunodeficiency were excluded from the study.  
Adenotonsillar MNCs were then isolated from the tissues as the standard protocol described 
in chapter 2 (see 2.7.1) and were resuspended in R10 at 4x106 cells/ml. Peripheral blood 
taken from the same patient was spun down to collect its plasma, termed “autologous 
human plasma (aHP)”. 
5.3.2. Vaccines/ Viruses 
MVA-pdmH1HA (#1531) is a recombinant Modified Vaccinia Ankara (MVA) expressing full-
length HA of A/California/04/2009 (pdmH1N1) under the control of the modified Vaccinia H5 
(mH5) promoter. MVA-wt  (#1533) was a non-recombinant virus used as a vector control. 
FluMist® season 2011-2012 (NR-36465, BEI resources, USA) is a trivalent live attenuated 
influenza vaccine (LAIV), containing A/California/07/2009 (pdmH1N1), A/Perth/16/2009 
(H3N2) and B/Brisbane/60/2008. It was used as a positive control for the antibody 
production study. 
The following two inactivated whole influenza viruses were used as antigens for 
haemagglutination inhibition assay; A/California/07/2009 (GPO, Thailand) and A/Vietnam/ 
1203/2004 (FR-736, IRR, USA). 
5.3.3. Influenza recombinant proteins  
Recombinant HA protein from influenza subtypes; A/California/04/2009 (pdmH1N1, NR-
13691), A/Brisbane/59/2007 (sH1N1, NR-28607), A/Brisbane/10/2007 (H3N2, NR-19238), 
A/Vietnam/1203/2004 (H5N1, NR-10510), A/Hong Kong/33982/2009 (H9N2, NR-41792) and 
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A/Anhui/1/2013 (H7N9, NR-44081) were obtained from BEI resources, USA and used for 
enzyme-linked immunosorbent assay (ELISA) to detect HA-specific IgG antibodies. Unless 
otherwise stated, each HA was a full-length glycosylated recombinant protein that was 
produced in Sf9 insect cells using a baculovirus expression vector system.
 
It was purified 
under conditions that preserve its biological activity and tertiary structure.  
5.3.4. Measurement of HLA-DR expression  
To measure the expression of HLA-DR on MVA-pdmH1HA-infected adenotonsillar B cells, 
the MNCs were cultured with MVA-pdmH1HA at a final concentration of 5x104 pfu/ml (or 
MOI of 0.00125) for 18-20 hours. The MNCs were harvested and stained for surface CD19-
FITC (clone HIB19) and HLA-DR-APC (clone G46-6) (Both BD Biosciences, UK) before 
intracellular staining with RPE-conjugated monoclonal anti-pandemic H1N1 HA antibody, 
followed by flow-cytometry. 
5.3.5. Cell stimulation and culture for antibody production study 
Adenotonsillar MNCs were cultured with either MVA-wt or MVA-pdmH1HA at the final 
concentration of 5x104 pfu/ml unless otherwise stated or left without any stimulation (medium 
control). The MNCs stimulated with FluMist® season 2011-2012 at the final concentration of 
2 µl/ml (approximately 105 FFU/ml per each virus) were used as positive control [205]. Cell 
culture media was additionally supplemented with 2%aHP and seeded in 96-well plate. The 
plate was incubated for 10 days before cell culture supernatant was collected and stored at -
20°C until analysis. 
5.3.6. Detection of HA-specific IgG antibodies by indirect ELISA 
Cell culture supernatant following 10-day in vitro vaccine stimulation (see 5.3.5) was 
analysed for HA-specific IgG antibodies by ELISA assay (see 2.13). The cell culture 
supernatant was thawed at room temperature and pre-diluted in ELISA blocking buffer 
(10%ΔFBS in 1XPBS) at different ratio before tested. If the sample showed the optical 
density (OD) out of the standard range, the sample dilution needed to be adjusted either 
higher or lower than the previous one and retested. Nevertheless, the lowest sample dilution 
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of all samples was 1:5, due to the limit of sample volume. The antibody concentration 
(Units/ml; U/ml) of each sample was calculated based on the standard curve with four-
parameter logistic curve fit using DeltaSoft 1.61.0 programme. Any sample demonstrating an 
antibody concentration lower than the limit of detection of the assay (undetectable value by 
DeltaSoft programme) was re-calculated its concentration based on the standard curve with 
polynomial regression using Microsoft Excel programme.  
Due to the background caused by the pre-existing anti-influenza antibodies in aHP, the 
antibody concentration in cell culture supernatants following in vitro MVA-wt or MVA-
pdmH1HA stimulation was subtracted from that of medium control unless otherwise stated 
before being used for any statistical analysis.  
For qualitative analysis to determine the breadth of cross-reactive antibody, the positive 
antibody response was defined when the subtracted antibody concentration of the 
MVApdmH1HA-stimulated cell culture supernatant was higher than that of the MVA-wt-
stimulated one and was not below the lowest limit of detection of the assay (The value was 
obtained from DeltaSoft programme). 
5.3.7. Haemagglutination inhibition (HAI) assay 
Antibodies in cell culture supernatants following in vitro MVA-wt and MVA-pdmH1HA 
stimulation and medium control were characterised by HAI assay (see 2.14) to homologous 
(pdmH1N1) and heterologous virus strains (H5N1) (Figure 5.7). Briefly, cell culture 
supernatant was heated followed by chicken red blood cell treatment to remove non-specific 
haemagglutinin before performing the HAI assay. The HAI titre in cell culture supernatants 
from each individual after MVA-wt and MVA-pdmH1HA stimulations was compared. HAI 
conversion was defined as 2 or more fold change when the HAI titre of MVA-pdmH1HA-
stimulated cell culture supernatant was divided by that of the MVA-wt-stimulated one. 
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5.3.8. Statistical analysis  
For two-group comparisons, based on the normality of distribution of data. Nonparametric 
Wilcoxon matched-pairs signed rank test and nonparametric Mann-Whitney test were 


















5.4.1. Optimisation of in vitro cell stimulation with MVA-pdmH1HA 
Optimisation was initially performed on the cell culture supplement and MVA-pdmH1HA 
vaccine doses. Cell culture was routinely supplemented with 10% ΔFBS. In order to enhance 
antibody production, autologous human plasma (aHP) was also added to cell culture 
medium and the concentration of aHP was optimised. The use of aHP increased HA-specific 
IgG antibodies to pdmH1N1 detected by ELISA assay as seen in medium control. The 
higher the aHP concentration added, the higher the anti-pdmH1N1 antibody were detected, 
suggesting that pre-existing anti-influenza antibodies were contained in aHP. 2% aHP 
supplement was shown among other aHP concentrations to maximally enhance the amount 
of HA-specific IgG anti-pdmH1 antibodies in the MNCs following in vitro MVA-pdmH1HA 
stimulation (Figure 5.1). 
 
Figure 5.1   Optimisation of autologous human plasma concentration  
Adenotonsillar mononuclear cells were cultured with either MVA-wt or MVA-pdmH1HA at 5x104 pfu/ml 
or left without any stimulation (medium control) without or with autologous human plasma (aHP) 
supplement, varied from 1-3%v/v. HA-specific anti-pdmH1N1 IgG antibody was measured in cell 
culture supernatant by enzyme-linked immunosorbent assay. The antibodies were shown in medium 
control (grey line), MVA-wt (black line) and MVA-pdmH1HA (red line) stimulation. Dots and error bars 
indicated medians and interquartile ranges (n=7).  





























With 2% aHP supplement, adenotonsillar MNCs were then stimulated with MVA-pdmH1HA 
doses ranging from 2.5x104, 5x104 and 1x105 pfu/ml and anti-pdmH1HA antibody was 
measured. The antibody concentration in medium control and MVA-wt-stimulated cell culture 
supernatant was comparable for each vaccine dose tested. Following the in vitro stimulation 
of MVA-pdmH1HA, the highest antibody response was shown with the use of vaccine at the 
concentration of 5x104 pfu/ml. The use of the higher vaccine dose decreased the magnitude 
of the antibody response (Figure 5.2). 
Therefore, for the antibody production study, adenotonsillar MNCs would be stimulated with 
MVA-pdmH1HA at a final concentration of 5x104 pfu/ml and incubated for 10 days before the 
cell culture supernatant was analysed for HA-specific IgG antibodies to influenza subtypes. 
 
 
Figure 5.2   Optimisation of MVA-pdmH1HA vaccine dose 
Adenotonsillar mononuclear cells were stimulated with either MVA-wt or MVA-pdmH1HA at different 
concentrations with 2% autologous human plasma supplement. HA-specific anti-pdmH1N1 antibody 
was measured by enzyme-linked immunosorbent assay. The antibody concentration in medium control 
(grey) and MVA-wt - (black) and MVA-pdmH1HA (red) -stimulated cell culture supernatant at different 

























 MVA-wt  
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5.4.2. HLA-DR upregulation in influenza HA-expressing tonsillar B cells 
Having shown in chapter 3 that influenza HA was abundantly expressed in B cells, it was 
questioned whether there was an upregulation of HLA class II molecules, which are 
important for antigen presentation to activate CD4+ T cell responses, helping the B cell-
mediated antibody response. The use of MVA-pdmH1HA dose at 5x104 pfu/ml resulted in 
approximately 8% of the MNCs mainly B cells to express HA. The expression of HLA-DR 
was measured in adenotonsillar B cells following in vitro MVA-pdmH1HA stimulation. It was 
observed that HLA-DR was upregulated in influenza HA-expressing B cells. The higher 
fluorescence intensity of HA antigen was shown, the higher HLA-DR was expressed. Of 
CD19+ B cells, the median fluorescence intensity (MFI) of HLA-DR was 419, 258 and 139 in 
HAhigh, HAint and HAneg cells, respectively, while the MFI of CD19- non-B cells was as low as 
5.79 (Figure 5.3). 
 
 
Figure 5.3   The upregulation of HLA-DR in HA-expressing B cells. 
Adenotonsillar mononuclear cells were stimulated with MVA-pdmH1HA at 5x104 pfu/ml for 18-20 
hours. Cells were harvested and stained for CD19 and HLA-DR on the cell surface before intracellular 
staining for HA of pandemic H1N1. The flow cytometry dot plot showed 1) CD19- HAneg (black line) 2) 
CD19+ HAneg (grey shade) 3) CD19+ HAint (blue line) and 4) CD19+ HAhigh (red line) and the histogram 
compared the median fluorescent intensity (MFI) of HLA-DR between the four cell populations as 
described above.  
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5.4.3. MVA-pdmH1HA elicited cross-reactive HA-specific IgG antibodies to 
influenza subtypes  
MVA-pdmH1HA was then assessed for its capacity to elicit HA-specific IgG antibodies in 
adenotonsillar MNCs to homologous (pandemic H1N1) and heterologous influenza subtypes 
(Figure 5.4). Following 10-day in vitro stimulation with MVA-wt and MVA-pdmH1HA, HA-
specific anti-pdmH1N1 antibodies in cell culture supernatant was analysed by ELISA. The 
MNCs stimulated with LAIV was used as positive control. Only MNCs that showed positive 
anti-pdmH1N1 antibody response to LAIV were included in the study, as they seemed to 
respond well in antibody production. The quality of tissues and the MNCs after isolation may 
affect the response of cells to the vaccine. Over half of children and almost all adults 
responded to LAIV, showing the higher anti-pdmH1N1 antibody compared to medium control.  
 
Figure 5.4   Experimental and analysis flow of the antibody production study 
The diagram shows the experimental flow for the antibody production study of MVA-pdmH1HA vaccine 
including the criteria to exclude any data from the analysis. 
Adenotonsillar mononuclear cells 
stimulated with     No (Medium control) 
MVA-wt 
MVA-pdmH1HA 
LAIV (positive control) 
Cell culture supernatant collected at day10 
Children (≤15) 
n = 61 
Adults (>15) 
n = 33 
Excluded:  
negative anti-pdmH1N1 Abs 
to LAIV 
ELISA 
IgG antibodies to pdmH1N1 
n = 33  
(54.1%) 
n = 30 
(90.9%) 
n = 18 
(54.5%) 
n = 23 
(76.7%) 
Excluded:  
negative anti-pdmH1N1 Abs 
to MVA-pdmH1HA 
ELISA 
IgG antibodies to sH1N1, H5N1, 
H9N2, H3N2 and H7N9 
Hemagglutination inhibition (HAI) assay 
to pdmH1N1 and H5N1 
n = 11  (selected) 
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The MNCs showing positive antibody responses to LAIV were then measured for the HA-
specific IgG antibody response to MVA-pdmH1HA. It was shown that in vitro stimulation by 
MVA-pdmH1HA elicited a significant increase in anti-pdmH1N1 HA antibody levels 
compared to the MVA-wt control in adenotonsillar MNCs from both children (n=33, 
p<0.0001) and adults (n=30, p <0.0001) (Figure 5.5a).  
The cell culture supernatant that demonstrated the positive anti-pdmH1N1 antibody 
response following MVA-pdmH1HA stimulation were further measured HA-specific IgG 
antibodies to heterologous influenza viruses in HA group 1 (sH1N1, H5N1, H9N2) and HA 
group 2 (H3N2 and H7N9) then the magnitude and breadth of reactivity antibody were 
assessed in children and adults. Following in vitro MVA-pdmH1HA stimulation, 
adenotonsillar MNCs from both children and adults were shown to produce IgG antibodies 
recognising influenza in HA group 1. The antibodies to HA group 2 viruses were only 
observed in adults towards H3N2. No antibodies to H7N9 were observed in both children 
and adults (Figure 5.5b). The magnitude of antibody response was highest towards 
pdmH1N1, followed by to HA group1 viruses. The antibodies to HA group 2 viruses were 
generally low, although they were detectable in a few samples.  
When compared between 2 age groups, adults were shown to produce a higher level of 
antibodies than children to both homologous and heterologous influenza strains particularly 
in HA group1. The median IgG antibodies (U/ml) to pdmH1N1, sH1N1, H5N1, H9N2 were 
13.65, 0.47, 0.81 and 0.26 in adults and were 1.58, 0.04, 0.04 and 0.00 in children, 
respectively (Figure 5.6a). In addition to the higher magnitude of antibody, adenotonsillar 
MNCs from adults in general produced antibodies with the greater breadth of reactivity than 
that from children. Approximately 40% of children were shown to produce HA-specific IgG 
antibodies to only homologous pdmH1N1 without cross-reactivity to other viruses tested, 
whereas the MNC from almost all adults produced cross-reactive antibodies to other virus 
strains.  The majority of adults (~50%) produced antibodies that cross-reacted to 2 or 3 virus 
subtypes, mainly in HA group 1. There were approximately 15% of adults produced cross-
reactive antibodies to the tested virus strains in both HA group 1 and group 2 (Figure 5.6b,c).  
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Figure 5.5   Cross-reactive HA-specific IgG antibodies to homologous and 
heterologous influenza subtypes elicited by MVA-pdmH1HA 
Adenotonsillar mononuclear cell culture supernatants following 10-day stimulation with either MVA-wt 
or MVA-pdmH1HA or left without stimulation (medium control) were analysed for HA-specific IgG 
antibodies to pdmH1N1 and other heterologous subtypes by enzyme-linked immunosorbent assay 
(ELISA). Background-subtracted antibody concentrations (U/ml) were compared between MVA-wt 
(grey circle) and MVA-pdmH1HA stimulation (red open circle). a) MVA-pdmH1HA significantly elicited 
higher IgG anti-pdmH1N1 antibodies in both children (n=33, ****p<0.0001) and adults (n=30, ****p 
<0.0001). b) MVA-pdmH1HA significantly elicited higher IgG antibodies to sH1N1 (**p=0.002), H5N1 
(**p=0.0026) and H9N2 (*p=0.0259), but not HA group 2; H3N2 (p=0.1484) and H7N9 (p=0.0640) in 
children (n=18). The vaccine also significantly elicited higher IgG antibodies to sH1N1 (***p=0.0007), 
H5N1 (****p<0.0001) and H9N2 (****p<0.0001) and HA group 2; H3N2 (*p=0.0417) but not H7N9 
(p=0.2078) in adults (n=23). Wilcoxon matched-pair signed rank test was used for comparison between 
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Figure 5.6   The magnitude and the breadth of reactivity of antibodies elicited by MVA-
pdmH1HA in children and adults 
Following 10-day in vitro MVA-pdmH1HA stimulation, adenotonsillar mononuclear cell culture 
supernatants that showed positive IgG anti-pdmH1N1 antibody response were analysed for HA-



































HA group 1 group 2 
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to all six influenza strains was compared between children (n=18) and adults (n=23). Bar and error 
bars indicated medians and interquartile ranges. b) Colour indicated the positive antibody response to 
each virus strain (yellow – pdmH1N1, orange – sH1N1, purple – H5N1, pink – H9N2, blue – H3N2, 
green – H7N9) in each individual. The subjects were in the order of ages from young to old. Star (*) 
over the number indicated the sample selected for haemagglutination inhibition assay. c) The breadth 
of reactivity of antibodies between children (n=18) and adults (n=23) was compared based on the 
positive antibody response to heterosubtypic viruses. The bar in different colours illustrated the number 
of heterologous subtypes that the antibodies cross-reacted to, ranging from zero (0) to five (5). Zero 
meant the antibodies only reacted to homologous pdmH1N1. 
5.4.4. Haemagglutination inhibition (HAI) activity of MVA-pdmH1HA-elicited 
antibodies  
Having shown that MVA-pdmH1HA elicited cross-reactive HA-specific IgG antibodies 
against homologous (pdmH1N1) and heterologous viruses in HA group 1 (sH1N1, H5N1 and 
H9N2), it was then characterised whether these antibodies were HA-stalk specific by 
performing HAI assay. Cell culture supernatants showing positive anti-pdmH1N1 and anti-
H5N1 antibodies were selected to perform the HAI assay against inactivated pdmH1N1 and 
H5N1 viruses (Figure 5.7).  
 
Figure 5.7  Haemagglutination inhibition (HAI) assay. 
Representative data from a sample showing HAI activity against pdmH1N1 virus interpreting as a red 
button. Cell culture supernatant following in vitro MVA-pdmH1HA stimulation showed an HAI titre of 2, 
while that following MVA-wt stimulation and medium control did not show any inhibition, shown as HAI 
titre less than 2. This sample therefore showed HAI conversion with a 2-fold change. Human serum as 
















Adenotonsillar MNC culture supernatant following in vitro LAIV stimulation was used to 
perform the preliminary test and the HAI titre to pdmH1N1 virus was determined.  Median 
anti-pdmH1N1 antibody titre were 32.4 (8-145) and 164.4 (85-893) U/ml in medium control 
and LAIV-stimulated cell culture supernatant, respectively. Almost all samples (12 of 14; 
85.7%) showed HAI conversion upon LAIV stimulation as compared to medium control 
(p=0.0005) with 2-16-fold change (Figure 5.8a).  
The HAI assay was then performed to measure the HAI titre in the cell culture supernatant 
following in vitro MVA-wt and MVA-pdmH1HA stimulation. Of selected 11 samples, anti-
pdmH1N1 and anti-H5N1 antibodies were shown in Table 5.1. 
Table 5.1   Antibody concentration (U/ml) in cell culture supernatant samples selected 
for HAI assay 
Antibodies to Median (range) antibody concentration (U/ml) 
Medium control MVA-wt MVA-pdmH1HA 
pdmH1N1 36.2 (7-131) 36.0 (6-125) 148.8 (9-339) 
H5N1 1.3 (0.4-4.4) 1.3 (0.4-4.0) 5.1 (0.8-8) 
 
Low HAI titre (between 1 and 4) was detected against pdmH1N1 and H5N1 in medium 
control and MVA-wt-stimulated cell culture supernatant. Following MVA-pdmH1HA 
stimulation, 5 of 11 (45.5%) were observed HAI conversion with 4-16-fold change against 
pdmH1N1, but did not reach significance, whereas no HAI conversion was observed against 













Figure 5.8   Hemagglutination inhibition (HAI) titre against influenza viruses. 
HAI assay was performed to measure the HAI titre in adenotonsillar MNC culture supernatants 
following in vitro live attenuated influenza vaccine (LAIV), MVA-wt, MVA-pdmH1HA stimulation and no 
stimulation (medium control) a) LAIV-induced antibodies showed significant HAI conversion to 
pdmH1N1 virus (n=14, ***p=0.0005). b) MVA-pdmH1HA-elicited antibodies in some individuals 
showed HAI conversion to pdmH1N1 (n=11, p=0.0625), but no HAI conversion to H5N1 (n=11) was 
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5.5. Discussion and conclusion 
HA stalk-reactive antibodies recognise multiple influenza subtypes and therefore could 
mediate the broadly protective responses [195], [202]. These cross-reactive antibodies were 
shown to be efficiently boosted in humans after pandemic H1N1 infection [20], [21], [83]–
[85], raising the possibility of developing novel vaccines to confer such antibody-mediated 
broad protection from a range of influenza subtypes. In this study, a MVA-pdmH1HA vaccine 
candidate was assessed for its potential to elicit cross-reactive HA-specific IgG antibodies in 
human NALT in vitro. 
The cell culture system was firstly optimised. 2%v/v aHP supplement in cell culture media 
appeared to enhance antibody induction in adenotonsillar MNCs following in vitro vaccine 
stimulation (Figure 5.1). The addition of aHP may provide a more favourable physiological 
environment and essential nutrients or cytokines that would be beneficial for cell signaling 
and enhance the T-helper cell activity [206], [207]. Although the supplement of aHP in cell 
culture media resulted in increased anti-influenza HA antibodies detected in cell culture 
supernatant, the presence of such antibodies was unlikely to interfere with the detection of 
antibodies induced following in vitro MVA-pdmH1HA stimulation. Those pre-existing anti-
influenza antibody in aHP could be subtracted so that the antibody newly produced upon 
MVA-pdmH1HA stimulation was obtained. In addition, there may be concern about the 
impact of anti-MVA vector antibody in aHP on the induction of antibody. Although the anti-
MVA antibody in aHP was not measured, influenza HA expression in tonsillar MNCs upon 
the MVA-pdmH1HA stimulation was less likely to be affected by aHP (data not shown). This 
is consistent with the previous report showing that pre-existing antibodies to MVA in human 
serum did not compromise the efficacy of MVA-expressing H5N1 HA vaccine [67]. The 
optimal MVA-pdmH1HA vaccine dose was shown at the final concentration of 5x104 pfu/ml. 
The use of higher vaccine dose led to a decrease of antibody response (Figure 5.2).  This 
may be explained in that the use of the high vaccine dose to stimulate the MNCs could 
cause a larger number of MVA-infected B cells, which were subsequently induced to 
apoptosis [143] and this may abrogate the antibody induction. 
126 
Upon vaccine stimulation, the expression of influenza HA from the MVA-pdmH1HA was 
previously shown. It was also shown here that HA-expressing B cells upregulated the 
expression of HLA-DR (Figure 5.3), indicating the occurrence of antigen processing and 
presentation within these B cells. HLA-DR is one of the HLA class II molecules that are 
essential for antigen presentation to CD4+ T-helper cells and the activation of T-helper cells 
could help B cell-mediated antibody responses [208]. We have recently demonstrated that 
TFH is a T-helper cell subset, having a critical role in the antibody induction in response to 
LAIV in human NALTs in vitro [209]. Circulating influenza-specific TFH were also shown to 
positively correlate with the antibody response in humans following immunisation with split 
seasonal influenza vaccine [210]. The results suggested that the induction of antibody 
responses by MVA-pdmH1HA may be T-cell dependent and this finding needed further 
investigation on the activation of HA-specific TFH. 
In addition to SIgA, IgG antibodies at respiratory mucosa were also shown to protect mice 
from influenza infection [211]. Our previous finding showed that IgG antibodies were the 
predominant isotype of antibodies induced by LAIV in human NALT in vitro [212]. Regarding 
its importance, mucosal IgG antibody production was examined in human NALT following in 
vitro MVA-pdmH1HA stimulation. MVA-pdmH1HA elicited a significant HA-specific IgG 
antibody response in adenotonsillar MNCs to pdmH1N1 (homologous strain) and also to a 
number of heterosubtypic influenza viruses, including A/Brisbane/59/2007 (seasonal H1N1), 
A/Vietnam/1203/2004 (avian H5N1) and A/Hong Kong/33982/ 2009 (avian H9N2), which 
were HA group 1 viruses. Cross-reactive antibodies to HA group 2 viruses 
(A/Brisbane/10/2007; H3N2 and A/Anhui/1/2013; H7N9) were observed only in some 
individuals (Figure 5.5). These extended results support our previous finding [147] and 
indicate that the vaccine-elicited antibodies are more likely to cross-react to only HA-group 1 
viruses. This may not be surprising as pdmH1N1 belongs to the HA group 1, thus the 
antibody induced by its HA antigen is mainly towards other viruses within the same HA 
phylogeny [79]. Similar finding were also reported on the limited breadth of reactivity of 
antibodies towards group 1 haemagglutinins in animals and humans following vaccination 
with HA antigens from pdmH1N1 and H5N1 [67], [203], [204], [213]–[216]. Cross-reactive 
antibodies to both HA groups were even rarely found as the antibody needed to adopt 
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multiple binding sites to cope with the high amino acid diversity and structural constraint by 
the presence of glycans surrounding the target epitopes [200]. The breadth of cross-
reactivity of antibodies was extended to divergent influenza A viruses by sequential 
immunisation of HA from both phylogenetic groups as shown in mice [217]. Recently, 
antibodies that broadly reacted to both HA group 1 and 2 were discovered in people 
following H7N9 vaccination [218]. 
Having shown that MVA-pdmH1HA elicited cross-reactive antibodies in adenotonsillar 
MNCs, the antibody response was compared between children and adults. The MNCs from 
adults produced stronger responses than those from children in terms of the magnitude and 
the breadth of reactivity of antibody towards a range of influenza viruses (Figure 5.6). Our 
previous study demonstrated the broader and stronger cross-reactive anti-HA antibodies in 
adults compared to children following 2009 pdmH1N1 infection [85]. Moreover, an age-
dependent induction of HA stalk-reactive antibodies by recombinant chimeric HA-based 
vaccine was also shown [219]. These may explain the broader cross-reactive antibodies 
produced in adults upon MVA-pdmH1HA stimulation. Adults in general develop memory B 
cells recognising a wider range of influenza viruses compared to children via seasonal 
vaccination or natural infection through their lifetime [19]. Anti-HA stalk antibodies are also 
likely to be generated from pre-existing memory B cells [41], which are differentiated to 
plasma cells for anti-influenza antibody responses [220]. Taken together, age and the 
exposure history to influenza would have an impact on the induction of cross-reactive 
antibody responses. 
Heterosubtypic protective responses are mediated by the antibodies targeting conserved HA 
stalk region rather than the hypervariant globular head region [35], [136]. The antibodies 
detected by ELISA assay could be either HA head- or HA stalk-reactive, due to the use of 
full-length HA. Thus, MVA-pdmH1HA-elicited cross-reactive antibodies in cell culture 
supernatant were characterised regarding whether they were HA stalk-specific or not by HAI 
assay. The undetectable HAI activity to H5N1 as shown in Figure 5.8b could imply that the 
antibodies recognising H5N1 by binding to its HA stalk [198]. However, since the level of 
antibodies to H5N1 was relatively low in the cell culture supernatant, one may argue on the 
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sensitivity of the assay to detect the HAI activity in these samples. A recent study has 
reported that the species of erythrocytes have a significant impact on the titres obtained from 
haemagglutination (HA) and haemagglutination inhibition (HAI) assays. Chicken and turkey 
erythrocytes seem to be the most appropriate for both assays with seasonal influenza 
strains, in addition to pigeon erythrocytes, particularly for the B strains. In the case of the 
avian strain, chicken erythrocytes are suitable for HA assay and horse erythrocytes for HAI 
assay [221]. It was also found that the sensitivity of HAI assay against H5N1 avian virus was 
significantly improved by the use of the horse erythrocytes instead of the chicken 
erythrocytes as they exclusively showed α-2, 3 linkage of sialic acid molecules, which avian 
strains preferentially bind [222]. Therefore, the HAI assay against H5N1 strain needed 
repeating with the use of horse erythrocytes.  
Furthermore, the antibody responses to influenza HA stalk domain needed analysing by 
other assays. HA-stalk reactive antibodies could be directly determined by ELISA when the 
plate coated with stable trimeric HA stalk or chimeric HA proteins [81], [82], [223], [224]. 
Moreover, the broadly neutralising activity of the antibodies can be measured by using 
influenza virus or pseudotyped virus expressing chimeric HA molecules [225]–[227].  
On the other hand, the observation of positive HAI activity to pdmH1N1 in some individuals 
(Figure 5.8b) suggested that MVA-pdmH1N1 elicited HA head-reactive antibodies to 
pdmH1N1. Anti-HA head antibodies to pdmH1N1 in tonsillar MNCs were detectable upon 
MVA-pdmHN1 stimulation as previously reported [147]. As all subjects were recruited during 
2015-2017 when pdmH1N1 predominantly circulated, their MNCs were most likely to contain 
the virus-specific memory B cells. Upon the recognition of the head domain of HA in the 
vaccine antigen expressed from MVA-pdmH1HA, HA head-specific antibodies could be 
elicited by activation of the pre-existing pdmH1N1-specific memory B cells in the MNCs.  
In general, memory B cells are likely to be trained to react predominantly to the head rather 
than the stalk part of HA following exposure to the same or antigenically close influenza virus 
strains [228]. Although the infection or the vaccination by pdmH1N1 virus, having a distinct 
HA head region, efficiently enhanced anti-HA stalk antibodies in people during the outbreak, 
it was later shown that re-immunisation with inactivated pdmH1N1 vaccines resulted in 
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modest anti-HA stalk antibody production as the response preferentially targeted 
immunodominant globular head HA epitopes [228], [229]. Although the presence of the 
pdmH1N1 HA head domain as the vaccine antigen in MVA-pdmH1HA could lead to the 
activation of anti-HA head specific antibody responses, the broadly cross-reactive anti-HA 
stalk antibody response by the vaccine may result from the self-adjuvant effect as one of the 
advantages of the MVA vector, which allows the influx of various immune cells due to the 
lose of immunoevasive factors of MVA [63]–[66]. The adjuvant effect could broaden the 
antibody response by the more efficient recruitment of a broader repertoire of influenza-
specific memory B cells [19]. The MVA-based vaccines thus may confer the cross-reactive 
antibody response by the activation of memory B cells specific to cross-reactive HA 
epitopes. It would be valuable in the future to study the impact of these pre-existing 
pdmH1N1 HA head-specific memory B cells in humans on the capacity of MVA-pdmH1HA to 
boost cross-reactive anti-HA stalk antibodies. 
In conclusion, the study showed that MVA-pdmH1HA vaccine had the capacity to elicit 
cross-reactive HA-specific IgG antibodies to homologous virus (pdmH1N1) and to 
heterologous subtypes in phylogenetic HA group1 viruses (seasonal H1, H5 and H9) in 
human NALT in vitro, although the response to group 2 viruses (H3 and H7) was limited. The 
magnitude and breadth of cross-reactive antibodies elicited by the vaccine may be affected      
by age and history of exposure to influenza. This vaccine candidate may have the potential 
to be used as a mucosal vaccine to activate cross-reactive antibody response, providing 
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6.1.  Discussion 
Influenza virus infection causes widespread morbidity and mortality in humans, despite the 
available vaccines. IIV provides narrow protection, mediated by serum HA-specific 
neutralising antibodies against circulating viruses that matched or are closely antigenically 
related to vaccine strains. The vaccine efficacy therefore markedly reduces in some seasons 
due to mismatching vaccine strains [26]. Despite lower serum IgG antibody induction, LAIV 
is considered to be superior to IIV as it elicits mucosal IgA and T cell responses, resulting in 
broader protection [25], [230]. However, for safety reasons, LAIV is only recommended for 
children at 2 years of age and over and adults less than 50 years old [231]. Besides the 
modest efficacy and limitation of current available vaccines, the H1N1 pandemic outbreak in 
2009 and the potential of future pandemics of avian influenza (e.g. H5N1, H7N9 and H9N2) 
[232] also highlight the urgent need for more effective vaccines that confer broad immunity 
against multiple types of influenza viruses including those with the potential to cause 
pandemics.  
Mucosal immunity is considered as the frontline defence against pathogenic infection and 
transmission at mucosal sites [100], [233], [234]. As influenza virus is a respiratory pathogen 
that infects humans through the nasopharyngeal mucosa, local vaccine delivery that 
activates cross-reactive mucosal immunity may offer an attractive vaccination strategy 
against influenza. The first licensed intranasal LAIV has been shown to induce local and 
systemic antibodies and T cell immunity in children [30], [168], [169], [235]. Intranasal 
immunisation relies on the local immune system such as nasopharynx-associated lymphoid 
tissue (NALT) to induce T and B cell immunity [236]. Adenoids and tonsils are major 
components of human NALT [173], [174], [171] and are known to be important inductive 
sites for mucosal immunity against respiratory pathogens including influenza [235], [236].  
Viral vector-based vaccines have been widely studied recently as novel and promising 
vaccines against cancer and infectious diseases such as malaria, HIV, tuberculosis and 
influenza [50], [51], [54]. We hypothesised that some novel viral vector-based influenza 
vaccines expressing conserved influenza proteins have the capacity to induce mucosal 
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immune responses if administered by the intranasal route. So in this project, I investigated 
the potential of MVA- and PanAd3-vectored influenza vaccine candidates as intranasal 
vaccines to induce either T cell or B cell-mediated broad immunity against a range of 
influenza subtypes in human NALT. 
6.1.1.  Influenza transgene expression and protein localisation in NALT 
The first critical step to successfully induce immune responses by vector-based vaccines is 
that the transgene inserted in the vector is efficiently expressed and presented by APCs [52]. 
In chapter 3, the vaccine antigen expression in adenotonsillar MNCs was studied following in 
vitro MVA- and PanAd3-vectored vaccine stimulation using the established method based on 
fluorochrome-conjugated monoclonal antibody-labeling and flow-cytometry. The expression 
of influenza NP and M1 from MVA-NP+M1 and that of influenza HA from MVA-pdmH1HA 
were detected in the adenotonsillar MNCs predominantly in B cells and DCs. The results 
suggest that MVA targets APCs which is in accordance to previous studies [141]–[143], 
[149] and the vaccine antigens could be efficiently expressed in NALT if administered 
intranasally. In contrast, the expression of influenza NP from PanAd3-NPM1 was not 
observed in the T and B cells of adenotonsillar MNCs, despite the fact that it was detected in 
the permissive HEK293 T cell line following vaccine stimulation. This indicates that the 
PanAd3 virus vectored vaccine may not be able to infect human NALT lymphocytes, similar 
to human adenovirus type 5, which is in the same species as previously reported [153]–
[155]. Unless PanAd3-vectored vaccines infect DCs in the MNCs when used at the high 
dose, which remains to be answered, the vaccines may not have the capacity to induce 
significant immune responses in NALT. Subsequent studies are therefore focused on MVA-
based vaccines; MVA-NP+M1 and MVA-pdmH1HA.  
The expression of influenza proteins in MVA-infected B cells was observed as early as 6 
hours and peaked at about 24 hours following vaccine stimulation, suggesting rapid kinetics 
of MVA infection and transgene expression, which is in agreement with previous studies 
[141]–[143]. MVA-based vaccines were also shown to have shorter time of antigen 
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presentation, which resulted in a rapid peak time of T cell response to the antigens [188], 
[237]. 
In addition to the expression of influenza proteins from the MVA-vectored vaccines, it was 
observed that influenza NP accumulated in the cell cytoplasm, whereas influenza HA 
migrated to cell membrane of MVA-infected tonsillar B cells, despite the fact that both 
proteins were initially synthesised in the cell cytosol. The different cellular localisation 
patterns of two influenza proteins was reported previously [150]. Without transgene 
modification, influenza NP and HA are most likely to be expressed in the native structure, 
and the localisation of both proteins may mimic that occurring during influenza virus 
infection, where HA continuously binds to sialic acid at the cell membrane, while NP binds to 
viral RNA in the nucleus before being imported to the cell cytoplasm for the virus assembly 
[1]. The results suggest each vaccine protein antigen may have different sites of localisation 
after expression from the vector. The findings would be useful for better vaccine design, 
which allows the antigen proteins to have longer retention in the cell cytoplasm or are highly 
degraded [151] to enhance the T cell immune responses. In addition, a well-designed 
antigen could increase the accumulation of antigens on cell membranes or could enable the 
secretion of the antigen from infected cells to be captured by APCs [152], inducing antibody 
production. 
Having shown the efficient expression of the influenza vaccine antigens from either MVA-
NP+M1 or MVA-pdmH1HA in human NALT immune cells, I further investigated the potential 
of both vaccines to induce mucosal cross-reactive T cell and B cell-mediated antibody 
immune responses towards influenza viruses, respectively. 
6.1.2. Activation of cross-reactive CTL response by MVA-NP+M1 
There is increasing evidence supporting the critical role of CTLs in protection against 
influenza virus infection, including in individuals who lack virus-specific antibodies [93]–[95]. 
Heterosubtypic T cell immunity is mainly generated by CTLs, which recognise conserved 
epitopes of NP, M1 and PB. The magnitude and functional quality of CD8+ T cell responses 
are critical for the efficacy of T cell-based vaccines. 
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In chapter 4, I examined the CTL response, focusing on the M1 antigen-specific CTL 
response and the functional properties of the CTLs in adenotonsillar MNCs induced by MVA-
NP+M1 in vitro stimulation. MVA-NP+M1 activated a marked increase of M1-specific CD8+ T 
cells in human NALT, as shown by IFN-γ ELISPOT assay and a significant increase of M158-
66-specific CD8+ T cells, which recognise one of the most conserved M1 epitopes shared 
across influenza A viruses [44], [182], [183] as shown by M158-66 tetramer staining. These 
results on the significant response to M1 protein in particular suggest the vaccine would at 
least benefit approximately 50% of Caucasians [185] or 20-30% of all ethnicities [184], who 
have HLA-A2, which is restricted for M158-66 presentation.  
In addition, the most frequently detected M158-66-specific CTLs were CD107a+ IFN-γ+ TNF-
α+, demonstrating their functionality with the release of cytotoxic molecules (perforin and 
granzymes) and the production of multiple potent pro-inflammatory cytokines, in response to 
recall antigen challenge. This functional profile of these CTLs seemed to reflect the 
phenotypes of short-lived effector and effector memory CD8+ T cells [190], [191] and similar 
findings have been also reported [167], [189]. In addition to the effector functional properties, 
M158-66-specific CTLs were able to kill M1-peptide-pulsed target cells in vitro. 
The M158-66-specific T cell response was shown in an age-dependent manner, where 
significant T cell responses were observed in children over 4 years olds and in adults. The 
results support the hypothesis that MVA-NP+M1 has the capacity to boost M1-specific 
mucosal CD8+ T cell response in addition to systemic T cell responses in adults [165], [167] 
and elderly [164]. This is likely via activating the memory CD8+ T cells primed by previous 
natural exposure to influenza viruses or vaccination. The activation of memory T cells by 
MVA-vectored vaccines has been shown in other studies [164], [188]. The results also 
suggests that a single dose vaccination of MVA-NP+M1 would benefit those whose immune 
cells are already primed for influenza including older children, adults and elderly. Young 
children may need a heterologous prime-boost regime to enhance the response.  
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6.1.3.  Activation of broadly reactive antibody-mediated response by MVA-
pdmH1HA 
In addition to cytotoxic T cell immunity, the broadly protective response across influenza 
subtypes could be mediated by broadly neutralising antibodies [35], [136], which target the 
highly conserved stalk domain of HA [41], [200]. HA stalk-reactive antibodies therefore can 
recognise multiple influenza virus strains and could provide broad protection [195], [202]. 
In chapter 5, antibody responses in adenotonsillar MNCs to HA antigens following in vitro 
MVA-pdmH1HA stimulation were studied. It was shown that MVA-pdmH1HA elicited cross-
reactive HA-specific IgG antibodies in human NALT recognising homologous (pdmH1N1) 
and heterologous influenza in HA group 1 (sH1N1, H5 and H9), but not those in HA group 2 
(H3 and H7) as shown by ELISA assay. The magnitude of antibody response activated by 
MVA-pdmH1N1 was dominant towards the homologous pdmH1N1 strain, followed by that to 
other HA group 1 viruses which showed relatively lower response. The results extend our 
previous finding [147] and indicate that MVA-pdmH1HA elicits antibodies that cross-react to 
primarily HA group 1 viruses. Many isolated broadly neutralising monoclonal antibodies 
discovered so far showed cross-reactivity to HA group 1 viruses [79]. Moreover, the breadth 
of reactivity of antibodies tends to toward other influenza subtypes within the same HA 
phylogeny of vaccine antigen as previously reported in many studies [67], [203], [204], 
[213]–[216]. 
When the cross-reactive antibody responses were compared, both the magnitude and the 
breadth of the responses in adults were shown to be higher than in children. The age-
dependent increase in the cross-reactive antibody response was also reported in other 
studies [85], [219]. These cross-reactive antibodies were most likely to be derived from the 
activation of HA stalk-specific memory B cells [41] generated from previous exposure to 
influenza through their lifetime [19]. The results support the hypothesis that the MVA-
pdmH1HA vaccine activates cross-reactive memory B cells specific to conserved HA regions 
including the stalk, thus boosting the cross-reactive antibodies. It is possible that age and the 
exposure history to influenza may affect the cross-reactive antibody response in NALT 
immune cells by the MVA-pdmH1HA vaccine. 
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6.1.4. MVA-vectored influenza vaccines as mucosal vaccines 
It has been generally considered that mucosal immunisation has the capacity to generate a 
superior local immune response, thus can efficiently prevent infection and control 
transmission of pathogens including influenza [25], [100]. To be effective, a mucosal vaccine 
needs to be immunogenic and capable of activating local mucosal immune tissue [234]. In 
this project, I have shown that MVA-NP+M1 and MVA-pdmH1HA candidate vaccines are 
capable of eliciting mucosal cross-reactive T cell and B cell antibody responses respectively 
in human NALT, using our in vitro cell culture system.  
The results from this project also support the concept that MVA is a good virus vector for 
boosting memory responses in humans, as the MVA-vectored vaccines demonstrated the 
capacity to significantly enhance both T cell and B cell antibody responses in older children 
and adults who are most likely to be primed by previous exposure/ infection. MVA has been 
employed as a boosting vector following either homologous/heterologous vector or protein 
priming in many prime-boost studies against malaria and HIV, showing the synergistic effect 
on the magnitude of immune responses [238]–[240]. It has been shown previously that MVA-
NP+M1 as a booster enhanced the frequency of antigen-specific CD8+ T cells in 
bronchoalveolar lavage and lungs of hAd5-primed mice, and intranasal compared to other 
routes of administration showed the highest T cell responses [241].  
In addition to immunogenicity, MVA has an excellent safety profile as it has been used for 
smallpox vaccination without problems in humans [242]. Moreover, it did not show any 
virulence in immunodeficient animals after virus injection [163]. MVA was also shown to be 
safe in mice following intranasal administration as MVA mainly targeted NALT, lungs and 
draining lymph nodes and no inflammatory reactions were detected in the central nervous 
system as well as the upper and lower airways [243]. The study in rhesus macaques has 
shown that aerosol delivery of MVA-vectored vaccines was safe and there was no vaccine-
associated pathology, including in the brain and lungs [244]. 
Taken together, the results from this study support that intranasal administration of MVA-
NP+M1 and MVA-pdmH1HA in humans can elicit mucosal immunity, involving the activation 
of T cell and B cell memory responses in human NALT. 
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6.2. Conclusion 
In this project, I studied two MVA-vectored vaccines; MVA-NP+M1 and MVA-pdmH1HA in 
our in vitro human cell culture system modeling NALT. I firstly demonstrated that influenza 
vaccine antigens (NP, M1 and HA) were efficiently expressed in the NALT immune cells, 
predominantly in adenotonsillar B cells and DCs. Following in vitro vaccine stimulation, MVA-
NP+M1 was shown to activate cross-reactive polyfunctional M1-specific CTLs, exhibiting 
specific target killing. MVA-pdmH1HA vaccine elicited HA-specific IgG antibodies that 
broadly reacted to influenza subtypes in phylogenetic HA group 1. The magnitude of both 
CTL and antibody responses were shown in an age-dependent manner, supporting the 
capacity of these MVA-vectored vaccines to elicit memory T and B cell responses. Our 
results suggest that both MVA-NP+M1 and MVA-pdmH1HA have the potential as intranasal 
mucosal vaccines to boost cross-reactive mucosal T and B cell-mediated immune responses 
against a range of influenza viruses. These data provide important supporting information for 
a potential new vaccination strategy using MVA-vectored universal influenza vaccines in 
intranasal vaccination against influenza in humans. 
6.3. Future directions 
6.3.1. Phenotypes of M1-specific CTLs 
Having shown that MVA-NP+M1 induced a prominent and functional M158-66-specific T cell 
response in this project, it will be useful to further characterise these cells, in terms of their 
memory phenotypes, particularly on how they relate to tissue-resident memory T cells (TRM).  
TRM in human lungs have been suggested to mount a rapid response and kill influenza-
infected epithelial cells and contribute to protection [245], [246]. Recent studies have shown 
that TRM are also found in secondary lymphoid tissues, including tonsils [178], [247], [248]. 
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6.3.2. Mechanisms of action of MVA-pdmH1HA-elicited antibodies 
The functional properties of MVA-pdmH1HA-elicited antibodies were not investigated in this 
study. However, we have shown in the previous study that the antibodies had neutralising 
activity to heterologous H1N1 subtypes (A/Brisbane/59/2007 and A/South Carolina/1918) 
and to H5N1 (A/Vietnam/1203/2004) [147]. In addition to neutralisation, there is increasing 
evidence supporting that HA stalk-reactive antibodies could mediate in vivo protection via 
Fc-mediated cytotoxicity [87], [200], [249]. The interaction of Fc of antibody with Fc receptors 
on immune cells (e.g. NK cells) or complement could induce cell cytotoxicity or phagocytosis 
by macrophages [88], [90], [250], [251]. It was shown in mice that MVA-expressing modified 
HA of H5N1 induced neutralising antibodies, correlating with the protection against H5N1 
viruses in different clades, while antibody‐dependent cellular cytotoxicity (ADCC) [252] and 
cytotoxic T cell immunity [211] were associated with protection from heterologous virus 
strains such as pdmH1N1. Thus, it would be useful in future studies to determine other 
mechanisms of action in MVA-pdmH1HA-elicited antibodies that may correlate with 
protection. 
6.3.3. Activation of HA-specific T follicular helper cells by MVA-pdmH1HA 
In addition to antibody induction, it was shown that HA-expressing adenotonsillar B cells 
upregulated their HLA-DR, which indicates the antigen processing and presentation capacity 
via HLA class II. The antigen presented by HLA class II can activate CD4+ T cells. We have 
shown that the induction of antigen-specific TFH by LAIV in human NALT in vitro correlated 
with the antibody response [209]. Circulating influenza-specific TFH were also shown to 
correlate with the antibody response in humans following immunisation with split seasonal 
influenza vaccine [210]. Since the upregulation of HLA-DR suggests the activation of CD4+ T 
cells, it will be valuable to investigate the correlation between TFH activation and antibody 
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Appendix-1: Preparation of reagents and buffers 
AEC substrate  
AEC substrate is for ELISPOT assay. 
 
1. Prepare 0.1 M acetate solution (pH 5.0) 
1.1 Prepare 0.2 M acetic acid and 0.2 M sodium acetate 
0.2 M acetic acid 
Glacial acetic acid     1.15  ml 
Deionised water    added to 100   ml 
0.2 M sodium acetate 
Sodium acetate (MW 82.03) 1.64  g   
Deionised water    added to 100   ml 
1.2 Mix 0.2 M acetic acid and 0.2 M sodium acetate and adjust pH to 5.0 
0.2 M acetic acid  14.8  ml 
0.2 M sodium acetate  35.2  ml 
Deionised water  50.0  ml 
Note: The solution could be stored at room temperature. 
 
2. Prepare AEC stock solution 
3-Amino-9-ethylcarbazole (AEC)  100 mg 
N, N-Dimethylformamide, anhuydrous (DMF)   10  ml 
 
Note: 1) The solution could be stably stored at 4°C with tightly sealed and protected 
from light.  
2) Prepare in fume hood using polypropylene tubes (i.e. 15-ml centrifuge 
tube, Corning) and avoid using any polystyrene containers and disposable 
pipettes due to their incompatibility to DMF.  
 
3. Dilute AEC stock solution in 0.1 M acetate solution to make working AEC substrate 
 AEC stock solution  333  µl 
 0.1 M acetate solution  10  ml 
  
The solution needs filtering through 0.45 µm filter before adding 5 µl of 30% 
hydrogen peroxide, mixed well. The substrate should be immediately used and 
protected from light while incubating the plate. 
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p-Nitrophenylphosphate (PNPP) substrate  
PNPP substrate is for ELISA assay. 
1. Preparing PNPP substrate diluent solution 
   Diethanolamine   97        ml 
  MgCl2 . 6H20   100      mg 
  Deionised water  800    ml 
 
The pH was measured and adjusted to 9.8 by adding 10 M hydrochloric acid. Once 
adjusted, deionised water is added to obtain a final volume of 1000 ml. The solution could 
be stored at 4°C.  
 
2. Dissolve PNPP substrate (1 mg/ml) in diluent buffer to make PNPP substrate 
  p-Nitrophenylphosphate tablet  5     mg 
  PNPP substrate solution  5     ml 
 
    The substrate should be immediately used and protected from light while incubating the plate. 
 
 
0.5% chicken red blood cells 
3 ml of chicken blood in Alsever’s solution (First link, UK) was pipetted in centrifuge tube. 
After centrifugation at 1500 rpm for 5 min, supernatant and buffy layer are aspirated, leaving 
only red blood cells (RBC). RBCs are washed, by adding 10 ml 1XPBS followed by 
centrifugation at 1,500 rpm for 5 min. The washing is repeated for three times. The end 
result is packed chicken RBCs. 10% chicken RBCs is prepared by resuspending 0.3 ml of 
packed RBCs in 2.7 ml. Then 0.5% chicken RBCs is prepared as following 
10% chicken RBCs    2.5   ml 
1X PBS    47.5   ml 
The reagent could be kept at 4°C for 24 hours. It should be gently shaken to homogenously 






Standardised influenza virus antigen 
 
1. Each influenza virus antigen (whole inactivated virus) is firstly examined for the HA 
titre. A HA unit is defined as the amount of virus needed to agglutinate an equal 
volume of RBCs suspension. 
1.1 Add 50 µl of PBS to two successive row for testing 1 antigen (i.e. A and B) 
1.2 Add 50 µl of standardized antigen to A1, B1 and make two-fold dilution by 
transferring 50 µl through 11 wells (A11) and discard the final 50 µl. Leave the 
last well (A12) for negative control. 
1.3 Add 50 µl of 0.5% chicken RBCs in every well. 
1.4 Mix by using a mechanical vibration or manually agitating the plates thoroughly 
1.5 Incubate the microplate for 30 min at room temperature and check the result 
when the RBCs control completely settle. 
 
HA titre is determined as the highest dilution that showed positive haemagglutination 
activity, where the RBCs are suspended in the solution and no RBC button is found at 
the bottom of the well. 
 
2. When HA titre is measured, the antigen is diluted with 1X PBS to 8 HA units/ 50 µl by 
calculation. For example;   
HA titre of H1N1 antigen is 320 HA units/ 50 µl. 
The antigen need to be diluted at the ratio of 1:40 to make 8 HA units/ 50 µl. 
 
3. The diluted antigen is performed back titration to verify the correction of HA units. The 
antigen is 2-fold serial diluted and 3-fold serial diluted in 1X PBS before adding 0.5% 
chicken RBCs as following steps; 
3.1 Add 50 µl of PBS to two successive row for testing 1 antigen (i.e. A and B) 
3.2 Add 50 µl of standardized antigen to A1, B1 and make two-fold dilution by 
transferring 50 µl through 5 wells (A6, B6) and discard the final 50 µl 
3.3 Add 25 µl of standardized antigen to A7, B7 and make three-fold dilution by 
transferring 50 µl through 5 wells (A11, B11) and discard the final 50 µl.      
Column 12 is left for the RBCs control (negative control). 
3.4 Add 50 µl of 0.5% chicken RBCs in every well. 
3.5 Mix by using a mechanical vibration or manually agitating the plates thoroughly 
3.6 Incubate the microplate for 30 min at room temperature and check the result 
when the RBCs control completely settle. 
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4. The standardised antigen must show the complete agglutination in the first three wells 
of two-fold dilution and the first two wells of three-fold dilution, meaning HA titre is in 
between 6 and 8 as shown in the following table. 
Dilution 2-fold dilution 3-fold dilution PBS 
Row 1 2 3 4 5 6 7 8 9 10 11 12 
Result + + + - - - + + - - - - 
 
If the antigen does not have an HA titer of 8, it must be adjusted accordingly by adding 
more original antigen stock to increase units or by diluting with PBS to decrease units and 


















Appendix-2: Measurement of cell viability using propidium iodide  
Tonsillar MNCs following 10-day incubation without any stimulation were harvested and 
resuspended in 100 µl FACS staining buffer then stained with 5 µl propidium iodide solution 
(eBiosciences, UK) for 5-15 minutes at room temperature with protection from light. Without 
washing, labeled-cells were acquired their data of cell viability by flow-cytometry.  
Gating on the majority of two main populations on FSC-SSC plot, the gate left most debris 
on the bottom left corner. The selected population was plotted in histogram against 
propidium iodide, showing three peaks that may refer to three different stage of cell viability 
within cell population. Cells with lowest intensity of PI (blue) were referred to live cells, 
whereas cells with increasing intensity of PI (yellow) were referred to dying cells (or in 
intermediate stage). The cells with the highest PI intensity (red) were dead cells, so they 
could not resist to dye penetration. With PI staining, it showed that the majority of viable cells 
were the population on the far right on the FSC-SSC plot, while the dying and dead cells 
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